



Factors" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, which we filed with the United States Securities and Exchange Commission ("SEC") on March 12, 2024 (the "2023 Form 10-K"), (ii) Item 2 of this Quarterly Report, under the heading "Management's Discussion and Analysis of Financial Condition and Results of Operations – Factors Which May Influence Future Results of Operations" and (iii) Part II, Item 1.A of this Quarterly Report. As a result of these risk factors, we cannot assure you that the forward-looking statements in this Quarterly Report will prove to be accurate. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. We do not undertake to update any of the forward-looking statements after the date of this Quarterly Report, except to the extent required by applicable securities laws.

**PART I** **FINANCIAL INFORMATION**  
**ITEM 1. FINANCIAL STATEMENTS**  
**CLEARPOINT NEURO, INC.** Condensed Consolidated Balance Sheets (in thousands, except for share and per share data)  
**September 30, 2024**  
**December 31, 2023**  
**(Unaudited)**  
**ASSETS**  
**Current assets:**  
**À Cash and cash equivalents** \$21,573A \$23,140A  
**Accounts receivable, net** 3,875A 3,211A  
**Inventory, net** 7,059A 7,911A  
**Prepaid expenses and other current assets** 1,823A 1,910A  
**Total current assets** \$34,330A \$36,172A  
**Property and equipment, net** 1,695A 1,389A  
**Operating lease, right-of-use assets** 3,210A 3,564A  
**Software license inventory** 198A 386A  
**Licensing rights** 612A 1,041A  
**Other assets** 148A 109A  
**Total assets** \$40,193A \$42,661A  
**LIABILITIES AND STOCKHOLDERS' EQUITY**  
**Current liabilities:**  
**Accounts payable** \$955A \$393A  
**Accrued compensation** 3,635A 2,947A  
**Other accrued liabilities** 1,76A 1,053A  
**Operating lease liabilities, current portion** 536A 424A  
**Deferred product and service revenue, current portion** 1,252A 2,613A  
**Total current liabilities** 7,554A 7,430A  
**Operating lease liabilities, net of current portion** 3,158A 3,568A  
**Deferred product and service revenue, net of current portion** 480A 541A  
**Convertible note payable, net** 9,949A  
**Total liabilities** 11,192A 11,488A  
**Commitments and contingencies**  
**Stockholders' equity:**  
**Preferred stock, \$0.01 par value; 25,000,000 shares authorized; none issued and outstanding at September 30, 2024 and December 31, 2023** 0A 0A  
**À Common stock, \$0.01 par value; 90,000,000 shares authorized at September 30, 2024 and December 31, 2023; 27,588,819 shares issued and outstanding at September 30, 2024; and 24,652,729 issued and outstanding at December 31, 2023** 276A 247A  
**Additional paid-in capital** 124,709A 193,382A  
**Accumulated deficit** (185,984) (172,456)  
**Total stockholders' equity** 29,001A 21,173A  
**Total liabilities and stockholders' equity** \$40,193A \$42,661A  
**See accompanying notes to Condensed Consolidated Financial Statements.**  
**1. CLEARPOINT NEURO, INC.** Condensed Consolidated Statements of Operations (Unaudited) (in thousands, except for share and per share data)  
**For The Three Months Ended**  
**September 30, 2024**  
**2023**  
**Revenue:**  
**À Product revenue** \$5,474A \$2,410A  
**Service and other revenue** 2,648A 3,352A  
**Total revenue** 8,122A 5,762A  
**Cost of revenue** 3,275A 2,489A  
**Gross profit** 4,847A 3,273A  
**Research and development costs** 3,315A 2,429A  
**Sales and marketing expenses** 3,549A 2,841A  
**General and administrative expenses** 1,562A 2,900A  
**Operating loss** (5,172) (4,897)  
**Other income (expense):**  
**Other expense, net** (11) (12)  
**Interest income, net** 209A 100A  
**Net loss** \$(4,974) \$(4,809)  
**Net loss per share attributable to common stockholders:**  
**Basic and diluted** \$(0.18) \$(0.20)  
**Weighted average shares used in computing net loss per share:**  
**Basic and diluted** 27,591,623A 24,630,181A  
**For The Nine Months Ended**  
**September 30, 2024**  
**2023**  
**Revenue:**  
**À Product revenue** \$14,053A \$7,377A  
**Service and other revenue** 9,566A 9,768A  
**Total revenue** 23,619A 17,145A  
**Cost of revenue** 9,259A 7,544A  
**Gross profit** 14,360A 9,601A  
**Research and development costs** 9,060A 9,057A  
**Sales and marketing expenses** 10,673A 9,248A  
**General and administrative expenses** 8,769A 9,036A  
**Operating loss** (14,142) (17,740)  
**Other income (expense):**  
**Other expense, net** (32) (25)  
**Interest income, net** 646A 295A  
**Net loss** \$(13,528) \$(17,470)  
**Net loss per share attributable to common stockholders:**  
**Basic and diluted** \$(0.50) \$(0.71)  
**Weighted average shares used in computing net loss per share:**  
**Basic and diluted** 26,840,119A 24,599,191A  
**See accompanying notes to Condensed Consolidated Financial Statements.**  
**2. CLEARPOINT NEURO, INC.** Condensed Consolidated Statements of Stockholders' Equity (Unaudited) (Dollars in thousands)  
**For The Three and Nine Months Ended**  
**September 30, 2024**  
**Common Stock**  
**Additional Paid-in Capital**  
**Accumulated Deficit**  
**Total Shares**  
**Amount**  
**Balance, January 1, 2024** 24,652,729A \$247A \$193,382A \$(172,456) 21,173A  
**Issuances of common stock:**  
**Public offering of common stock, net of offering costs** 2,653,848A 26A 16,157A 0A  
**À 16,183A Share-based compensation** 126,315A 1A 1,503A 0A  
**À 1,504A Option exercises** 7,500A 0A 21A 0A  
**À 21A Payments for taxes related to net share settlement of equity awards** (24,047) 0A (151) 0A  
**À (151) Net loss for the period** 0A 0A (4,146) (4,146)  
**Balances, March 31, 2024** 27,588,819A \$276A \$210,912A \$(176,602) 23,584A  
**Issuances of common stock:**  
**Share-based compensation** 3,782A 0A 1,307A 0A  
**À 1,307A Payments for taxes related to net share settlement of equity awards** (514) 0A (5) 0A  
**À (5) Net loss for the period** 0A 0A (5,609) (5,609)  
**Balances, June 30, 2024** 27,588,819A \$276A \$212,866A \$(181,010) 23,132A  
**Issuances of common stock:**  
**Share-based compensation** 4,547A 0A 1,904A 0A  
**À 1,904A Option exercises (cashless)** 860A 0A 0A 0A  
**À 0A Payments for taxes related to net share settlement of equity awards** (5,400) 0A (61) 0A  
**À (61) Net loss for the period** 0A 0A (4,974) (4,974)  
**Balances, September 30, 2024** 27,588,819A \$276A \$214,709A \$(185,984) 23,001A  
**For The Three and Nine Months Ended**  
**September 30, 2023**  
**Common Stock**  
**Additional Paid-in Capital**  
**Accumulated Deficit**  
**Total Shares**  
**Amount**  
**Balance, January 1, 2023** 24,599,191A \$246A \$188,310A \$(155,976) 23,580A  
**Issuances of common stock:**  
**Share-based compensation** 3,782A 0A 1,307A 0A  
**À 1,307A Payments for taxes related to net share settlement of equity awards** (514) 0A (5) 0A  
**À (5) Net loss for the period** 0A 0A (5,609) (5,609)  
**Balances, March 31, 2023** 24,599,191A \$246A \$188,310A \$(155,976) 23,580A  
**Issuances of common stock:**  
**Share-based compensation** 5,484A 0A 1,645A 0A  
**À 1,645A Payments for taxes related to net share settlement of equity awards** (11,102) 0A (77) 0A  
**À (77) Issuance of common stock under employee stock purchase plan** 51,041A 0A 314A 0A  
**À 314A Net loss for the period** 0A 0A (7,052) (7,052)  
**Balances, June 30, 2023** 24,652,729A \$246A \$190,192A \$(163,028) 27,410A  
**Issuances of common stock:**  
**Share-based compensation** (1,001) 0A 1,584A 0A  
**À 1,584A Option exercises (cashless)** 14,312A 0A 0A 0A  
**À 0A Payments for taxes related to net share settlement of equity awards** (15,315) 0A (91) 0A  
**À (91) Net loss for the period** 0A 0A (4,809) (4,809)  
**Balances, September 30, 2023** 24,652,729A \$246A \$191,685A \$(167,837) 24,094A  
**See accompanying notes to Condensed Consolidated Financial Statements.**  
**3. CLEARPOINT NEURO, INC.** Condensed Consolidated Statements of Cash Flows (Unaudited) (in thousands)  
**For The Three Months Ended**  
**September 30, 2024**  
**2023**  
**Cash flows from operating activities:**  
**À Net loss** \$(13,528) \$(17,470)  
**Adjustments to reconcile net loss to net cash flows from operating activities:**  
**Allowance for credit losses (recoveries)** (507) 903A  
**Depreciation and amortization** 740A 443A  
**Share-based compensation** 5,204A 4,536A  
**Amortization of debt issuance costs and original issue discounts** 51A 42A  
**Amortization of lease right-of-use, net of accretion in lease liabilities** 692A 590A  
**Accretion of discounts on short-term investments** 0A (126)  
**Increase (decrease) in cash resulting from changes in:**  
**Accounts receivable** (157) (662)  
**Inventory, net** 444A 263A  
**Prepaid expenses and other current assets** 88A 241A  
**Other assets** (40) 22A  
**Accounts payable and accrued expenses** 1,373A (1,023)  
**Lease liabilities** (635) (553)  
**Deferred revenue** (1,422) 243A  
**Net cash flows from operating activities** (7,707) (12,551)  
**Cash flows from investing activities:**  
**Purchases of property and equipment** (12) (696)  
**Acquisition of licensing rights** 0A (167)  
**Proceeds from maturities of short-term investments** 0A 10,000A  
**Net cash flows from investing activities** (12) 9,137A  
**Cash flows from financing activities:**  
**Proceeds from public offering of common stock, net of offering costs** 16,183A 0A  
**À 0A Repayment of 2020 senior secured convertible note** (10,000) 0A  
**À 0A Proceeds from stock option exercises** 21A 0A  
**À 0A Payments for taxes related to net share settlement of equity awards** (340) (173)  
**Proceeds from issuance of common stock under employee stock purchase plan** 51A 314A  
**Net cash flows from financing activities** 6,152A 141A  
**Net change in cash and cash equivalents** (1,567) (3,273)  
**Cash and cash equivalents, beginning of period** 23,140A 27,615A  
**Cash and cash equivalents, end of period** 21,573A \$24,342A  
**SUPPLEMENTAL CASH FLOW INFORMATION**  
**Cash paid for:**  
**Income taxes** 0A 0A  
**À 0A Interest** 480A 555A  
**NON-CASH INVESTING AND FINANCING TRANSACTIONS:**  
**À 0A During the nine months ended September 30, 2024 and 2023, the Company recorded net transfers of ClearPoint reusable components having an aggregate net book value of \$0.4 million and less than \$0.1 million, respectively, between loaned systems, which are included in property and equipment in the accompanying condensed consolidated balance sheets, and inventory. As discussed in Note 7, the Company entered into a lease for a manufacturing facility in Carlsbad, California, which commenced in June 2023. In connection with the new lease, the Company recorded a right-of-use asset in exchange for an operating lease liability in the amount of approximately \$2.5 million. See accompanying notes to Condensed Consolidated Financial Statements.**  
**6. ClearPoint Neuro, Inc.** Notes to Condensed Consolidated Financial Statements (Unaudited)  
**1. Description of the Business and Financial Condition**  
**ClearPoint Neuro, Inc. (the "Company") is a commercial-stage medical device company focused on the development and commercialization of innovative platforms for performing minimally invasive surgical procedures in the brain. From the Company's inception in 1998, the Company has deployed significant resources to fund its efforts to develop the capabilities for enabling neurosurgery interventions, building an intellectual property portfolio, and identifying and building out commercial applications for the technologies it develops. In 2021, the Company's efforts expanded beyond the MRI suite to encompass development and commercialization of new neurosurgical device products for the operating room setting. In 2022, the Company commercialized the ClearPoint Prism Neuro Laser Therapy System as its first therapy product offering. The Company has exclusive global commercialization rights to the ClearPoint Prism Neuro Laser Therapy System through its Swedish partner, Clinical Laserthermia Systems ("CLS"). Since 2021, a growing part of the Company's revenue is derived from professional services to pharmaceutical and biotech companies, academic institutions, and contract research organizations having a focus on biologics and drug delivery. The Company's services include protocol consultation and solutions for preclinical study design and execution for the delivery of pharmaceutical agents to the brain. The Company also partners with customers to develop devices used for administration of therapies into the central nervous system. Currently, the Company has more than 50 biologics and drug delivery customers who are evaluating or using its products and services in trials to inject gene and cell therapies directly into the brain. These relationships involve drug development programs that are at various stages of development ranging from preclinical research to late-stage regulatory trials for multiple distinct disease states. This part of the Company's business potentially represents the largest opportunity for growth; however, the Company's ability to grow in this market is dependent on its ability to maintain and establish new relationships with customers, such as customers' continuation of research and product development plans, and such customers' achievement of success in completion of clinical trials and subsequent regulatory approvals of their biologics and drugs. Macro-economic Trends**  
**The Company continues to monitor the impact of various macro-economic trends, such as global economic and supply chain disruptions, geopolitical instability (including instability resulting from military conflicts), labor shortages, inflationary conditions, and legislative and political developments. Impacts from inflationary pressures, such as increasing costs for research and development of the Company's products, administrative and other costs of doing business, and the Company's access to capital markets and other sources of funding in the future could adversely affect the Company's business, financial condition and results of operations. Additionally, these trends could adversely affect the Company's customers, which could impact their willingness to spend on the Company's products and services, or their ability to make payment, which could harm the Company's collection of accounts receivable and financial results. The continued development and fluidity of these situations preclude any prediction as to the ultimate impact they will have on the Company's business, financial condition, results of operation and cash flows.**  
**Liquidity**  
**The Company has incurred net losses since its inception, which has resulted in a cumulative deficit at September 30, 2024 of \$186.0 million. In addition, the Company's use of cash from operations amounted to \$7.7 million for the nine months ended September 30, 2024, and \$13.7 million for the year ended December 31, 2023. Since its inception, the Company has financed its operations principally from the sale of equity securities and the issuance of notes payable, however, there is no assurance a future sale of equity securities and/or issuance of notes payable will be at terms favorable to the Company or available at all. As required by generally accepted accounting principles in the U.S., the Company has evaluated its ability to continue as a going concern and has determined that based on current forecasts, existing cash and cash equivalent balances at September 30, 2024 are sufficient to support the Company's operations and meet its obligations for at least the next twelve months. In March 2024, the Company completed a public offering of 2,653,848 shares of its common stock from which the net proceeds totaled approximately \$16.2 million after deducting underwriting discounts and commissions, and other offering expenses paid by the Company. See Note 8 below for additional information with respect to the common stock offering.**  
**7. ClearPoint Neuro, Inc.** Notes to Condensed Consolidated Financial Statements (Unaudited)  
**In August 2024, the Company repaid in full the remaining \$10 million outstanding under a Securities Purchase Agreement entered into in 2020 (the "SPA"), pursuant to which the Company issued secured convertible notes to two investors raising gross proceeds of \$25 million, of which \$15 million had been previously converted to common stock. See Note 6 below for additional information with respect to these notes.**  
**2. Basis of Presentation and Summary of Significant Accounting Policies**  
**Basis of Presentation**  
**The accompanying unaudited condensed consolidated financial statements of the Company should be read in conjunction with the audited financial statements and notes thereto as of and for the year ended December 31, 2023 included in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC"). The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States ("U.S. GAAP") for interim financial information and in accordance with the rules and regulations of the SEC related to a quarterly report on Form 10-Q. Accordingly, since they are interim statements, the accompanying unaudited condensed consolidated financial statements do not include all of the information and notes required by U.S. GAAP for complete financial statements. In the opinion of management, the accompanying unaudited condensed consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, that are necessary for a fair statement of financial position, results of operations, cash flows, and stockholders' equity for the interim periods presented. Interim results are not necessarily indicative of results for a full year. Use of Estimates**  
**The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ from those estimates.**  
**Inventory**  
**Inventory is carried at the lower of cost or net realizable value. The costs of inventory are determined using the standard cost method, which approximates actual cost based on a first-in, first-out method. Items in inventory relate predominantly to the Company's ClearPoint system and related disposables. Software license inventory related to ClearPoint systems undergoing on-site customer evaluation is included in inventory in the accompanying condensed consolidated balance sheets. All other software license inventory is classified as a non-current asset. The Company periodically reviews its inventory for excess and obsolete items and provides a reserve upon identification of potentially excess or obsolete items.**  
**Intangible Assets**  
**The Company is a party to a license agreement that provides rights to the Company for the development and commercialization of products. Under the terms of the license agreement, the Company made payments to the licensor upon execution of the license agreement for access to the underlying technology, and future payments will be based upon achievement of regulatory and commercialization milestones as defined in the license agreement. In 2022, the Company made a payment to the licensor for the achievement of a regulatory milestone, which acts as a prepayment for future royalties. In conformity with Accounting Standards Codification Section (ASC) 350, "Intangibles – Goodwill and Other," the Company amortizes the payments related to the license rights described above over an expected useful life of up to five years, or as commercial sales occur that are related to the royalty prepayment. In addition, the Company periodically evaluates the recoverability of its investment in the license rights and records an impairment charge in the event such evaluation indicates that the Company's investment is not likely to be recovered.**  
**8. ClearPoint Neuro, Inc.** Notes to Condensed Consolidated Financial Statements (Unaudited)  
**Revenue Recognition**  
**The Company's revenue is comprised primarily of: (1) product revenue resulting from the sale of neurosurgery, navigation, therapy, and biologics and drug delivery disposable products; (2) product revenue resulting from the sale of ClearPoint capital equipment and software; (3) service revenue and case support revenue in connection with customer-sponsored preclinical and clinical trials; (4) license revenue for the granting of licenses to develop and commercialize the Company's SmartFlow Canula devices with the Company's customers' proprietary biologics as a combination product; and (5) revenue resulting from the service, installation, training, and shipping related to ClearPoint capital equipment and software. The Company recognizes revenue when (i) control of the Company's products is transferred to its customers or (ii) services are provided to customers, each in an amount that reflects the consideration the Company expects to receive from its customers in exchange for those products and services, in a process that involves identifying the contract with a customer, identifying the performance obligations in the contract, determining the transaction price, allocating the transaction price to the distinct performance obligations in the contract, and recognizing revenue when or as the performance obligations have been satisfied. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. When a contract calls for the**

satisfaction of multiple performance obligations for a single contract price, the Company typically allocates the contract price among the performance obligations based on the relative stand-alone selling prices for each such performance obligation customarily charged by the Company. The Company considers a performance obligation satisfied once it has transferred control of a good or service to the customer, meaning the customer has the ability to use and obtain the benefit of the good or service. The Company recognizes revenue for satisfied performance obligations only when it determines there are no uncertainties regarding payment terms or transfer of control. Lines of Business; Timing of Revenue Recognition

Neurosurgery navigation product, biologics and drug delivery systems product, and therapy product sales: Revenue from the sale of neurosurgery navigation products (consisting of disposable products sold commercially and related to cases utilizing the Company's ClearPoint system), biologics and drug delivery products (consisting primarily of disposable products related to customer-sponsored clinical trials utilizing the ClearPoint system), and therapy products (consisting primarily of disposable laser-related products used in neurosurgical procedures) is generally based on customer purchase orders, the predominance of which require delivery within one week of the order having been placed, and is generally recognized at the point in time of shipping to the customer, which is the point at which legal title, and risks and rewards of ownership, transfer to the customer. For certain customers, legal title and risks and rewards of ownership transfer upon delivery to the customer as stated in their respective contracts, in which case revenue is recognized upon delivery. Capital equipment and software sales: Capital equipment and software sales preceded by evaluation periods: The predominance of capital equipment and software sales (consisting of integrated computer hardware and software that are integral components of the Company's ClearPoint system) are preceded by customer evaluation periods. During these evaluation periods, installation of, and training of customer personnel on, the systems have been completed and the systems have been in operation. Accordingly, revenue from capital equipment and software sales following such evaluation periods is recognized at the point in time that the Company is in receipt of an executed purchase agreement or purchase order. Capital equipment and software sales not preceded by evaluation periods: A Revenue from sales of capital equipment and software not having been preceded by an evaluation period is recognized upon delivery to the customer and installation. For capital equipment that does not require installation, revenue is recognized upon shipment; however, for those customers where legal title and risks and rewards of ownership transfer upon delivery, revenue is recognized at such time. For both types of capital equipment and software sales described above, the determination of the point in time at which to recognize revenue represents that point at which the customer has legal title, physical possession, and the risks and rewards of ownership, and the Company has a present right to payment.

ClearPoint Neuro, Inc. Notes to Condensed Consolidated Financial Statements (Unaudited)

Neurosurgery navigation and therapy services: The Company recognizes revenue for such services over time as the services are delivered to the customer based on the extent of progress towards completion of the performance obligation. Biologics and drug delivery services and other revenue: Professional and Consulting Services: The Company recognizes professional and consulting revenue over time as the services are delivered to the customer based on the extent of progress towards completion of the performance obligation. The Company may use output methods, such as time elapsed, or input methods, such as labor hours expended or costs incurred, to measure progress depending on which better depicts the transfer of control to the customer. Clinical Service Access Fees: For contracts in which the Company receives a periodic fixed fee, irrespective of the number of cases attended by the Company's personnel or hours incurred during such periods, revenue is recognized ratably over the period covered by such fees. A time-elapsed output method is used for such fees because the Company transfers control evenly by providing a stand-ready service. Procedure-Based Service Fees: The Company recognizes revenue at the point in time a relevant case is completed. License fees: License fees represent the use of functional intellectual property as it exists at the point in time at which the license is granted and does not require any significant development or customization. Accordingly, the Company recognizes license revenue at the point in time in which the license becomes effective and the intellectual property is made available to the customer. Milestone fees: Event-based payments which are subject to the customer's achievement of specified development or regulatory milestones are included in the transaction price if, in the Company's judgment, it is probable that these milestones will be achieved and a significant future reversal of cumulative revenue under the contract will not occur. The Company re-evaluates the probability of achievement of such milestones at the end of each reporting period and adjusts the transaction price as necessary. Capital equipment-related services: Equipment service: Revenue from service of ClearPoint capital equipment and software previously sold to customers is based on agreements with terms ranging from one to three years and is recognized ratably on a monthly basis over the term of the service agreement. A time-elapsed output method is used for service revenue because the Company transfers control evenly by providing a stand-ready service. The Company may also enter into contracts with customers who own ClearPoint capital equipment, which bundle maintenance and support services and access to software and hardware upgrades made commercially available over the term of the contract, for a single contract price, typically paid on an annual basis. The Company allocates the contract price among the performance obligations based on the relative stand-alone prices for each such performance obligation and recognizes the revenue ratably on a monthly basis. A time-elapsed output method is used as the Company is providing a stand-ready service for each of the performance obligations. Installation, training and shipping: Consistent with the Company's recognition of revenue for capital equipment and software sales as described above, fees for installation, training and shipping in connection with sales of capital equipment and software that have been preceded by customer evaluation periods are recognized as revenue at the point in time the Company is in receipt of an executed purchase agreement or purchase order for the equipment and software. Installation, training and shipping fees related to capital equipment and software sales not having been preceded by an evaluation period are recognized as revenue concurrent with the recognition of revenue from sales of the related capital equipment.

ClearPoint Neuro, Inc. Notes to Condensed Consolidated Financial Statements (Unaudited)

The Company operates in one industry segment, and the predominance of its sales are to U.S.-based customers. Payment terms under contracts with customers generally are in a range of 30-60 days after the customer's receipt of the Company's invoices. The Company's terms and conditions do not provide for a right of return unless for: (a) product defects; or (b) other conditions subject to the Company's approval. See Note 3 for additional information regarding revenue recognition. Net Loss Per Share The Company computes net loss per share using the weighted-average number of common shares outstanding during the period. Basic and diluted net loss per share are the same because the conversion, exercise or issuance of all potential common stock equivalents, which comprise the Company's outstanding common stock options and invested restricted stock units, as described in Note 8, would be anti-dilutive, due to the reporting of a net loss for each of the periods in the accompanying condensed consolidated statements of operations. Concentration Risks and Other Risks and Uncertainties Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable. The Company may at times invest its excess cash in interest bearing accounts and U.S. government debt securities. It classifies all highly liquid investments with original stated maturities of three months or less from the date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months but less than twelve months as short-term investments. The Company holds the remainder of its cash and cash equivalents on deposit with financial institutions in the U.S. insured by the Federal Deposit Insurance Corporation. At September 30, 2024, the Company had approximately \$1.1 million in bank balances that were in excess of the insured limits. At September 30, 2024, there was one customer whose accounts receivable balance represented 11% of accounts receivable at that date. At December 31, 2023, there were four customers whose accounts receivable balances represented 80% of accounts receivable at that date. One pharmaceutical customer, a related party who is a stockholder and whose chief executive officer is a member of the Company's Board of Directors, for whom the Company provides hardware, software, clinical services and market development services in support of the customer's clinical trials, and from whom the Company earns a quarterly fee, accounted for 9% and 12% of total sales in both the three and nine-month periods ended September 30, 2024 and 2023, respectively. There was one additional customer, who comprised 13% of the total sales in the three-month period ended September 30, 2024, and another customer who comprised 10% of the total sales in the three-month period ended September 30, 2023. Prior to granting credit to a customer, the Company generally performs credit evaluations of the customer's financial condition. In general, the Company does not require collateral from customers in connection with an extension of credit. The accounts receivable balance is reduced by an allowance for credit losses from the potential inability of the Company's customers to make required payments. The allowance for credit losses at September 30, 2024, and December 31, 2023, was \$0.9 million and \$1.4 million, respectively. The Company evaluates the historic loss experience on the accounts receivable balance and also considers separately customers with receivable balances that may be negatively impacted by current economic developments and market conditions. The estimate is a result of the Company's ongoing evaluation of collectability, customer creditworthiness, historical levels of credit losses and future expectations. The Company is subject to risks common to emerging companies in the medical device industry, including, but not limited to: new technological innovations; acceptance and competitiveness of its products; dependence on key personnel; dependence on key suppliers; its ability to maintain its third-party collaboration, license and joint development partners, and enter into new relationships; changes in general economic conditions and interest rates; its ClearPoint Neuro, Inc. Notes to Condensed Consolidated Financial Statements (Unaudited) ability to obtain additional funding to support its business; regulatory uncertainty; protection of proprietary technology; compliance with changing government regulations; uncertainty of widespread market acceptance of products; access to credit for capital purchases by customers; and intellectual property and product liability claims. Certain components used in manufacturing have relatively few alternative sources of supply and establishing additional or replacement suppliers for such components cannot be accomplished quickly. The inability of any of these suppliers to fulfill the Company's supply requirements may negatively impact future operating results. Recent Accounting Standards Not Yet Adopted In November 2023, the FASB issued ASU 2023-07, "Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures." The amendments improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. In addition, the amendments enhance interim disclosure requirements, clarify circumstances in which an entity can disclose multiple segment measures of profit or loss, provide new segment disclosure requirements for entities with a single reportable segment, and contain other disclosure requirements. ASU 2023-07 is effective for calendar year-end public business entities in 2024 annual reporting and in 2025 interim reporting. Early adoption is permitted. The Company expects to adopt ASU 2023-07 retrospectively in its 2024 annual financial reporting and its 2025 interim financial reporting, and is currently evaluating the impact of this ASU on its consolidated financial statements. In December 2023, the FASB issued ASU 2023-09, "Improvements to Income Tax Disclosures," which requires that an entity, on an annual basis, disclose additional income tax information, primarily related to the rate reconciliation and income taxes paid. The provisions of the ASU are intended to enhance the transparency and decision usefulness of income tax disclosures. The guidance may be applied on a prospective basis with the option to apply the standard retrospectively and is effective for calendar year-end public business entities in the 2025 annual period and in 2026 for interim periods with early adoption permitted. The Company is currently evaluating the impact of this ASU on its consolidated financial statements.

Revenue Recognition	Revenue by Service Line	Three Months Ended	September 30, (in thousands)	
Biologics and drug delivery	Disposables	\$2,062A	\$455A	
Services and license fees	2,369A	3,032A	Subtotal	
Biologics and drug delivery	revenue	4,431A	3,487A	
Neurosurgery navigation and therapy	Disposables	\$2,860A	1,874A	
Services	444A	Subtotal	4,704A	
Neurosurgery navigation and therapy	revenue	2,860A	1,918A	
Capital equipment and software	Systems and software	products	552A	
Services	279A	276A	Subtotal	831A
Capital equipment and software	revenue	552A	831A	
Systems and software	revenue	831A	357A	
Total revenue	\$8,122A	\$5,762A	12	
ClearPoint Neuro, Inc. Notes to Condensed Consolidated Financial Statements (Unaudited)	Nine Months Ended	September 30, (in thousands)	2024	
Biologics and drug delivery	Disposables	\$4,286A	\$1,395A	
Services and license fees	8,779A	8,136A	Subtotal	13,065A
Biologics and drug delivery	revenue	4,286A	1,395A	
Neurosurgery navigation and therapy	Disposables	products	7,373A	5,550A
Services	2,944A	432A	Subtotal	10,317A
Neurosurgery navigation and therapy	revenue	7,373A	5,550A	
Capital equipment and software	revenue	3,181A	1,134A	
Total revenue	\$23,619A	\$17,145A	Contract Balances	Contract assets

The timing of revenue recognition may differ from the time of billing to the Company's customers. In most cases, customers are billed upon shipment of such products or delivery of such services and the related contract assets, which represent an unconditional right to consideration, comprise the accounts receivable balance. When revenue is recognized in advance of its right to bill and receive consideration, the Company records this unbilled receivable as a contract asset, which is classified as other current assets in the accompanying condensed consolidated balance sheets. September 30, 2024 December 31, 2023 (in thousands) Accounts receivable, net \$3,875A \$3,211A Other contract assets Unbilled receivables \$662A \$733A Contract liabilities Contract liabilities consist of amounts that have been invoiced and for which the Company has the right to bill, but that have not been recognized as revenue as the related goods or services have not been transferred. The Company's contract liabilities are generally comprised of the following: (1) capital equipment and software-related service fees that are typically billed and collected at the inception of the service agreements, which have terms ranging from one to three years; (2) annual fees for agreements with customers that bundle the capital equipment and software-related service fees with software and hardware upgrades that are made commercially available over the term of the contract; and (3) up-front payments from customers made in connection with consulting services. The unearned portion of all such fees is classified as deferred revenue. September 30, 2024 December 31, 2023 (in thousands) Deferred revenues \$1,732A \$3,154A During the three and nine months ended September 30, 2024, the Company recognized approximately \$0.2 million and \$2.2 million of revenue, respectively, which was previously included in deferred revenue in the accompanying condensed consolidated balance sheet at December 31, 2023. Transaction price allocated to remaining performance obligations represents contracted revenue that has not yet been recognized, which includes deferred revenue that will be recognized as revenue in future periods. The majority of the remaining performance obligations relate to capital equipment and software-related service agreements and the upfront 13 ClearPoint Neuro, Inc. Notes to Condensed Consolidated Financial Statements (Unaudited) payments discussed under the heading "Contract Liabilities" above, which amounted to approximately \$1.7 million at September 30, 2024. The Company expects to recognize 71% of this revenue over the next twelve months and the remainder thereafter. 4. Fair Value Measurement Fair value measurements are based on a three-tier hierarchy that prioritizes the inputs used to measure fair value. These tiers include: Level 1, defined as observable inputs such as quoted market prices in active markets; Level 2, defined as inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly; and Level 3, defined as unobservable inputs for which little or no market data exists, therefore requiring an entity to develop its own assumptions. The fair value of cash and cash equivalents of \$21.6 million and \$23.1 million as of September 30, 2024, and December 31, 2023, respectively, is derived using Level 1 inputs. The cash equivalents are comprised of short-term bank deposits, money market funds, and U.S. Government debt securities with original maturities of three months or less, and the carrying value is a reasonable estimate of fair value. 5. Inventory Inventory consists of the following as of September 30, 2024 and December 31, 2023. (in thousands) September 30, 2024 December 31, 2023 Raw materials and work in process \$5,591A \$6,466A Software licenses 1,742A 2,111A Finished goods 1,294A 1,234A Inventory, net, included in current assets \$7,059A 7,911A Software licenses non-current 1,98A 386A Total \$7,257A \$8,297A 6. Note Payable In January 2020, the Company completed a financing transaction with two investors (the "2020 Convertible Noteholders"), whereby the Company issued an aggregate principal amount of \$17.5 million of secured convertible notes (the "First Closing Notes") pursuant to the SPA, which, unless earlier converted or redeemed, were to mature on January 29, 2025, and bore interest at a rate equal to the sum of (i) the greater of (a) the three (3)-month Secured Overnight Financing Rate ("SOFR") and (b) two percent (2%), plus (ii) a margin of 2% on the outstanding balance of the First Closing Notes, payable quarterly on the first business day of each calendar quarter. The First Closing Notes were convertible at a price of \$6.00 per share, subject to certain adjustments set forth in the SPA and the note agreement, and could not be pre-paid without the consent of the noteholder. In May 2021, one of the 2020 Convertible Noteholders (the "Converting Noteholder") converted the entire \$7.5 million principal amount of such Converting Noteholder's First Closing Note, and related accrued interest of approximately \$0.04 million, into 1,256,143 shares of the Company's common stock. In December 2020, the Company issued the Second Closing Note (as defined in the SPA) to one of the 2020 Convertible Noteholders in an aggregate principal amount of \$7.5A million. In November 2021, the holder of the Second Closing Note converted the entire \$7.5A million principal amount of such note, along with related accrued and payment in-kind interest aggregating \$0.3A million, into 773,446 shares of the Company's common stock. On August 23, 2024, the Company repaid all amounts owing under the remaining First Closing Note, which included the principal amount of \$10A million, and related accrued interest of \$0.1A million. In connection with the prepayment, the noteholder waived all prohibitions on prepayment of the note, and all collateral securing the note was released. 14 ClearPoint Neuro, Inc. Notes to Condensed

Consolidated Financial Statements(Unaudited)7.LeasesThe Company subleases office space in Solana Beach, California, that serves as its corporate headquarters and houses certain management and personnel. The sublease term commenced on December 15, 2020, is set to expire on December 31, 2026, and is renewable for an additional five-year period, at the Company's option, provided that the Company's landlord has entered into an extension of its prime lease for the office space that encompasses the Company's office space for at least five years. The Company leases space in Carlsbad, California, that serves as office space and a manufacturing facility under a lease that commenced on June 1, 2023 and ends on May 31, 2033. The Company has two options to extend the lease term for thirty-six or sixty months, at the then fair market rental value. Upon establishment of the new manufacturing facility in Carlsbad, the Company terminated its prior manufacturing facility lease in Irvine, California, effective October 2023. The lease termination did not have a material impact to the financial statements. The aforementioned leases are classified as operating leases in conformity with GAAP. The aggregate lease costs, included in general and administrative expense, were \$0.2 million for each of the three months ended September 30, 2024 and 2023, and \$0.7 million and \$0.5 million for the nine months ended September 30, 2024 and 2023, respectively.8.Stockholders' Equity2024 Public OfferingIn March 2024, the Company completed a public offering of 2,653,848 shares of its common stock, composed of 2,307,694 shares of common stock offered at a public offering price of \$6.50 per share and an additional 346,154 shares of common stock sold pursuant to the exercise of the underwriters' option to purchase additional shares at the public offering price. Net proceeds from the offering totaled approximately \$16.2 million after deducting underwriting discounts and commissions, and other offering expenses paid by the Company. The underwriting agreement contains representations, warranties, agreements and indemnification obligations by the Company that are customary for this type of transaction. Equity Compensation PlansIn May 2024, the Company's stockholders approved the Fifth Amended and Restated 2013 Incentive Compensation Plan, which increased the number of shares of common stock available for awards under the plan by 1.95 million shares. The plan permits the issuance of options, restricted stock, restricted stock units and other awards to select 15 ClearPoint Neuro, Inc. Notes to Condensed Consolidated Financial Statements(Unaudited)employees, directors and consultants of the Company. The equity incentive plans are more fully described in Note 9 in the consolidated financial statements in the 2023 Form 10-K. Share-Based Compensation ExpenseThe Company records share-based compensation expense on a straight-line basis over the vesting periods of the related grants and recognizes forfeitures as they occur. The following table sets forth share-based compensation expense included in the condensed consolidated statements of operations: Three Months Ended September 30, (in thousands)20242023Cost of revenue\$31.4 \$26.6 Research and development461.4 357.4 Sales and marketing537.4 431.4 General and administrative875.4 770.4 Share-based compensation expense\$1,904.4 \$1,584.4 Nine Months Ended September 30, (in thousands)20242023Cost of revenue\$82.4 \$74.4 Research and development1,204.1 1,009.4 Sales and marketing1,482.4 1,277.4 General and administrative2,436.2 2,176.4 Share-based compensation expense\$5,204.4 \$4,536.4 Share-based compensation expense by type of share-based award is summarized below: Three Months Ended September 30, (in thousands)20242023Stock options\$151.4 \$233.4 RSAs and RSUs1,719.4 1,308.4 ESPP\$34.4 43.4 \$1,904.4 \$1,584.4 Nine Months Ended September 30, (in thousands)20242023Stock options\$554.4 \$747.4 RSAs and RSUs\$4,495.4 3,612.4 ESPP\$155.4 177.4 \$5,204.4 \$4,536.4 Total unrecognized compensation expense by type of award and the weighted-average remaining requisite holding period over which such expense is expected to be recognized is as follows (in thousands, unless otherwise noted): 16 ClearPoint Neuro, Inc. Notes to Condensed Consolidated Financial Statements(Unaudited)September 30, 2024Unrecognized ExpenseRemaining Weighted-Average Recognition Period (in years)Stock options\$446.1 1.13RSAs and RSUs\$9,548.1 1.85Stock Option ActivityStock option activity during the nine months ended September 30, 2024 is summarized below: Stock OptionsWeighted-averageExercise price per shareWeighted-averageRemaining Contractual Life (in years)Intrinsic Value(1) (in thousands)Outstanding at December 31, 20231,478,157\$ 8.40A Exercised(12,000)\$2.89A Forfeited or expired(7,237)\$42.19A Outstanding at September 30, 20241,458,920A \$8.28A 4.74\$8,187A Exercisable at September 30, 20241,328,249A \$8.19A 4.40\$7,911A Vested and expected to vest at September 30, 20241,458,920A \$8.28A 4.74\$8,187A 17 ClearPoint Neuro, Inc. Notes to Condensed Consolidated Financial Statements(Unaudited)(1) Intrinsic value is calculated as the estimated fair value of the Company's stock at the end of the related period less the option exercise price of in-the-money options. Restricted Stock Award ActivityRestricted stock award ("RSA") activity for the nine months ended September 30, 2024 is summarized below: Restricted Stock AwardsWeighted - Average Grant Date Fair ValueOutstanding at December 31, 2023376,914A \$12.02A Vested(195,173)\$12.93A Forfeited(6,019)\$12.35A Outstanding at September 30, 2024175,722A \$10.99A Restricted Stock Unit ActivityRestricted stock unit ("RSU") activity for the nine months ended September 30, 2024 is summarized below: Restricted Stock UnitsWeighted - Average Grant Date Fair ValueOutstanding at December 31, 2023768,139A \$8.15A Granted1,197,646A \$6.16A Vested(267,328)\$7.99A Forfeited(17,849)\$8.40A Outstanding at September 30, 20241,680,608A \$6.75A ESPPOn June 3, 2021, the Company's common stock through payroll deductions at a discount to market price. A total of 400,000 shares of the Company's common stock were made available for issuance pursuant to the terms of the ESPP. Each offering period is for six months, and the first offering period commenced on July 1, 2021. During the first offering period of 2024, 62,800 shares were purchased at an average per share price of \$4.58. 18 ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. The following discussion and analysis of our financial condition and results of operations should be read together with our unaudited Condensed Consolidated Financial Statements and the related notes thereto appearing in Part I, Item 1 of this Quarterly Report. This discussion and analysis contains forward-looking statements that are based upon current expectations and involve risks, assumptions and uncertainties. You should review the section titled "Risk Factors" appearing in the 2023 Form 10-K and in Part II, Item 1.A of this Quarterly Report for a discussion of important risk factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements described in the following discussion and analysis. In addition, historical results and trends that might appear in this Quarterly Report should not be interpreted as being indicative of future operations. Overview We are a commercial-stage medical device company that develops and commercializes innovative platforms for performing minimally invasive surgical procedures in the brain. We have deployed significant resources to fund our efforts to develop the capabilities for enabling neurosurgery interventions, building an intellectual property portfolio, and identifying and building out commercial applications for the technologies developed by our company. The foundational part of our business is providing medical devices for neurosurgery applications. Our primary medical device product, the ClearPoint system, is an integrated system comprised of hardware components, disposable components, and intuitive, menu-driven software, which is in commercial use globally. The primary applications for the ClearPoint system are to target and guide the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the delivery of pharmaceuticals into the brain. The ClearPoint system was originally designed for use in an MRI setting. In 2021, we launched the SmartFrame Array Neuro Navigation System and Software, which allow for operating room placement of the ClearPoint system, and in 2024, we released the SmartFrame OR Stereotactic System, which allows for complete procedures to be performed in the operating room. In 2022, we commercialized the ClearPoint Prism Neuro Laser Therapy System as our first therapy product offering. We have exclusive global commercialization rights to the ClearPoint Prism Neuro Laser Therapy System through our Swedish partner, CLS. The second part of our business is focused on partnerships in the biologics and drug delivery space. Our services include protocol consultation and solutions for preclinical study design and execution for the delivery of pharmaceutical agents to the brain. We also partner with customers to develop devices used for administration of therapies into the central nervous system. Currently, we have more than 50 biologics and drug delivery customers who are evaluating or using our products and services in trials to inject gene and cell therapies directly into the brain. These partnerships involve drug development programs that are at various stages of development ranging from preclinical research to late-stage regulatory trials for multiple distinct disease states. This part of our business potentially represents the largest opportunity for growth; however, our ability to grow in this market is dependent on our ability to maintain and establish new relationships with customers, such as customers' continuation of research and development plans, and such customers' achievement of success in completion of clinical trials and subsequent regulatory approvals of their biologics and drugs. Substantially all our revenue for the three and nine months ended September 30, 2024 and 2023 relates to (i) sales of our ClearPoint system products and related services and (ii) providing services to our customers in the biologics and drug delivery space. We have financed our operations and internal growth primarily through the sale of equity securities and the issuance of notes payable. We have incurred significant losses since our inception in 1998 as we have devoted substantial efforts to research and development. As of September 30, 2024, we had accumulated losses of \$186.0 million. We may continue to incur operating losses as we expand our ClearPoint system platform, services to our pharmaceutical and other medical technology customers, and our business generally. Factors Which May Influence Future Results of Operations The following is a description of factors that may influence our future results of operations, and that we believe are important to an understanding of our business and results of operations. Macroeconomic Trends We continue to monitor the impact of various macroeconomic trends, such as global economic and supply chain disruptions, geopolitical instability (including instability resulting from military conflicts), labor shortages, inflationary conditions, and legislative and political developments. Impacts from inflationary pressures, such as increasing costs for research and development of our products, administrative and other costs of doing business, and our access to capital markets and other sources of funding in the future could adversely affect our business, financial condition and results of operations. Additionally, these trends could adversely affect our customers, which could impact their willingness to spend on our products and services, or their ability to make payment, which could harm the Company's collection of accounts receivable and financial results. The continued development and fluidity of these situations precludes any prediction as to the ultimate impact they will have on our business, financial condition, results of operation and cash flows. Revenue In 2010, we received 510(k) clearance from the U.S. Food and Drug Administration (the "FDA") to market our ClearPoint system in the U.S. for general neurosurgical procedures; in February 2011 and May 2018, we also obtained CE marking for our ClearPoint system and SmartFlow cannula, respectively; and in June 2020, we obtained CE marking for version 2.0 of our ClearPoint software and our Inflexion head fixation frame. In January 2021, we received 510(k) clearance for the SmartFrame Array Neuro Navigation System. In September 2022, the ClearPoint Prism Neuro Laser Therapy System, for which we have exclusive global rights to commercialize, received 510(k) clearance through our Swedish partner, CLS. The Prism laser represents the first therapy product we have commercialized. In January 2024, we received 510(k) clearance from the FDA for the SmartFrame OR Stereotactic System. In 2021, we started providing services to our pharmaceutical and other medical technology customers for improving outcome predictability and optimizing preclinical and clinical workflows. Our expertise is concentrated in benchtop testing, preclinical studies, clinical trial support, regulatory consultation, and over-arching translation from the preclinical to the clinical setting to enhance accuracy and precision of drug delivery. In 2024, we expanded our services to our pharmaceutical and other medical technology customers to include development of devices used for administration of therapies into the central nervous system. Future revenue from sales of products and services is difficult to predict and may not be sufficient to offset our continuing research and development expenses and selling, general and administrative expenses. Generating recurring revenue from the sale of products is an important part of our business model for our ClearPoint system. Our product revenue was approximately \$5.5 million and \$14.1 million for the three and nine months ended September 30, 2024, respectively. Our service and other revenue was approximately \$2.6 million and \$9.6 million for the three and nine months ended September 30, 2024, respectively, of which 89% and 92%, respectively, is related to the biologics and drug delivery service line. Our revenue recognition policies are more fully described in Note 2 to the Condensed Consolidated Financial Statements included above in Part I, Item 1 in this Quarterly Report. Underlying the revenue from sales of products and services to our biologics and drug delivery customers is the number of direct customers and end users of our products and/or services ("Partners"). Our Partners consist of pharmaceutical and biotech companies, academic institutions, and customer-sponsored contract research organizations that are developing methods to deliver a wide variety of molecules, genes or proteins to targeted brain tissue or structures that would need to bypass the blood-brain barrier for the treatment of a variety of disorders. This is a novel area in which commercialization must be preceded by FDA-mandated clinical trials, which are expensive and time consuming to conduct, and for which the commercial success is uncertain, pending, in part, the outcome of those trials. While our revenue from sales of products and services to our biologics and drug delivery customers is indicative of growth, the number of Partner relationships is also of importance as we recognize the possibility that some Partners' research will reach commercial success, and others may not. To the extent our Partners achieve commercial success, our expectation is that we will share in such success through our Partners' use of our products and services in their delivery of therapies. At September 30, 2024, we had more than 50 Partners, which is similar to the number of Partners as of the same date in 2023. Cost of Revenue Cost of revenue includes the direct costs associated with the assembly and purchase of components for neurosurgery navigation products, biologics and drug delivery products, non-neurosurgery therapy products, and ClearPoint capital equipment and software that we have sold, and for which we have recognized the revenue in accordance with our revenue recognition policy, as well as labor hours and materials for the cost of providing preclinical, consulting, and service revenue. Cost of revenue also includes the allocation of manufacturing overhead costs and depreciation of loaned systems installed under our ClearPoint placement program, as well as provisions for obsolete, impaired, or excess inventory. Research and Development Costs Our research and development costs consist primarily of costs associated with the conceptualization, design, testing, and prototyping of our ClearPoint system products and enhancements. Such costs include salaries, travel, and benefits for research and development personnel; materials and laboratory supplies in research and development activities; outside consultant costs; and licensing costs related to technology not yet commercialized. We anticipate that, over time, our research and development costs may increase as we: (i) develop devices and services for delivery of therapeutics into the central nervous system; (ii) expand products into the operating room and therapeutics space; and (iii) expand the application of our technological platforms internationally. Product development timelines, likelihood of success, and total costs can vary widely by product candidate. There are also risks inherent in the regulatory clearance and approval process. At this time, we are unable to estimate with any certainty the costs that we will incur in our efforts to expand the application of our technological platforms. Sales and Marketing, and General and Administrative Expenses Our sales and marketing, and general and administrative expenses consist primarily of salaries, incentive-based compensation, travel and benefits, including share-based compensation; marketing costs; professional fees, including fees for outside attorneys and accountants; occupancy costs; insurance; and other general and administrative expenses, which include, but are not limited to, corporate licenses, director fees, hiring costs, taxes, postage, office supplies, information technology and meeting costs. Our sales and marketing expenses are expected to continue to increase due to costs associated with the continued commercialization of our products and services and the increased headcount necessary to support growth in operations. Critical Accounting Policies and Estimates There have been no significant changes in our critical accounting policies and estimates during the nine months ended September 30, 2024, as compared to the critical accounting policies and estimates described in our 2023 Form 10-K. Results of Operations Three Months Ended September 30, 2024, Compared to the Three Months Ended September 30, 2023 Three Months Ended September 30, (Dollars in thousands) 2024 2023 Percentage Change Product revenue \$5,474.4 \$2,410.4 127.4 % Service and other revenue 2,648.4 3,352.4 (21.1) % Total revenue 8,122.8 5,762.4 41.4 % Cost of revenue 3,275.4 2,489.4 32.4 % Gross profit 4,847.4 3,273.4 48.4 % Research and development costs 3,315.4 2,429.4 36.4 % Sales and marketing expenses 3,549.4 2,841.4 25.4 % General and administrative expenses 3,155.4 2,900.4 9.4 % Other income (expense) 1.4 0.4 250.0 % Net loss \$ (4,974.4) \$ (4,809.3) % Net loss \$ (4,974.4) \$ (4,809.3) % NM % The percentage change is not meaningful. 21 Revenue Total revenue was \$8.1 million for the three months ended September 30, 2024, and \$5.8 million for the three months ended September 30, 2023, which represents an increase of \$2.4 million, or 41%. Three Months Ended September 30, (Dollars in thousands) 2024 2023 Percentage Change Biologics and drug delivery Disposable products \$2,062.4 \$455.4 353.4 % Services and license fees 2,369.4 3,032.4 (22.1) % Subtotal Biologics and drug delivery revenue 4,431.8 3,487.8 27.4 % Neurosurgery navigation and therapy Disposable products 2,860.4 1,874.4 53.4 % Services 444.4 (100.0) % Subtotal Neurosurgery navigation and therapy 2,860.4 1,918.4 49.4 % Capital equipment and software Systems and software products 552.8 814.4 31.8 % Services 279.4 276.4 1.1 % Subtotal Capital equipment and software revenue 831.6 357.4 133.4 % Total revenue 8,122.8 5,762.4 41.4 % Biologics and drug delivery revenue, which includes sales of services and disposable products related to customer-sponsored preclinical and clinical trials utilizing our products, increased 27% to \$4.4 million for the three months ended September 30, 2024, from \$3.5 million for the same period in 2023. Our overall revenue growth is attributable to a \$1.6 million increase in product revenue resulting from higher demand for disposables as multiple partners progress in their trials, partially offset

by a decrease of \$0.7 million in service and other revenue due to a reduction in the number of preclinical studies performed, during the three months ended September 30, 2024, compared to the same period in 2023. Neurosurgery navigation and therapy revenue, which primarily consists of disposable product commercial sales related to cases utilizing the ClearPoint system, increased 49% to \$2.9 million for the three months ended September 30, 2024, from \$1.9 million for the same period in 2023. The increase is driven by higher product revenue of \$1.0 million resulting from newly activated accounts, increased case count, and new product offerings, including the SmartFrame OR and Prism Laser Therapy, during the three months ended September 30, 2024, compared to the same period in 2023. Capital equipment and software revenue, consisting of sales of ClearPoint reusable hardware and software and related services, increased 133% to \$0.8 million for the three months ended September 30, 2024, from \$0.4 million for the same period in 2023 due to an increase in the placements of ClearPoint navigation capital equipment and software and Prism laser units. Cost of Revenue and Gross Profit. Cost of revenue was \$3.3 million, resulting in gross profit of \$4.8 million and gross margin of 60%, for the three months ended September 30, 2024, and was \$2.5 million, resulting in gross profit of \$3.3 million and gross margin of 57% for the three months ended September 30, 2023. The increase in gross margin was primarily due to lower costs for the three months ended September 30, 2024 due to the transition to the new manufacturing facility, occurring in 2023, and higher volumes for the three months ended September 30, 2024. Research and Development Costs. Research and development costs were \$3.3 million for the three months ended September 30, 2024, compared to \$2.4 million for the same period in 2023, an increase of \$0.9 million, or 36%. The increase was due primarily to higher personnel costs and product and software development costs, each in the amount of \$0.5 million, partially offset by lower trial costs of \$0.1 million. Sales and Marketing Expenses. Sales and marketing expenses were \$3.5 million for the three months ended September 30, 2024, compared to \$2.8 million for the same period in 2023, an increase of \$0.7 million, or 25%. This increase was due primarily to higher personnel costs, including share-based compensation, of \$0.6 million resulting from increases in headcount, and increased travel costs of \$0.1 million. General and Administrative Expenses. General and administrative expenses were \$3.2 million for the three months ended September 30, 2024, compared to \$2.9 million for the same period in 2023, an increase of \$0.3 million, or 9%. This increase was due primarily to higher personnel costs and share-based compensation of \$0.4 million, higher occupancy costs of \$0.2 million, and higher professional fees of \$0.1 million, partially offset by lower bad debt expense of \$0.5 million mainly as a result of subsequent recoveries. Interest Income (Expense). Net interest income was \$0.2 million for the three months ended September 30, 2024, compared to \$0.1 million for the same period in 2023, as a result of increased investment in U.S. Government debt securities stemming from the capital raise in March 2024 as well as lower interest expense due to the early repayment of the First Closing Note. Nine months ended September 30, 2024, compared to the Nine months ended September 30, 2023. Nine Months Ended September 30, (Dollars in thousands) 2024 2023 Percentage Change Product revenue \$14,053 \$7,377 90% Service and other revenue \$9,566 \$9,768 (2%) Total revenue \$23,619 \$17,145 38% Cost of revenue \$9,259 \$7,544 23% Gross profit \$14,360 \$9,601 50% Research and development costs \$9,060 \$9,057 (0%) Sales and marketing expenses \$10,673 \$9,248 15% General and administrative expenses \$8,769 \$9,036 (3%) Other income (expense) \$0 Other expense, net \$(32) (25) NM Interest income, net \$64 \$295 11% Net losses \$(13,528) \$(17,470) (23)% NM % The percentage change is not meaningful. Revenue. Total revenue was \$23.6 million for the nine months ended September 30, 2024, and \$17.1 million for the nine months ended September 30, 2023, which represents an increase of \$6.5 million, or 38%. Nine Months Ended September 30, (Dollars in thousands) 2024 2023 Percentage Change Biologics and drug delivery Disposable products \$4,286 \$1,395 207% Services and license fees \$8,779 \$8,136 8% Subtotal Biologics and drug delivery revenue \$13,065 \$9,531 37% Neurosurgery navigation and therapy Disposable products \$7,373 \$5,550 33% Services \$9,304 \$9,304 (100)% Subtotal Neurosurgery navigation and therapy \$17,373 \$14,480 20% Capital equipment and software Systems and software products \$3,944 \$3,244 21% Services \$787 \$702 12% Subtotal Capital equipment and software revenue \$4,181 \$4,180 0% Total revenue \$23,619 \$17,145 38% Biologics and drug delivery revenue, which includes sales of services and disposable products related to customer-sponsored preclinical and clinical trials utilizing our products, increased 37% to \$13.1 million for the nine months ended September 30, 2024, from \$9.5 million for the same period in 2023. Our overall revenue growth is attributable to a \$2.9 million increase in product revenue resulting from higher demand for disposables as multiple partners progress in their trials, and a \$0.6 million increase in service and other revenue related to new preclinical trials and service agreements entered into with our Partners during the nine months ended September 30, 2024, as compared to the same period in 2023. Neurosurgery navigation and therapy revenue, which primarily consists of disposable product commercial sales related to cases utilizing the ClearPoint system, increased 14% to \$7.4 million for the nine months ended September 30, 2024, from \$6.5 million for the same period in 2023. Product revenue increased 33%, or \$1.8 million, resulting from newly activated accounts, increased case count, and new product offerings, including the SmartFrame OR and Prism Laser Therapy, during the nine months ended September 30, 2024, compared to the same period in 2023. This was partially offset by a decrease in service and other revenue of \$0.9 million primarily as a result of pausing a co-development program with one of our Brain Computer Interface partners. Capital equipment and software revenue, consisting of sales of ClearPoint reusable hardware and software and related services, increased 180% to \$3.2 million for the nine months ended September 30, 2024, from \$1.1 million for the same period in 2023 due to an increase in the placements of ClearPoint navigation capital equipment and software and Prism laser units. Cost of Revenue and Gross Profit. Cost of revenue was \$9.3 million, resulting in gross profit of \$14.4 million and gross margin of 61%, for the nine months ended September 30, 2024, and was \$7.5 million, resulting in gross profit of \$9.6 million and gross margin of 56% for the nine months ended September 30, 2023. The increase in gross margin was primarily due to lower costs for the nine months ended September 30, 2024 due to the transition to the new manufacturing facility, occurring in 2023, and higher volumes for the nine months ended September 30, 2024. Research and Development Costs. Research and development costs were relatively flat at \$9.1 million for the nine months ended September 30, 2024 and 2023. Personnel costs, including share-based compensation, were higher for the nine months ended September 30, 2024 by \$0.7 million as compared to the same period in 2023. This was offset by lower product and software development costs of \$0.7 million as a result of reprioritization of certain research and development initiatives. Sales and Marketing Expenses. Sales and marketing expenses were \$10.7 million for the nine months ended September 30, 2024, compared to \$9.2 million for the same period in 2023, an increase of \$1.4 million, or 15%. This increase was due primarily to higher personnel costs, including share-based compensation, of \$1.1 million resulting from increases in headcount, and increased travel costs of \$0.3 million. General and Administrative Expenses. General and administrative expenses were \$8.8 million for the nine months ended September 30, 2024, compared to \$9.0 million for the same period in 2023, a decrease of \$0.3 million, or 3%. This decrease was due primarily to lower bad debt expense of \$1.4 million mainly as a result of subsequent recoveries, partially offset by higher personnel costs and share-based compensation of \$0.8 million and higher occupancy costs of \$0.3 million. Interest Income (Expense). Net interest income was \$0.6 million for the nine months ended September 30, 2024, compared to \$0.3 million for the same period in 2023, as a result of increased investment in U.S. Government debt securities stemming from the capital raise in March 2024 as well as lower interest expense due to the early repayment of the First Closing Note. Liquidity and Capital Resources. We have incurred net losses since our inception, which has resulted in a cumulative deficit at September 30, 2024 of \$186.0 million. In addition, our use of cash from operations amounted to \$7.7 million for the nine months ended September 30, 2024, and \$13.7 million for the year ended December 31, 2023. Since inception, we have financed our operations principally from the sale of equity securities and the issuance of notes payable. As discussed in Note 8, in March 2024, we completed a public offering of 2,653,848 shares of our common stock from which the net proceeds totaled approximately \$16.2 million after deducting our payment of underwriting discounts and commissions and other offering expenses. In August 2024, we repaid in full the remaining \$10 million outstanding under the SPA entered into in 2020, pursuant to which we issued secured convertible notes to two investors raising gross proceeds of \$25.4 million, of which \$15 million had been previously converted to common stock. See Note 6 to the Condensed Consolidated Financial Statements included above in Part I, Item 1 in this Quarterly Report for additional information with respect to the secured convertible notes. As a result of these transactions and our business operations, our cash and cash equivalents totaled \$21.6 million at September 30, 2024. In management's opinion, based on our current forecasts for revenue, expense and cash flows, our existing cash and cash equivalent balances at September 30, 2024, are sufficient to support our operations and meet our obligations for at least the next twelve months. Cash Flows. Cash activity for the nine months ended September 30, 2024 and 2023 is summarized as follows: Nine months ended September 30, (in thousands) 2024 2023 Cash used in operating activities \$(7,707) \$(12,551) Cash (used in) provided by investing activities (12) 9,137 Cash provided by financing activities 6,152 1,414 Net change in cash and cash equivalents \$(1,567) \$(3,273) Net Cash Flows from Operating Activities. Net cash flows used in operating activities for the nine months ended September 30, 2024, were \$7.7 million, a decrease of \$4.8 million from the nine months ended September 30, 2023. This decrease was due to a lower net loss of \$3.9 million, and a net decrease in operating assets and liabilities of \$1.1 million, partially offset by a net decrease in non-cash items of \$0.2 million. The change in operating assets and liabilities is primarily due to higher accounts payable and accrued liabilities, partially offset by lower deferred revenue. The change in the non-cash items results primarily from recoveries in the allowance for credit losses, partially offset by higher share-based compensation expense. Net Cash Flows from Investing Activities. Net cash flows used in investing activities for the nine months ended September 30, 2024, were nominal and related to equipment acquisitions. Net cash flows provided by investing activities for the nine months ended September 30, 2023, were \$9.1 million and consisted of proceeds from the maturities of short-term investments, partially offset primarily by equipment acquisitions related to our new manufacturing site in Carlsbad, California. Net Cash Flows from Financing Activities. Net cash flows provided by financing activities for the nine months ended September 30, 2024, consisted of proceeds, net of offering costs, of \$16.2 million received from the public offering of our common stock and \$0.3 million in proceeds from the issuance of common stock under the employee stock purchase plan. This is partially offset by the repayment of the 2020 secured convertible note of \$10.0 million and payments of \$0.3 million for taxes related to shares withheld in connection with the vesting of restricted stock awards. Net cash flows provided by financing activities for the nine months ended September 30, 2023, consisted of proceeds from the issuance of common stock under the employee stock purchase plan, partially offset by payments for taxes related to shares withheld in connection with the vesting of restricted stock awards. Operating Capital and Capital Expenditure Requirements. To date, we have not achieved profitability. We could continue to incur net losses as we continue our efforts to expand the commercialization of our products and services and pursue additional applications for our technology platforms. Our cash balances are primarily held in a variety of demand accounts with a view to liquidity and capital preservation. Because of the numerous risks and uncertainties associated with the development and commercialization of medical devices, we are unable to estimate the exact amounts of capital outlays and operating expenditures necessary to successfully commercialize our products and pursue additional applications for our technology platforms. Our future capital requirements will depend on many factors, including, but not limited to, the following: the ability of our Partners to achieve commercial success, including their use of our products and services in their preclinical studies, clinical trials and delivery of therapies; the ultimate duration and impact of macroeconomic trends, including inflationary pressures, supply chain disruptions, geopolitical instability (including military conflicts), and legislative and political developments; the ability to maintain our existing relationships with our Partners and to enter into new relationships; the timing of broader market acceptance and adoption of our products; the scope, rate of progress and cost of our ongoing product development activities relating to our products; the cost and timing of expanding our sales, clinical support, marketing and distribution capabilities, and other corporate infrastructure; the cost and timing of establishing inventories at levels sufficient to support our sales; the effect of competing technological and market developments; the cost of pursuing additional applications of our technology platforms under current collaborative arrangements, and the terms and timing of any future collaborative, licensing or other arrangements that we may establish; the cost and timing of any clinical trials; the cost and timing of regulatory filings, clearances and approvals; and the cost of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights. 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK. Interest Rate Risk. Our exposure to market risk is limited primarily to interest income and expense sensitivity, which is affected by changes in the general level of U.S. interest rates. Our investments are in short-term bank deposits, short-term U.S. Government debt securities, and institutional money market funds. The primary objective of our investment activities is to preserve principal while at the same time maximizing the income we receive without significantly increasing risk. In the event we invest in short-term investments, due to the nature of our short-term investments and the Company's intent to hold such debt securities to maturity, we believe that we are not subject to any material market risk exposure. Foreign Currency Risk. To date, we have not recorded a significant amount of sales in currencies other than U.S. dollars, and have only limited business transactions in foreign currencies. We do not currently engage in hedging or similar transactions to reduce our foreign currency risks, which at present, are not material. We do not believe we have material exposure to risk from changes in foreign currency exchange rates at this time. We will continue to monitor and evaluate our internal processes relating to foreign currency exchange, including the potential use of hedging strategies. 4. CONTROLS AND PROCEDURES. Disclosure Controls and Procedures. We have established disclosure controls and procedures, as such term is defined in Rule 13a-15(e) under the Securities Exchange Act of 1934 (the "Exchange Act"). Our disclosure controls and procedures are designed to ensure that material information relating to us is made known to our principal executive officer and principal financial officer by others within our organization. Under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, we conducted an evaluation of the effectiveness of our disclosure controls and procedures as of September 30, 2024 to ensure that the information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC's rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our principal executive officer and principal financial officer as appropriate, to allow timely decisions regarding required disclosure. Based on this evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective as of September 30, 2024. Changes in Internal Control Over Financial Reporting. During the quarter ended September 30, 2024, there were no changes in our internal control over financial reporting that materially affected, or that are reasonably likely to materially affect, our internal control over financial reporting. 27 PART II 6. OTHER INFORMATION. 1. A. LEGAL PROCEEDINGS. We are involved from time-to-time with various legal matters arising in the ordinary course of business. These claims and legal proceedings are of a nature we believe are normal and incidental to a medical device company, and may include product liability, intellectual property, employment matters, and other general claims. We make provisions for liabilities when it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Such provisions are assessed at least quarterly and adjusted to reflect the impact of any settlement negotiations, judicial and administrative rulings, advice of legal counsel, and other information and events pertaining to a particular case. We are currently not aware of any such legal proceedings or claim that we believe will have, individually or in the aggregate, a material adverse effect on our consolidated results of operations, cash flows, or financial condition. 10. A. RISK FACTORS. There have been no material changes to the risk factors as disclosed in the 2023 Form 10-K. 2. A. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS. None. 3. A. DEFAULTS UPON SENIOR SECURITIES. None. 4. A. MINE SAFETY DISCLOSURES. None. 5. A. OTHER INFORMATION. Not applicable. Without limiting the generality of the foregoing, during the quarter ended September 30, 2024, no director or Section 16 officer adopted or terminated any Rule 10b5-1 or non-Rule 10b5-1 trading arrangements, as defined in Item 408(a) of Regulation S-K. 28 ITEM 6. A. EXHIBITS. The exhibits listed below are filed, furnished, or incorporated by reference as part of this Quarterly Report. Exhibit Number Exhibit Description. 1. Amended and Restated Certificate of Incorporation of MRI Interventions, Inc. (incorporated by reference to Exhibit 3.1 to the Company's Quarterly Report on Form 10-Q, filed with the SEC on May 11, 2012). 3.2 Certificate of Amendment to the Amended and Restated Certificate of Incorporation of MRI Interventions, Inc. (incorporated by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K, filed with the SEC on June 8, 2015). 3.3 Certificate of Amendment to the Amended and Restated Certificate of Incorporation of MRI Interventions, Inc. (incorporated by reference to Exhibit 3.3 to the Company's Registration Statement on Form S-1, filed with the SEC on August 2, 2016). 3.4 Certificate of Amendment to the Amended and Restated Certificate of Incorporation of ClearPoint Neuro, Inc. (incorporated by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K, filed with the SEC on February 12, 2020). 3.5 Certificate of Amendment to the Amended and Restated Certificate of Incorporation of ClearPoint Neuro, Inc.

(incorporated by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K filed with the SEC on May 25, 2023), 3.6Fourth Amended and Restated Bylaws of ClearPoint Neuro, Inc. (incorporated by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K filed with the SEC on December 14, 2022), 31.1\*Certification of Chief Executive Officer Pursuant to Rule 13a-14(a) Under the Securities Exchange Act of 1934, 31.2\*Certification of Chief Financial Officer Pursuant to Rule 13a-14(a) Under the Securities Exchange Act of 1934, 31.3\*Certification of Chief Executive Officer and Chief Financial Officer Pursuant to Rule 13a-14(b) under the Securities Exchange Act of 1934 and Section 1350 of Chapter 60 of Title 18 of the United States Code, 101.INSMXBRL Instance, 101.SCHXBRL Taxonomy Extension Schema, 101.CALXBRL Taxonomy Extension Schema, 101.DEFXBRL Taxonomy Extension Definition, 101.LABXBRL Taxonomy Extension Labels, 101.PREXBRL Taxonomy Extension Presentation, 104\*Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)\*Filed herewith. +A A A This certification is being furnished solely to accompany this Quarterly Report pursuant to 18 U.S.C. Section 1350, and it is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934 and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing. 2SIGNATURESPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Date: November 7, 2024CLEARPOINT NEURO, INC. By: /s/ Joseph M. Burnett Joseph M. Burnett Chief Executive Officer (Principal Executive Officer) By: /s/ Danilo Dac Alessandro Danilo Dac Alessandro Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer) 30 EX-31.1 2 clpt-20240930xex311.htm EX-31.1 Document Exhibit 31.1 CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO RULE 13a-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, Joseph M. Burnett, certify that: 1.I have reviewed this quarterly report on Form 10-Q for the quarter ended September 30, 2024, of ClearPoint Neuro, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 4. The registrant is not the sole certifying officer(s) and I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: (a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; (b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; (c) evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and (d) disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and 5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): (a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and (b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. Date: November 7, 2024/s/ Joseph M. Burnett Joseph M. Burnett Chief Executive Officer EX-31.2 3 clpt-20240930xex312.htm EX-31.2 Document Exhibit 31.2 CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO RULE 13a-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, Danilo Dac Alessandro, certify that: 1.I have reviewed this quarterly report on Form 10-Q for the quarter ended September 30, 2024, of ClearPoint Neuro, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 4. The registrant is, our other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: (a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; (b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; (c) evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and (d) disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and 5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): (a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and (b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. Date: November 7, 2024/s/ Danilo Dac Alessandro Danilo Dac Alessandro Chief Financial Officer EX-32 4 clpt-20240930xex32.htm EX-32 Document Exhibit 32 CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER PURSUANT TO RULE 13a-14(b) UNDER THE SECURITIES EXCHANGE ACT OF 1934 AND SECTION 1350 OF CHAPTER 63 OF TITLE 18 OF THE UNITED STATES CODE Each of the undersigned, Joseph M. Burnett and Danilo Dac Alessandro, certifies pursuant to Rule 13a-14(b) under the Securities Exchange Act of 1934 and Section 1350 of Chapter 63 of Title 18 of the United States Code, that (1) this quarterly report on Form 10-Q for the quarter ended September 30, 2024, of ClearPoint Neuro, Inc. (the "Company") fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934, and (2) the information contained in this quarterly report fairly presents, in all material respects, the financial condition and results of operations of the Company. Date: November 7, 2024/s/ Joseph M. Burnett Joseph M. Burnett Chief Executive Officer /s/ Danilo Dac Alessandro Danilo Dac Alessandro Chief Financial Officer EX-101.SCH 5 clpt-20240930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link: presentationLink link: calculationLink link: definitionLink link: definitionLink 9952151 - Statement - Condensed Consolidated Balance Sheets link: presentationLink link: calculationLink link: definitionLink link: definitionLink 9952152 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link: presentationLink link: calculationLink link: definitionLink link: definitionLink 9952153 - Statement - Condensed Consolidated Statements of Operations link: presentationLink link: calculationLink link: definitionLink link: definitionLink 9952154 - Statement - Condensed Consolidated Statements of Stockholders' Equity link: presentationLink link: calculationLink link: definitionLink link: definitionLink 9952155 - Statement - Condensed Consolidated Statements of Cash Flows link: presentationLink link: calculationLink link: definitionLink link: definitionLink 9952156 - Statement - Condensed Consolidated Statements of Cash Flows (Parenthetical) link: presentationLink link: calculationLink link: definitionLink link: definitionLink 9952157 - Disclosure - Description of the Business and Financial Condition link: presentationLink link: calculationLink link: definitionLink link: definitionLink 9952158 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies link: presentationLink link: calculationLink link: definitionLink link: definitionLink 9952159 - Disclosure - Revenue Recognition link: presentationLink link: calculationLink link: definitionLink link: definitionLink 9952160 - Disclosure - Fair Value Measurement link: presentationLink link: calculationLink link: definitionLink link: definitionLink 9952161 - Disclosure - Inventory link: presentationLink link: calculationLink link: definitionLink link: definitionLink 9952162 - Disclosure - Note Payable link: presentationLink link: calculationLink link: definitionLink link: definitionLink 9952163 - Disclosure - Leases link: presentationLink link: calculationLink link: definitionLink link: definitionLink 9952164 - Disclosure - Stockholders' Equity link: presentationLink link: calculationLink link: definitionLink link: definitionLink 9954471 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies) link: presentationLink link: calculationLink link: definitionLink link: definitionLink 9954472 - Disclosure - Revenue Recognition (Tables) link: presentationLink link: calculationLink link: definitionLink link: definitionLink 9954473 - Disclosure - Inventory (Tables) link: presentationLink link: calculationLink link: definitionLink link: definitionLink 9954474 - Disclosure - Stockholders' Equity (Tables) link: presentationLink link: calculationLink link: definitionLink link: definitionLink 9954475 - Disclosure - Description of the Business and Financial Condition (Details) link: presentationLink link: calculationLink link: definitionLink link: definitionLink 9954477 - Disclosure - Revenue Recognition - Schedule of Revenue by Service Line (Details) link: presentationLink link: calculationLink link: definitionLink link: definitionLink 9954478 - Disclosure - Revenue Recognition - Schedule of Other Current Assets (Details) link: presentationLink link: calculationLink link: definitionLink link: definitionLink 9954479 - Disclosure - Revenue Recognition - Narrative (Details) link: presentationLink link: calculationLink link: definitionLink link: definitionLink 9954480 - Disclosure - Revenue Recognition - Schedule of Revenue Recognized by Contract Liability (Details) link: presentationLink link: calculationLink link: definitionLink link: definitionLink 9954481 - Disclosure - Fair Value Measurement (Details) link: presentationLink link: calculationLink link: definitionLink link: definitionLink 9954482 - Disclosure - Inventory - Schedule of Inventory (Details) link: presentationLink link: calculationLink link: definitionLink link: definitionLink 9954483 - Disclosure - Note Payable - (Details) link: presentationLink link: calculationLink link: definitionLink link: definitionLink 9954484 - Disclosure - Leases (Details) link: presentationLink link: calculationLink link: definitionLink link: definitionLink 9954485 - Disclosure - Stockholders' Equity - Narrative (Details) link: presentationLink link: calculationLink link: definitionLink link: definitionLink 9954486 - Disclosure - Stockholders' Equity - Schedule of Share Based Compensation Expense (Details) link: presentationLink link: calculationLink link: definitionLink link: definitionLink 9954487 - Disclosure - Stockholders' Equity - Schedule of Unrecognized Compensation Expense and Weighted-Average Requisite Period (Details) link: presentationLink link: calculationLink link: definitionLink link: definitionLink 9954488 - Disclosure - Stockholders' Equity - Schedule of Stock Option Activity (Details) link: presentationLink link: calculationLink link: definitionLink link: definitionLink 9954489 - Disclosure - Stockholders' Equity - Schedule of Restricted Stock Activity (Details) link: presentationLink link: calculationLink link: definitionLink link: definitionLink EX-101.CAL 6 clpt-20240930.cal.xml XBRL TAXONOMY EXTENSION SCHEMA CALCULATION LINKBASE DOCUMENT EX-101.DEF 7 clpt-20240930.def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 8 clpt-20240930.lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Vested and expected to vest Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Statistical Measurement [Domain] Statistical Measurement [Domain] Statistical Measurement [Domain] Cover [Abstract] Cover [Abstract] Net change in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Accrued interest included in the conversion of debt Accrued Interest Included in the Conversion of Debt Accrued Interest Included in the Conversion of Debt Trading Symbol Trading Symbol All Trading Arrangements All Trading Arrangements [Member] Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Non-NEOs Non-NEOs [Member] Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Pay vs Performance Disclosure [Line Items] Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis] Accounts receivable Increase (Decrease) in Accounts Receivable Net Loss Per Share Earnings Per Share, Policy [Policy Text Block] Lease liabilities Increase (Decrease) in Operating Lease Liability Inventory Inventory, Policy [Policy Text Block] Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Fair Value Measurement Fair Value Disclosures [Text Block] Proceeds from stock option exercises Proceeds from Stock Options Exercised Award Timing Disclosures [Line Items] Other Performance Measure, Amount Other Performance Measure, Amount Leases Lessee, Operating Leases [Text Block] Common stock, shares outstanding (in shares) Beginning balance (in shares) Ending balance (in shares) Common Stock, Shares, Outstanding Interest income, net Interest Income (Expense), Operating Grant (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Operating lease liabilities, net of current portion Operating Lease, Liability, Noncurrent Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Abstract] Sale of stock, price per share (in dollars per share) Sale of Stock, Price Per Share Plan Name [Domain] Plan Name [Domain] Other assets Other Assets, Noncurrent Entity Tax Identification Number Entity Tax Identification Number Leases [Abstract] Leases [Abstract] Net cash flows from operating activities Net cash used in operations Net Cash Provided by (Used in) Operating Activities Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Office Lease - Solana Beach, California Office Lease - Solana Beach, California [Member] Office Lease - Solana Beach, California Plan Name [Axis] Plan Name [Axis] Third Amended and Restated 2013 Incentive Compensation Plan Third Amended and Restated 2013 Incentive Compensation Plan [Member] Third Amended and Restated 2013 Incentive Compensation Plan Equity Components [Axis] Equity Components [Axis] Award Timing Method Award Timing Method [Text Block] Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Entity Common Stock, Shares Outstanding (in shares) Entity Common Stock, Shares Outstanding Insider Trading Policies and Procedures [Line Items] Use of Estimates Use of Estimates, Policy [Policy Text Block] Four Customers Four Customers [Member] Four Customers Number of renewal options Lessee, Operating Lease, Number Of Renewal Options Lessee, Operating Lease, Number Of Renewal Options Total Inventory, Net Including Noncurrent Inventory, Net Including Noncurrent Adjustment to Compensation, Amount Adjustment to Compensation Amount Intrinsic value, outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Additional paid-in capital Additional Paid in Capital, Common Stock Compensation Amount Outstanding Recovery Compensation Amount Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member] Entity Small Business Entity Small Business Company Selected Measure Amount Company Selected Measure Amount Tabular List, Table Tabular List [Table Text Block] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-based Payment Award [Line Items] Sales and marketing Selling and Marketing Expense [Member] Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Issuance of common stock under employee stock purchase plan (in shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans Biologics and Drug Delivery - Disposable Products Biologics And Drug Delivery - Disposable Products [Member] Biologics And Drug Delivery - Disposable Products Cash and cash equivalents, beginning of period Cash and cash equivalents, end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Debt instrument, variable interest rate Debt Instrument, Variable Interest Rate Debt Instrument, Variable Interest Rate Accretion of discounts on short-term investments Accretion (Amortization) of Discounts and Premiums, Investments Current assets: Assets, Current [Abstract] Cash, unsecured amount Cash, Unsecured Amount Allowance for doubtful accounts Accounts Receivable, Allowance for Credit Loss Option exercises (cashless) (in shares) Option Exercises, Cashless, Shares Option Exercises, Cashless, Shares Payments for taxes related to net share settlement of equity awards Payment, Tax Withholding, Share-Based Payment Arrangement

Inventory Inventory Disclosure [Text Block] Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Biologics and drug delivery Biologics And Drug Delivery [Member] Biologics And Drug Delivery Product and Service [Domain] Product and Service [Domain] Stock options Share-Based Payment Arrangement, Option [Member] Vested (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Fair Value Disclosures [Abstract] Common stock initially offered at public offering (in shares) Common Stock Initially Offered At Public Offering Common Stock Initially Offered At Public Offering Principal repayment Debt Instrument, Repaid, Principal Amount of accrued and paid-in-kind interest included in converted debt Amount of Accrued and Paid-in-kind Interest Included In Converted Debt Amount of related accrued and payment-in-kind interest included with converted debt. Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Security Exchange Name Security Exchange Name Debt instrument, basis spread on variable rate Debt Instrument, Basis Spread on Variable Rate Award Type [Axis] Award Type [Axis] Exercised (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Restricted Stock Awards Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Raw materials and work in process Inventory, Work in Process, Net of Reserves Property and equipment, net Property, Plant and Equipment, Net Repayments of debt Repayments of Debt Total liabilities Liabilities Exercisable at ending (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Neurosurgery Navigation and Therapy - Services Neurosurgery Navigation and Therapy - Services [Member] Neurosurgery Navigation and Therapy - Services Convertible Debt Convertible Debt [Member] Common stock par value (in dollars per share) Common Stock, Par or Stated Value Per Share Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Research and development costs Research and Development Expense Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Expiration Date Trading Arrangement Expiration Date Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Operating lease liabilities, current portion Operating Lease, Liability, Current Total Shareholder Return Amount Total Shareholder Return Amount Common stock, shares issued (in shares) Common Stock, Shares, Issued Equity Awards Adjustments, Footnote Equity Awards Adjustments, Footnote [Text Block] Concentration risk, percentage Concentration Risk, Percentage Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Option exercises (in shares) Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period 2020 senior secured convertible note payable, net Secured convertible notes Secured Long-Term Debt, Noncurrent Debt Instrument [Line Items] Debt Instrument [Line Items] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Weighted-average Exercise price per share Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Research and development Research and Development Expense [Member] Common stock, shares authorized (in shares) Common Stock, Shares Authorized Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Description Of Business And Liquidity [Abstract] Description Of Business And Liquidity Total stockholders' equity Beginning balance Ending balance Equity, Attributable to Parent Term of service agreements Term Of Service Agreements Represents the term for service agreements. Renew the lease for two additional periods Lessee, Operating Lease, Renewal Term Concentration Risk Type [Domain] Concentration Risk Type [Domain] General and administrative expenses Selling, General and Administrative Expense Accounts receivable, net Accounts Receivable, after Allowance for Credit Loss, Current Debt instrument, conversion price (in dollars per share) Debt Instrument, Convertible, Conversion Price Cost of revenue Cost of Sales [Member] Product revenue Product [Member] Sale of Stock [Domain] Sale of Stock [Domain] Pension Adjustments Prior Service Cost Pension Adjustments Prior Service Cost [Member] Document Fiscal Period Focus Document Fiscal Period Focus All Executive Categories All Executive Categories [Member] Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Remaining Weighted-Average Recognition Period Outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term ASSETS [Abstract] Document Type Document Type Pension Benefits Adjustments, Footnote Pension Benefits Adjustments, Footnote [Text Block] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Additional Customer 2 Additional Customer 2 [Member] Additional Customer 2 Exercisable at ending Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Vested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Schedule of Revenue Recognized by Contract Liability Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block] Amortization of lease right-of-use, net of accretion in lease liabilities Depreciation, Amortization and Accretion, Net Maximum Maximum [Member] Deferred revenues Contract with Customer, Liability Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Description of the Business and Financial Condition Business Description and Accounting Policies [Text Block] Accounts payable Accounts Payable, Current Accounting Policies [Abstract] Accounting Policies [Abstract] Revenue: Revenues [Abstract] Current Fiscal Year End Date Current Fiscal Year End Date Lease cost Lease, Cost Statistical Measurement [Axis] Statistical Measurement [Axis] PEO Name PEO Name Additional Customer 1 Additional Customer 1 [Member] Additional Customer 1 Cash paid for: Cash paid for: [Abstract] Cash Paid For Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Award Type [Domain] Award Type [Domain] Name Outstanding Recovery, Individual Name Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Share-based compensation (in shares) Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Non-PEO NEO Non-PEO NEO [Member] Additional Paid-in Capital Additional Paid-in Capital [Member] Capital Equipment and Software-Related Service Capital Equipment and Software-Related Service [Member] Capital Equipment and Software-Related Service Award Timing Predetermined Award Timing Predetermined [Flag] Recent Accounting Standards Not Yet Adopted New Accounting Pronouncements, Policy [Policy Text Block] Diluted (in dollars per share) Earnings Per Share, Diluted Name Measure Name Entity Interactive Data Current Entity Interactive Data Current Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Intangible Assets Intangible Assets, Finite-Lived, Policy [Policy Text Block] Number of industry segments Number of Operating Segments Income taxes Income Taxes Paid Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Customer [Axis] Customer [Axis] Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Customer 1 Customer 1 [Member] Customer 1 Share-based compensation Share-Based Payment Arrangement, Noncash Expense Capital Equipment Related Service Revenue Capital Equipment Related Service Revenue [Member] The member represent capital equipment related service revenue. Sales and marketing expenses Selling and Marketing Expense Shares sold pursuant to exercise of underwriters option (in shares) Shares Sold Pursuant To Exercise Of Underwriters Option Shares Sold Pursuant To Exercise Of Underwriters Option Repayment of 2020 senior secured convertible note Repayments of Secured Debt Other income (expense): Nonoperating Income (Expense) [Abstract] Security Purchase Agreement Amended Security Purchase Agreement Amended [Member] Security Purchase Agreement Amended Forfeited or expired (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period SUPPLEMENTAL CASH FLOW INFORMATION Supplemental Cash Flow Information [Abstract] Total revenue Revenue from Contract with Customer, Excluding Assessed Tax Product Information [Line Items] Product Information [Line Items] Acquisition of licensing rights Payments to Acquire Intangible Assets Service and other revenue Service [Member] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Net cash flows from investing activities Net Cash Provided by (Used in) Investing Activities Operating loss Operating Income (Loss) Capital equipment and software Capital Equipment And Software [Member] Capital Equipment And Software Office Lease and Manufacturing facility - Carlsbad, California Office Lease and Manufacturing facility - Carlsbad, California [Member] Total liabilities and stockholders' equity Liabilities and Equity Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] All Adjustments to Compensation All Adjustments to Compensation [Member] Accrued compensation Employee-related Liabilities, Current Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Schedule of Restricted Stock Activity Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block] Right-of-use assets obtained in exchange for operating lease liability Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Underlying Security Market Price Change Underlying Security Market Price Change, Percent Individual: Individual [Axis] Neurosurgery navigation and therapy Neurosurgery Navigation and Therapy [Member] Neurosurgery Navigation and Therapy Payments for taxes related to net share settlement of equity awards Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation Revenue, remaining performance obligation, period Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period Inventory, net, included in current assets Inventory, Net Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Product and Service [Axis] Product and Service [Axis] Entity Address, State or Province Entity Address, State or Province Statement [Line Items] Statement [Line Items] Purchase plan, per share weighted average price of shares purchased (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Per Share Weighted Average Price of Shares Purchased Erroneous Compensation Analysis [Text Block] Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Outstanding, beginning balance (in dollars per share) Outstanding, ending balance (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities and Equity [Abstract] Number of customers (more than) Number Of Customers Number Of Customers Minimum Minimum [Member] Restatement Determination Date Restatement Determination Date Vested and expected to vest at ending (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Adoption Date Trading Arrangement Adoption Date Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Outstanding, beginning balance (in dollars per share) Outstanding, ending balance (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Operating lease, right-of-use assets Operating Lease, Right-of-Use Asset Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Outstanding, beginning balance (in shares) Outstanding, ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Allowance for credit losses (recoveries) Accounts Receivable, Credit Loss Expense (Reversal) Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] Biologics and Drug Delivery - Services and license fees Biologics And Drug Delivery - Services and License Fees [Member] Biologics And Drug Delivery - Services and License Fees Schedule of Other Current Assets Schedule of Other Current Assets [Table Text Block] Exercise Price Award Exercise Price Arrangement Duration Trading Arrangement Duration Issuance of common stock under employee stock purchase plan Stock Issued During Period, Value, Employee Stock Purchase Plan Option exercises Stock Issued During Period, Value, Stock Options Exercised Stockholders' equity: Equity, Attributable to Parent [Abstract] Granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] All Individuals All Individuals [Member] Basis of Presentation and Summary of Significant Accounting Policies Basis of Presentation and Significant Accounting Policies [Text Block] PEO PEO [Member] Name Trading Arrangement, Individual Name Other expense, net Other Nonoperating Income (Expense) Statement of Stockholders' Equity [Abstract] Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Axis] Accrued interest Interest Payable Employee Stock Purchase Plan Employee Stock Purchase Plan [Member] Employee Stock Purchase Plan Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Common stock, capital shares reserved for future issuance (in shares) Common Stock, Capital Shares Reserved for Future Issuance Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] Licensing rights Indefinite-Lived Contractual Rights Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Local Phone Number Local Phone Number Other contract assets Contract with Customer, Contract Asset, Contract Liability, and Receivable [Abstract] Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Debt instrument, number of investors Convertible Notes, Number Of Investors Convertible Notes, Number Of Investors Weighted-average Remaining Contractual Life (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract] Other assets Increase (Decrease) in Other Operating Assets Increase (decrease) in cash resulting from changes in: Increase (Decrease) in Operating Capital [Abstract] PEO Total Compensation Amount PEO Total Compensation Amount Long-Lived Tangible Asset [Domain] Long-Lived Tangible Asset [Domain] Statement of Income Location, Balance [Axis] Statement of Income Location, Balance [Axis] Vested and expected to vest (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Debt Disclosure [Abstract] Debt Disclosure [Abstract] Common Stock Common Stock [Member] Measure: Measure [Axis] Share-based compensation Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Public offering of common stock, net of offering costs (in shares) Stock Issued During Period, Shares, New Issues Entity Emerging Growth Company Entity Emerging Growth Company Payments for taxes related to net share settlement of equity awards (in shares) Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation Central Index Key Entity Central Index Key Public Offering Public Offering [Member] Public Offering General and administrative General and Administrative Expense [Member] Schedule of Inventory Schedule of Inventory, Current [Table Text Block] Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Debt conversion, shares issued (in shares) Debt Conversion, Converted Instrument, Shares Issued Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Stockholders' Equity Equity [Text Block] Accounts payable and accrued expenses Increase (Decrease) in Accounts Payable and Accrued Liabilities Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Equity Component [Domain] Equity Component [Domain] Preferred stock par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Adjustments to reconcile net loss to net cash flows from operating activities: Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] RSAs and RSUs RSAs Restricted Stock [Member] Entity Shell Company Entity Shell Company Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Title Trading Arrangement, Individual Title Statement [Table] Statement [Table] City Area Code City Area Code Current liabilities: Liabilities, Current [Abstract] Interest Interest Paid, Excluding Capitalized Interest, Operating Activities Revenue Recognition Revenue [Policy Text Block] Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Total current assets Assets, Current Contract liabilities, service agreements, terms Contract Liabilities, Service Agreements, Terms Contract Liabilities, Service Agreements, Terms Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Debt instrument, conversion amount Debt Conversion, Converted Instrument, Amount Exercisable at ending (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Neurosurgery Navigation and Therapy - Disposable Products Neurosurgery Navigation and Therapy - Disposable Products [Member] Neurosurgery Navigation and Therapy - Disposable Products Net transfers of reusable components from loaned systems (less than \$0.1 million during the nine months ended September 30, 2023) Net Transfers Of Reusable Components From Loaned Systems Net Transfers Of

Reusable Components From Loaned Systems Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Weighted - Average Grant Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Revenue, remaining performance obligation, percentage Revenue, Remaining Performance Obligation, Percentage Net loss per share attributable to common stockholders: Earnings Per Share [Abstract] Schedule of Revenue by Service Line Revenue from External Customers by Products and Services [Table Text Block] Equity [Abstract] Equity [Abstract] Accumulated deficit Cumulative deficit Retained Earnings (Accumulated Deficit) Forfeited or expired (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Inventory, net Increase (Decrease) in Inventories Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Equity Awards Adjustments Equity Awards Adjustments [Member] Net cash flows from financing activities Net Cash Provided by (Used in) Financing Activities Underlying Securities Award Underlying Securities Amount Deferred product and service revenue, current portion Deferred Revenue, Current Amendment Flag Amendment Flag Entity Registrant Name Entity Registrant Name Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Depreciation and amortization Depreciation, Depletion and Amortization Gross profit Gross Profit Fair Value as of Grant Date Award Grant Date Fair Value Customer Concentration Risk Customer Concentration Risk [Member] Intrinsic value, vested and expected to vest Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Public offering (in shares) Sale of stock, shares issued (in shares) Sale of Stock, Number of Shares Issued in Transaction Note Payable Debt Disclosure [Text Block] Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Debt instrument, face amount Debt Instrument, Face Amount Public offering of common stock, net of offering costs Stock Issued During Period, Value, New Issues Unbilled receivables Unbilled Contracts Receivable Entity Address, Postal Zip Code Entity Address, Postal Zip Code Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Schedule of Share-Based Compensation Expense Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Restatement Determination Date: Restatement Determination Date [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Title of 12(b) Security Title of 12(b) Security Concentration Risk Type [Axis] Concentration Risk Type [Axis] Common stock, \$0.01 par value; 90,000,000 shares authorized at September 30, 2024 and December 31, 2023; 27,588,819 shares issued and outstanding at September 30, 2024; and 24,652,729 issued and outstanding at December 31, 2023 Common Stock, Value, Issued Software licenses Inventory, Software Licenses The carrying amount of software, net as of the balance sheet date. Capital Equipment and Software - Systems and Software Products Capital Equipment And Software - Systems and Software Products [Member] Capital Equipment And Software - Systems and Software Products Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Security Purchase Agreement Security Purchase Agreement [Member] Securities Purchase Agreement Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] Forfeited (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] Preferred stock, \$0.01 par value; 25,000,000 shares authorized; none issued and outstanding at September 30, 2024 and December 31, 2023 Preferred Stock, Value, Issued Estimated useful life Property, Plant and Equipment, Useful Life Stock Options Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] ESPP Employee Stock [Member] Basic (in dollars per share) Earnings Per Share, Basic Second Closing Note Second Closing Note [Member] Second Closing Note Issuances of common stock: Issuances of common stock: [Abstract] Issuances of Common Stock Proceeds from public offering of common stock, net of offering costs Net proceeds from offering Proceeds from issuance of common stock Proceeds from Issuance of Common Stock Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Nature of Operation, Product Information, Concentration of Risk [Table] Nature of Operation, Product Information, Concentration of Risk [Table] Aggregate Pension Adjustments Service Cost Aggregate Pension Adjustments Service Cost [Member] Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Total current liabilities Liabilities, Current Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] Weighted average shares used in computing net loss per share: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Unrecognized Expense Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Total assets Assets Concentration Risks and Other Risks and Uncertainties Concentration Risk, Credit Risk, Policy [Policy Text Block] Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Commitments and contingencies Commitments and Contingencies Termination Date Trading Arrangement Termination Date Total revenue Revenues Entity Address, City or Town Entity Address, City or Town Debt Instrument [Axis] Debt Instrument [Axis] Schedule of Stock Option Activity Share-Based Payment Arrangement, Option, Activity [Table Text Block] Proceeds from maturities of short-term investments Proceeds from Maturities, Prepayments and Calls of Short-Term Investments Share-based compensation expense Share-Based Payment Arrangement, Expense Net loss Net loss for the period Net loss Net Income (Loss) Attributable to Parent Trading Arrangement: Trading Arrangement [Axis] Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Proceeds from issuance of common stock under employee stock purchase plan Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Excluding Option Exercised Equity Awards Adjustments, Excluding Value Reported in Compensation Table Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member] Purchase plan, shares purchased (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Purchased for Award Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member] Entity File Number Entity File Number Offering period Share-Based Compensation Arrangement By Share-Based Payment Award, Offering Period Share-Based Compensation Arrangement by Share-Based Payment Award, Offering Period Revenue Recognition Revenue from Contract with Customer [Text Block] Document Fiscal Year Focus Document Fiscal Year Focus Income Statement [Abstract] Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two First Closing Notes First Closing Notes [Member] First Closing Notes Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Lessee, operating lease, term of contract (in years) Lessee, Operating Lease, Term of Contract Other accrued liabilities Other Accrued Liabilities, Current Name Forgone Recovery, Individual Name Intrinsic value, exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Document Period End Date Document Period End Date Sale of Stock [Axis] Sale of Stock [Axis] Deferred product and service revenue, net of current portion Deferred Revenue, Noncurrent Finished goods Inventory, Finished Goods, Net of Reserves Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Outstanding, beginning balance (in shares) Outstanding, ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Deferred revenue Increase (Decrease) in Deferred Revenue Insider Trading Arrangements [Line Items] Inventory Disclosure [Abstract] Inventory Disclosure [Abstract] Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Payment terms Revenue, Performance Obligation, Payment Terms Revenue, Performance Obligation, Payment Terms Cost of revenue Cost of Revenue Adjustment to Compensation: Adjustment to Compensation [Axis] Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Accounts Receivable Accounts Receivable [Member] Subsidiary or Equity Method Investee, Sale of Stock, Type [Table] Subsidiary or Equity Method Investee, Sale of Stock, Type [Table] Capital Equipment and Software - Services Capital Equipment And Software - Services [Member] Capital Equipment And Software - Services Document Transition Report Document Transition Report Document Quarterly Report Document Quarterly Report Customer [Domain] Customer [Domain] Entity Current Reporting Status Entity Current Reporting Status Accumulated Deficit Retained Earnings [Member] Pension Adjustments Service Cost Pension Adjustments Service Cost [Member] Basic (in shares) Weighted Average Number of Shares Outstanding, Basic Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Software license inventory Software licenses â€¢ non-current Inventory, Noncurrent Subsidiary, Sale of Stock [Line Items] Subsidiary, Sale of Stock [Line Items] RSUs Restricted Stock Units (RSUs) [Member] Amortization of debt issuance costs and original issue discounts Amortization of Debt Issuance Costs and Discounts Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Executive Category: Executive Category [Axis] Name Awards Close in Time to MNPI Disclosures, Individual Name Revenue Benchmark Revenue Benchmark [Member] Entity Filer Category Entity Filer Category Revenue, remaining performance obligation amount Revenue, Remaining Performance Obligation, Amount Statement of Income Location, Balance [Domain] Statement of Income Location, Balance [Domain] Company Selected Measure Name Company Selected Measure Name EX-101.PRE 9 clpt-20240930\_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 11 R1.htm IDEA: XBRL DOCUMENT v3.24.3 Cover - shares 9 Months Ended Sep. 30, 2024 Oct. 31, 2024 Cover [Abstract] A Document Type 10-Q A Document Quarterly Report true A Document Period End Date Sep. 30, 2024 A Document Transition Report false A Entity File Number 001-34822 A Entity Registrant Name ClearPoint Neuro, Inc. A Entity Incorporation, State or Country Code DE A Entity Tax Identification Number 58-2394628 A Entity Address, Address Line One 120 S. Sierra Ave. A Entity Address, Address Line Two Suite 100 A Entity Address, City or Town Solana Beach A Entity Address, State or Province CA A Entity Address, Postal Zip Code 92075 A City Area Code (888) A Local Phone Number 287-9109 A Title of 12(b) Security Common Stock, \$0.01 par value per share A Trading Symbol CLPT A Security Exchange Name NASDAQ A Entity Current Reporting Status Yes A Entity Interactive Data Current Yes A Entity Filer Category Non-accelerated Filer A Entity Small Business true A Entity Emerging Growth Company false A Entity Shell Company false A Entity Common Stock, Shares Outstanding (in shares) A 27,584,699 Central Index Key 0001285550 A Current Fiscal Year End Date -12-31 A Document Fiscal Year Focus 2024 A Document Fiscal Period Focus Q3 A Amendment Flag false A X - Definition Boolean flag that is true when the XBRL content amends previously-filed or accepted submission. + ReferencesNo definition available. + Details Name: dei\_AmendmentFlag Namespace Prefix: dei\_Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionArea code of city + ReferencesNo definition available. + Details Name: dei\_CityAreaCode Namespace Prefix: dei\_Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCover page. + ReferencesNo definition available. + Details Name: dei\_CoverAbstract Namespace Prefix: dei\_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionEnd date of current fiscal year in the format --MM-DD. + ReferencesNo definition available. + Details Name: dei\_CurrentFiscalYearEndDate Namespace Prefix: dei\_Data Type: xbrli:dateTimeItemType Balance Type: na Period Type: duration X - DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. + ReferencesNo definition available. + Details Name: dei\_DocumentFiscalPeriodFocus Namespace Prefix: dei\_Data Type: dei:fiscalPeriodItemType Balance Type: na Period Type: duration X - DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + ReferencesNo definition available. + Details Name: dei\_DocumentFiscalYearFocus Namespace Prefix: dei\_Data Type: xbrli:yearItemType Balance Type: na Period Type: duration X - DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. + ReferencesNo definition available. + Details Name: dei\_DocumentPeriodEndDate Namespace Prefix: dei\_Data Type: xbrli:dateTimeItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as an quarterly report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-Q -Number 240 -Section 308 -Subsection a + Details Name: dei\_DocumentQuarterlyReport Namespace Prefix: dei\_Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as a transition report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1 + Details Name: dei\_DocumentTransitionReport Namespace Prefix: dei\_Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'. + ReferencesNo definition available. + Details Name: dei\_DocumentType Namespace Prefix: dei\_Data Type: dei:submissionTypeItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 1 such as Attn, Building Name, Street Name + ReferencesNo definition available. + Details Name: dei\_EntityAddressAddressLine1 Namespace Prefix: dei\_Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 2 such as Street or Suite number + ReferencesNo definition available. + Details Name: dei\_EntityAddressAddressLine2 Namespace Prefix: dei\_Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the City or Town + ReferencesNo definition available. + Details Name: dei\_EntityAddressCityOrTown Namespace Prefix: dei\_Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCode for the postal or zip code + ReferencesNo definition available. + Details Name: dei\_EntityAddressPostalZipCode Namespace Prefix: dei\_Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the state or province. + ReferencesNo definition available. + Details Name: dei\_EntityAddressStateOrProvince Namespace Prefix: dei\_Data Type: dei:stateOrProvinceCodeItemType Balance Type: na Period Type: duration X - DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei\_EntityCentralIndexKey Namespace Prefix: dei\_Data Type: dei:centralIndexKeyItemType Balance Type: na Period Type: duration X - DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. + ReferencesNo definition available. + Details Name: dei\_EntityCommonStockSharesOutstanding Namespace Prefix: dei\_Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionIndicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesNo definition available. + Details Name: dei\_EntityCurrentReportingStatus Namespace Prefix: dei\_Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionIndicate if registrant meets the emerging growth company criteria. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei\_EntityEmergingGrowthCompany Namespace Prefix: dei\_Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. + ReferencesNo definition available. + Details Name: dei\_EntityFileNumber Namespace Prefix: dei\_Data Type: dei:fileNumberItemType Balance Type: na Period Type: duration X - DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei\_EntityFilerCategory Namespace Prefix:

dei\_DataType: dei:filerCategoryItemType Balance Type: on Period Type: duration X - DefinitionTwo-character EDGAR code representing the state or country of incorporation. + ReferencesNo definition available. + Details Name: dei EntityIncorporationStateCountryCode Namespace Prefix: dei\_DataType: dei:edgarStateCountryItemType Balance Type: on Period Type: duration X - DefinitionBoolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). + ReferencesReference 1:

Type: instant X - ReferencesNo definition available. + Details Name: us-gaap\_AssetsCurrentAbstract Namespace Prefix: us-gaap\_Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1:

-Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-599-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap LiabilitiesCurrent Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap LiabilitiesCurrentAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-599-1 + Details Name: us-gaap OtherAccruedLiabilitiesCurrent Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of noncurrent assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-599-1 + Details Name: us-gaap OtherAssetsNoncurrent Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-599-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-599-1 + Details Name: us-gaap PreferredStockValue Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-599-1 + Details Name: us-gaap PrepaidExpenseAndOtherAssetsCurrent Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-599-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478519/942-360-50-1 + Details Name: us-gaap PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-599-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-599-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-599-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-599-1 + Details Name: us-gaap RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying amount of collateralized debt obligations with maturities initially due after one year or beyond the operating cycle, if longer, excluding the current portion. Obligations include, but not limited to, mortgage loans, chattel loans, and other borrowings secured by assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-599-1 + Details Name: us-gaap SecuredLongTermDebt Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-599-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-599-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-599-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-599-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-599-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-599-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-599-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-599-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-599-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-599-2 + Details Name: us-gaap StockholdersEquity Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap StockholdersEquityAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 13 R3.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Balance Sheets (Parenthetical) - / shares Sep. 30, 2024 Dec. 31, 2023 Statement of Financial Position [Abstract] A Preferred stock par value (in dollars per share) \$ 0.01 \$ 0.01 Preferred stock, shares authorized (in shares) 25,000,000 25,000,000 Preferred stock, shares issued (in shares) 0 0 Preferred stock, shares outstanding (in shares) 0 0 Common stock par value (in dollars per share) \$ 0.01 \$ 0.01 Common stock, shares authorized (in shares) 90,000,000 90,000,000 Common stock, shares issued (in shares) 27,588,819 24,652,729 Common stock, shares outstanding (in shares) 27,588,819 24,652,729 X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-599-1 + Details Name: us-gaap CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap Data Type: dt:types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-599-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-599-1 + Details Name: us-gaap CommonStockSharesAuthorized Namespace Prefix: us-gaap Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-599-1 + Details Name: us-gaap CommonStockSharesIssued Namespace Prefix: us-gaap Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/214748112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-599-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-599-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-599-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting

Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap\_CommonStockSharesOutstanding Namespace Prefix: us-gaap Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - Definition: Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap PreferredStockParOrStatedValuePerShare Namespace Prefix: us-gaap Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: instant X - Definition: The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap PreferredStockSharesAuthorized Namespace Prefix: us-gaap Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - Definition: Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap PreferredStockSharesIssued Namespace Prefix: us-gaap Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - Definition: Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap PreferredStockSharesOutstanding Namespace Prefix: us-gaap Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap StatementOfFinancialPositionAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration XML 14 R4.htm IDEA: XBRL DOCUMENT V3.24.3 Condensed Consolidated Statements of Operations - USD (\$) in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Revenue: A A A Total revenue \$ 8,122 \$ 5,762 \$ 23,619 \$ 17,145 Cost of revenue 3,275 2,489 9,259 7,544 Gross profit 4,847 3,273 14,360 9,601 Research and development costs 3,315 2,429 9,060 9,057 Sales and marketing expenses 3,549 2,841 10,673 9,248 General and administrative expenses 3,155 2,900 8,769 9,036 Operating loss (5,172) (4,897) (14,142) (17,740) Other income (expense): A A A Other expense, net (11) (12) (32) (25) Interest income, net 209 100 646 295 Net loss \$ (4,974) \$ (4,809) \$ (13,528) \$ (17,470) Net loss per share attributable to common stockholders: A A A Basic (in dollars per share) \$ (0.18) \$ (0.20) \$ (0.50) \$ (0.71) Diluted (in dollars per share) \$ (0.18) \$ (0.20) \$ (0.50) \$ (0.71) Weighted average shares used in computing net loss per share: A A A Basic (in shares) 27,591,623 24,630,181 26,840,119 24,599,191 Diluted (in shares) 27,591,623 24,630,181 26,840,119 24,599,191 Profit revenue: A A A Revenue: A A A Total revenue \$ 5,474 \$ 2,410 \$ 14,053 \$ 7,377 Service and other revenue: A A A Revenue: A A A Total revenue \$ 2,648 \$ 3,352 \$ 9,566 \$ 9,768 X - Definition: The aggregate cost of goods produced and sold and services rendered during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(ii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B + Details Name: us-gaap CostOfRevenue Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap EarningsPerShareAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - Definition: The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap EarningsPerShareBasic Namespace Prefix: us-gaap Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: duration X - Definition: The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap EarningsPerShareDiluted Namespace Prefix: us-gaap Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: duration X - Definition: Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to



ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph \(SX 210.5-03\(4\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://www.xbrl.org/2003/role/exampleRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 48-Publisher FASB-URI https://asc.fasb.org/1943274/2147482785/200-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 41-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 3: http://www.xbrl.org/2003/role/disclosureRef-Topic 270-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (i)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph (ee)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/disclosureRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.4-08(g)(1)(ii))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 28-Subparagraph (f)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 10: http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(ii))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(ii))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(iii)(A))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(iv))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(5))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(i))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iii)(A))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iii)(B))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iv))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(5))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 30-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 21: http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 42-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 22: http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 22-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 23: http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 40-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 24: http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 22-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 25: http://www.xbrl.org/2003/role/disclosureRef-Topic 942-SubTopic 235-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.9-05(b)(2))-Publisher FASB-URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 26: http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph (SX 210.5-03(1))-Publisher FASB-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_Revenues Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_RevenuesAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe aggregate total amount of expenses directly related to the marketing or selling of products or services. + ReferencesNo definition available. + Details Name: us-gaap_SellingAndMarketingExpense Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc. + ReferencesReference 1: <a href=) + Details Name: us-gaap\_SellingGeneralAndAdministrativeExpense Namespace Prefix: us-gaap\_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 10-Publisher FASB-URI https://asc.fasb.org/1943274/2147482689/260-10-45-16](http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 10-Publisher FASB-URI https://asc.fasb.org/1943274/2147482689/260-10-45-16) + Details Name: us-gaap\_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap\_Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap\_WeightedAverageNumberOfSharesOutstandingAbstract Namespace Prefix: us-gaap\_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 10-Publisher FASB-URI https://asc.fasb.org/1943274/2147482689/260-10-45-10](http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 10-Publisher FASB-URI https://asc.fasb.org/1943274/2147482689/260-10-45-10) + Details Name: us-gaap\_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap\_Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: srt\_ProductOrServiceAxis-us-gaap\_ProductMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt\_ProductOrServiceAxis-us-gaap\_ServiceMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 15 R5.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Stockholders' Equity - USD (\$) in Thousands Total Common Stock Additional Paid-in Capital Accumulated Deficit Beginning balance (in shares) at Dec. 31, 2022 24,578,983 4 Beginning balance at Dec. 31, 2022 \$ 36,887 \$ 246 \$ 187,008 \$ (150,367) Issuances of common stock: 4 4 4 Share-based compensation (in shares) 3,782 4 4 Share-based compensation 1,307 1,307 4 Payments for taxes related to net share settlement of equity awards (in shares) 5 4 4 5 4 4 Payments for taxes related to net share settlement of equity awards (5) 4 4 5 4 4 Net loss for the period (5,609) 4 4 5 4 4 Ending balance (in shares) at Mar. 31, 2023 24,582,251 4 4 Ending balance at Mar. 31, 2023 32,580 \$ 246 188,310 (155,976) Beginning balance (in shares) at Dec. 31, 2022 24,578,983 4 4 Beginning balance at Dec. 31, 2022 36,887 \$ 246 187,008 (150,367) Issuances of common stock: 4 4 4 Net loss for the period (17,470) 4 4 4 Ending balance (in shares) at Sep. 30, 2023 24,625,670 4 4 Ending balance at Sep. 30, 2023 24,094 \$ 246 191,685 (167,837) Beginning balance (in shares) at Mar. 31, 2023 24,582,251 4 4 Beginning balance at Mar. 31, 2023 32,580 \$ 246 188,310 (155,976) Issuances of common stock: 4 4 4 Share-based compensation (in shares) 5,484 4 4 Share-based compensation 1,645 1,645 4 Payments for taxes related to net share settlement of equity awards (in shares) 11,102 4 4 4 Payments for taxes related to net share settlement of equity awards (77) 4 4 77 4 Issuance of common stock under employee stock purchase plan (in shares) 4 51,041 4 4 Issuance of common stock under employee stock purchase plan 314 4 314 4 Net loss for the period (7,052) 4 4 7,052 4 Ending balance (in shares) at Jun. 30, 2023 24,627,674 4 4 Ending balance at Jun. 30, 2023 27,410 \$ 246 190,192 (163,028) Issuances of common stock: 4 4 4 4 Share-based compensation (in shares) 1,001 4 4 4 Share-based compensation 1,584 1,584 4 Option exercises (cashless) (in shares) 14,312 4 4 Payments for taxes related to net share settlement of equity awards (in shares) 15,315 4 4 4 Payments for taxes related to net share settlement of equity awards (91) 4 4 91 4 Net loss for the period (4,809) 4 4 4 4 4 Ending balance (in shares) at Sep. 30, 2023 24,625,670 4 4 Ending balance at Sep. 30, 2023 24,094 \$ 246 191,685 (167,837) Beginning balance (in shares) at Dec. 31, 2023 24,652,729 4 4 24,652,729 4 4 Beginning balance at Dec. 31, 2023 21,173 \$ 247 193,382 (172,456) Issuances of common stock: 4 4 4 Public offering of common stock, net of offering costs (in shares) 1,645 4 4 4 Public offering of common stock, net of offering costs (in shares) 2,653,848 4 4 4 Public offering of common stock, net of offering costs 16,183 26 16,157 4 Share-based compensation (in shares) 126,315 4 4 4 Share-based compensation 1,504 \$ 1 1,503 4 Option exercises (in shares) 7,500 4 4 Option exercises 21 21 4 4 Payments for taxes related to net share settlement of equity awards (in shares) 24,047 4 4 4 Payments for taxes related to net share settlement of equity awards (151) 4 4 151 4 Net loss for the period (4,146) 4 4 4 4 4 Ending balance (in shares) at Mar. 31, 2024 27,416,345 4 4 Ending balance at Mar. 31, 2024 34,584 \$ 274 210,912 (176,602) Beginning balance (in shares) at Dec. 31, 2023 24,652,729 4 4 24,652,729 4 4 Beginning balance at Dec. 31, 2023 21,173 \$ 247 193,382 (172,456) Issuances of common stock: 4 4 4 Option exercises (in shares) 12,000 4 4 4 Net loss for the period \$ (13,528) 4 4 4 Ending balance (in shares) at Sep. 30, 2024 27,588,819 4 4 27,588,819 4 4 Ending balance at Sep. 30, 2024 29,001 \$ 276 214,709 (185,984) Beginning balance (in shares) at Mar. 31, 2024 27,416,345 4 4 Beginning balance at Mar. 31, 2024 34,584 \$ 274 210,912 (176,602) Issuances of common stock: 4 4 4 4 Share-based compensation (in shares) 130,447 4 4 4 Share-based compensation 1,796 \$ 1 1,795 4 Option exercises (cashless) (in shares) 1,373 4 4 4 Payments for taxes related to net share settlement of equity awards (in shares) 22,153 4 4 4 Payments for taxes related to net share settlement of equity awards (128) 4 4 128 4 Issuance of common stock under employee stock purchase plan (in shares) 62,800 4 4 Issuance of common stock under employee stock purchase plan 288 \$ 1 287 4 Net loss for the period (4,408) 4 4 4 4 4 Ending balance (in shares) at Jun. 30, 2024 27,588,819 4 4 Ending balance at Jun. 30, 2024 27,588,819 4 4 27,588,819 4 4 Ending balance at Sep. 30, 2024 29,001 \$ 276 214,709 (185,984) X - DefinitionIssuances of Common Stock + ReferencesNo definition available. + Details Name: clpt\_IssuancesOfCommonStockAbstract Namespace Prefix: clpt\_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionOption Exercises, Cashless, Shares + ReferencesNo definition available. + Details Name: clpt\_OptionExercisesCashlessShares Namespace Prefix: clpt\_Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAmount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement. + ReferencesNo definition available. + Details Name: us-gaap\_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation Namespace Prefix: us-gaap\_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1:





us-gaap\_NetCashProvidedByUsedInFinancingActivities Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap\_NetCashProvidedByUsedInFinancingActivitiesAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24> + Details Name: us-gaap\_NetCashProvidedByUsedInInvestingActivities Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap\_NetCashProvidedByUsedInInvestingActivitiesAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25> + Details Name: us-gaap\_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap\_NetCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15](http://www.xbrl.org/2003/role/disclosureRef-Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef-Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef-Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef-Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef-Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef-Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef-Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef-Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef-Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef-Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef-Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef-Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef-Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef-Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef-Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef-Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef-Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(ii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef-Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef-Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef-Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef-Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement. + ReferencesReference 1: <a href=) + Details Name: us-gaap\_PaymentsRelatedToTaxWithholdingForShareBasedCompensation Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13) + Details Name: us-gaap\_PaymentsToAcquireIntangibleAssets Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13) + Details Name: us-gaap\_PaymentsToAcquirePropertyPlantAndEquipment Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow from the additional capital contribution to the entity. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph \(a\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14) + Details Name: us-gaap\_ProceedsFromIssuanceOfCommonStock Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow from issuance of shares under share-based payment arrangement. Excludes option exercised. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph \(a\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 50 -Paragraph 2A -Subparagraph \(a\) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 50 -Paragraph 2A -Subparagraph (a) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A) + Details Name: us-gaap\_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph \(a\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13) + Details Name: us-gaap\_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow from exercise of option under share-based payment arrangement. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 50 -Paragraph 2A -Subparagraph \(a\) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 50 -Paragraph 2A -Subparagraph (a) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A) + Details Name: us-gaap\_ProceedsFromStockOptionsExercised Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of expense (reversal of expense) for expected credit loss on accounts receivable. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef-Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef-Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2) + Details Name: us-gaap\_ProvisionForDoubtfulAccounts Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash outflow to repay long-term debt that is wholly or partially secured by collateral. Excludes repayments of tax exempt secured debt. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15) + Details Name: us-gaap\_RepaymentsOfSecuredDebt Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(a\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28) + Details Name: us-gaap\_ShareBasedCompensation Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 17 R7.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Cash Flows (Parenthetical) - USD (\$) in Millions 1 Months Ended 9 Months Ended Jun. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Statement of Cash Flows [Abstract] Á Á A Net transfers of reusable components from loaned systems (less than \$0.1 million during the nine months ended September 30, 2023) Á \$ 0.4 \$ 0.1 Right-of-use assets obtained in exchange for operating lease liability \$ 2.5 Á X - DefinitionNet Transfers Of Reusable Components From Loaned Systems + ReferencesNo definition available. + Details Name: clpt\_NetTransfersOfReusableComponentsFromLoanedSystems Namespace Prefix: clpt Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase in right-of-use asset obtained in exchange for operating lease liability. + ReferencesReference 1: [http://www.xbrl.org/2003/role/exampleRef-Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef-Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph \(g\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4](http://www.xbrl.org/2003/role/exampleRef-Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef-Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4) + Details Name: us-gaap\_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap\_StatementOfCashFlowsAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration XML 18 R8.htm IDEA: XBRL DOCUMENT v3.24.3 Description of the Business and Financial Condition 9 Months Ended Sep. 30, 2024 Description Of Business And Liquidity [Abstract] Á Description of the Business and Financial Condition 1.Description of the Business and Financial

ConditionClearPoint Neuro, Inc. (the "Company") is a commercial-stage medical device company focused on the development and commercialization of innovative platforms for performing minimally invasive surgical procedures in the brain. From the Company's inception in 1998, the Company has deployed significant resources to fund its efforts to develop the capabilities for enabling neurosurgery interventions, building an intellectual property portfolio, and identifying and building out commercial applications for the technologies it develops. In 2021, the Company's efforts expanded beyond the MRI suite to encompass development and commercialization of new neurosurgical device products for the operating room setting. In 2022, the Company commercialized the ClearPoint Prism Neuro Laser Therapy System as its first therapy product offering. The Company has exclusive global commercialization rights to the ClearPoint Prism Neuro Laser Therapy System through its Swedish partner, Clinical Laserthermia Systems ("CLS"). Since 2021, a growing part of the Company's revenue is derived from professional services to pharmaceutical and biotech companies, academic institutions, and contract research organizations having a focus on biologics and drug delivery. The Company's services include protocol consultation and solutions for preclinical study design and execution for the delivery of pharmaceutical agents to the brain. The Company also partners with customers to develop devices used for administration of therapies into the central nervous system. Currently, the Company has more than 50 biologics and drug delivery customers who are evaluating or using its products and services in trials to inject gene and cell therapies directly into the brain. These relationships involve drug development programs that are at various stages of development ranging from preclinical research to late-stage regulatory trials for multiple distinct disease states. This part of the Company's business potentially represents the largest opportunity for growth; however, the Company's ability to grow in this market is dependent on its ability to maintain and establish new relationships with customers, such as customers' continuation of research and product development plans, and such customers' achievement of success in completion of clinical trials and subsequent regulatory approvals of their biologics and drugs. Macroeconomic Trends The Company continues to monitor the impact of various macroeconomic trends, such as global economic and supply chain disruptions, geopolitical instability (including instability resulting from military conflicts), labor shortages, inflationary conditions, and legislative and political developments. Impacts from inflationary pressures, such as increasing costs for research and development of the Company's products, administrative and other costs of doing business, and the Company's access to capital markets and other sources of funding in the future could adversely affect the Company's business, financial condition and results of operations. Additionally, these trends could adversely affect the Company's customers, which could impact their willingness to spend on the Company's products and services, or their ability to make payment, which could harm the Company's collection of accounts receivable and financial results. The continued development and fluidity of these situations preclude any prediction as to the ultimate impact they will have on the Company's business, financial condition, results of operation and cash flows. Liquidity The Company has incurred net losses since its inception, which has resulted in a cumulative deficit at September 30, 2024 of \$186.0 million. In addition, the Company's use of cash from operations amounted to \$7.7 million for the nine months ended September 30, 2024, and \$13.7 million for the year ended December 31, 2023. Since its inception, the Company has financed its operations principally from the sale of equity securities and the issuance of notes payable, however, there is no assurance a future sale of equity securities and/or issuance of notes payable will be at terms favorable to the Company or available at all. As required by generally accepted accounting principles in the U.S., the Company has evaluated its ability to continue as a going concern and has determined that based on current forecasts, existing cash and cash equivalent balances at September 30, 2024 are sufficient to support the Company's operations and meet its obligations for at least the next twelve months. In March 2024, the Company completed a public offering of 2,653,848 shares of its common stock from which the net proceeds totaled approximately \$16.2 million after deducting underwriting discounts and commissions, and other offering expenses paid by the Company. See Note 8 below for additional information with respect to the common stock offering. In August 2024, the Company repaid in full the remaining \$10 million outstanding under a Securities Purchase Agreement entered into in 2020 (the "SPA"), pursuant to which the Company issued secured convertible notes to two investors raising gross proceeds of \$25 million, of which \$15 million had been previously converted to common stock. See Note 6 below for additional information with respect to these notes. X - Definition Description Of Business And Liquidity + References No definition available. + Details Name: clpt\_DescriptionOfBusinessAndLiquidityAbstract Namespace Prefix: clpt\_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition The entire disclosure for the business description and accounting policies concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Accounting policies describe all significant accounting policies of the reporting entity. + References Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic235-NameAccountingStandardsCodification-PublisherFASB-URI> Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic275-NameAccountingStandardsCodification-PublisherFASB-URI> Details Name: us-gaap\_BusinessDescriptionAndAccountingPoliciesTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 19 R9.htm IDEA: XBRL DOCUMENT v3.24.3 Basis of Presentation and Summary of Significant Accounting Policies 9 Months Ended Sep. 30, 2024 Accounting Policies [Abstract] A Basis of Presentation and Summary of Significant Accounting Policies 2. Basis of Presentation and Summary of Significant Accounting Policies Basis of Presentation The accompanying unaudited condensed consolidated financial statements of the Company should be read in conjunction with the audited financial statements and notes thereto as of and for the year ended December 31, 2023 included in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC"). The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States ("U.S. GAAP") for interim financial information and in accordance with the rules and regulations of the SEC related to a quarterly report on Form 10-Q. Accordingly, since they are interim statements, the accompanying unaudited condensed consolidated financial statements do not include all of the information and notes required by U.S. GAAP for complete financial statements. In the opinion of management, the accompanying unaudited condensed consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, that are necessary for a fair statement of financial position, results of operations, cash flows, and stockholders' equity for the interim periods presented. Interim results are not necessarily indicative of results for a full year. Use of Estimates The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ from those estimates. Inventory Inventory is carried at the lower of cost or net realizable value. The costs of inventory are determined using the standard cost method, which approximates actual cost based on a first-in, first-out method. Items in inventory relate predominantly to the Company's ClearPoint system and related disposables. Software license inventory related to ClearPoint systems undergoing on-site customer evaluation is included in inventory in the accompanying condensed consolidated balance sheets. All other software license inventory is classified as a non-current asset. The Company periodically reviews its inventory for excess and obsolete items and provides a reserve upon identification of potentially excess or obsolete items. Intangible Assets The Company is a party to a license agreement that provides rights to the Company for the development and commercialization of products. Under the terms of the license agreement, the Company made payments to the licensor upon execution of the license agreement for access to the underlying technology, and future payments will be based upon achievement of regulatory and commercialization milestones as defined in the license agreement. In 2022, the Company made a payment to the licensor for the achievement of a regulatory milestone, which acts as a prepayment for future royalties. In conformity with Accounting Standards Codification Section (ASC) 350, "Intangibles - Goodwill and Other," the Company amortizes the payments related to the license rights described above over an expected useful life of up to five years, or as commercial sales occur that are related to the royalty prepayment. In addition, the Company periodically evaluates the recoverability of its investment in the license rights and records an impairment charge in the event such evaluation indicates that the Company's investment is not likely to be recovered. Revenue Recognition The Company's revenue is comprised primarily of: (1) product revenue resulting from the sale of neurosurgery, navigation, therapy, and biologics and drug delivery disposable products; (2) product revenue resulting from the sale of ClearPoint capital equipment and software; (3) service revenue and case support revenue in connection with customer-sponsored preclinical and clinical trials; (4) license revenue for the granting of licenses to develop and commercialize the Company's SmartFlow Cannula devices with the Company's customers' proprietary biologics as a combination product; and (5) revenue resulting from the service, installation, training, and shipping related to ClearPoint capital equipment and software. The Company recognizes revenue when (i) control of the Company's products is transferred to its customers or (ii) services are provided to customers, each in an amount that reflects the consideration the Company expects to receive from its customers in exchange for those products and services, in a process that involves identifying the contract with a customer, identifying the performance obligations in the contract, determining the transaction price, allocating the transaction price to the distinct performance obligations in the contract, and recognizing revenue when or as the performance obligations have been satisfied. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. When a contract calls for the satisfaction of multiple performance obligations for a single contract price, the Company typically allocates the contract price among the performance obligations based on the relative stand-alone selling prices for each such performance obligation customarily charged by the Company. The Company considers a performance obligation satisfied once it has transferred control of a good or service to the customer, meaning the customer has the ability to use and obtain the benefit of the good or service. The Company recognizes revenue for satisfied performance obligations only when it determines there are no uncertainties regarding payment terms or transfer of control. Lines of Business; Timing of Revenue Recognition Neurosurgery navigation product, biologics and drug delivery systems product, and therapy product sales: Revenue from the sale of neurosurgery navigation products (consisting of disposable products sold commercially and related to cases utilizing the Company's ClearPoint system), biologics and drug delivery products (consisting primarily of disposable products related to customer-sponsored clinical trials utilizing the ClearPoint system), and therapy products (consisting primarily of disposable laser-related products used in neurosurgical procedures) is generally based on customer purchase orders, the predominance of which require delivery within one week of the order having been placed, and is generally recognized at the point in time of shipping to the customer, which is the point at which legal title, and risks and rewards of ownership, transfer to the customer. For certain customers, legal title and risks and rewards of ownership transfer upon delivery to the customer as stated in their respective contracts, in which case revenue is recognized upon delivery. Capital equipment and software sales: Capital equipment and software sales preceded by evaluation periods: The predominance of capital equipment and software sales (consisting of integrated computer hardware and software that are integral components of the Company's ClearPoint system) are preceded by customer evaluation periods. During these evaluation periods, installation of, and training of customer personnel on, the systems have been completed and the systems have been in operation. Accordingly, revenue from capital equipment and software sales following such evaluation periods is recognized at the point in time that the Company is in receipt of an executed purchase agreement or purchase order. Capital equipment and software sales not preceded by evaluation periods: Revenue from sales of capital equipment and software not having been preceded by an evaluation period is recognized upon delivery to the customer and installation. For capital equipment that does not require installation, revenue is recognized upon shipment; however, for those customers where legal title and risks and rewards of ownership transfer upon delivery, revenue is recognized at such time. For both types of capital equipment and software sales described above, the determination of the point in time at which to recognize revenue represents that point at which the customer has legal title, physical possession, and the risks and rewards of ownership, and the Company has a present right to payment. Neurosurgery navigation and therapy services: The Company recognizes revenue for such services over time as the services are delivered to the customer based on the extent of progress towards completion of the performance obligation. Biologics and drug delivery services and other revenue: Professional and Consulting Services: The Company recognizes professional and consulting revenue over time as the services are delivered to the customer based on the extent of progress towards completion of the performance obligation. The Company may use output methods, such as time elapsed, or input methods, such as labor hours expended or costs incurred, to measure progress depending on which better depicts the transfer of control to the customer. Clinical Service Access Fees: For contracts in which the Company receives a periodic fixed fee, irrespective of the number of cases attended by the Company's personnel or hours incurred during such periods, revenue is recognized ratably over the period covered by such fees. A time-elapsed output method is used for such fees because the Company transfers control evenly by providing a stand-ready service. Procedure-Based Service Fees: The Company recognizes revenue at the point in time a relevant case is completed. License fees: License fees represent the use of functional intellectual property as it exists at the point in time at which the license is granted and does not require any significant development or customization. Accordingly, the Company recognizes license revenue at the point in time in which the license becomes effective and the intellectual property is made available to the customer. Milestone fees: Event-based payments which are subject to the customer's achievement of specified development or regulatory milestones are included in the transaction price if, in the Company's judgment, it is probable that these milestones will be achieved and a significant future reversal of cumulative revenue under the contract will not occur. The Company re-evaluates the probability of achievement of such milestones at the end of each reporting period and adjusts the transaction price as necessary. Capital equipment-related services: Equipment service: Revenue from service of ClearPoint capital equipment and software previously sold to customers is based on agreements with terms ranging from one to three years and is recognized ratably on a monthly basis over the term of the service agreement. A time-elapsed output method is used for service revenue because the Company transfers control evenly by providing a stand-ready service. The Company may also enter into contracts with customers who own ClearPoint capital equipment, which bundle maintenance and support services and access to software and hardware upgrades made commercially available over the term of the contract, for a single contract price, typically paid on an annual basis. The Company allocates the contract price among the performance obligations based on the relative stand-alone prices for each such performance obligation and recognizes the revenue ratably on a monthly basis. A time-elapsed output method is used as the Company is providing a stand-ready service for each of the performance obligations. Installation, training and shipping: Consistent with the Company's recognition of revenue for capital equipment and software sales as described above, fees for installation, training and shipping in connection with sales of capital equipment and software that have been preceded by customer evaluation periods are recognized as revenue at the point in time the Company is in receipt of an executed purchase agreement or purchase order for the equipment and software. Installation, training and shipping fees related to capital equipment and software sales not having been preceded by an evaluation period are recognized as revenue concurrent with the recognition of revenue from sales of the related capital equipment. The Company operates in one industry segment, and the predominance of its sales are to U.S.-based customers. Payment terms under contracts with customers generally are in a range of 30-60 days after the customer's receipt of the Company's invoices. The Company's terms and conditions do not provide for a right of return unless for: (a) product defects; or (b) other conditions subject to the Company's approval. See Note 3 for additional information regarding revenue recognition. Net Loss Per Share The Company computes net loss per share using the weighted-average number of common shares outstanding during the period. Basic and diluted net loss per share are the same because the conversion, exercise or issuance of all potential common stock equivalents, which comprise the Company's outstanding common stock options and unvested restricted stock units, as described in Note 8, would be anti-dilutive, due to the reporting of a net loss for each of the periods in the accompanying condensed consolidated statements of operations. Concentration Risks and Other Risks and Uncertainties Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable. The Company may at times invest its excess cash in interest bearing accounts and U.S. government debt securities. It classifies all highly liquid investments with original stated maturities of three months or less from the date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months but less than twelve months as short-term investments. The Company holds the remainder of its cash and cash equivalents on deposit with financial institutions in the U.S. insured by the Federal Deposit Insurance Corporation. At September 30, 2024, the Company had approximately \$1.1 million in bank balances that were in excess of the insured limits. At September 30, 2024, there was one customer whose accounts receivable balance represented 11% of accounts receivable at that date. At December 31, 2023, there were four customers whose accounts receivable balances represented 80% of accounts receivable at that date. One pharmaceutical customer, a related

party who is a stockholder and whose chief executive officer is a member of the Company's Board of Directors, for whom the Company provides hardware, software, clinical services and market development services in support of the customer's clinical trials, and from whom the Company earns a quarterly fee, accounted for 9% and 12% of total sales in both the three and nine-month periods ended September 30, 2024 and 2023, respectively. There was one additional customer, who comprised 13% of the total sales in the three-month period ended September 30, 2024, and another customer who comprised 10% of the total sales in the three-month period ended September 30, 2023. Prior to granting credit to a customer, the Company generally performs credit evaluations of the customer's financial condition. In general, the Company does not require collateral from customers in connection with an extension of credit. The accounts receivable balance is reduced by an allowance for credit losses from the potential inability of the Company's customers to make required payments. The allowance for credit losses at September 30, 2024, and December 31, 2023, was \$0.9 million and \$1.4 million, respectively. The Company evaluates the historic loss experience on the accounts receivable balance and also considers separately customers with receivable balances that may be negatively impacted by current economic developments and market conditions. The estimate is a result of the Company's ongoing evaluation of collectability, customer creditworthiness, historical levels of credit losses and future expectations. The Company is subject to risks common to emerging companies in the medical device industry, including, but not limited to: new technological innovations; acceptance and competitiveness of its products; dependence on key personnel; dependence on key suppliers; its ability to maintain its third-party collaboration, license and joint development partners, and enter into new relationships; changes in general economic conditions and interest rates; its ability to obtain additional funding to support its business; regulatory uncertainty; protection of proprietary technology; compliance with changing government regulations; uncertainty of widespread market acceptance of products; access to credit for capital purchases by customers; and intellectual property and product liability claims. Certain components used in manufacturing have relatively few alternative sources of supply and establishing additional or replacement suppliers for such components cannot be accomplished quickly. The inability of any of these suppliers to fulfill the Company's supply requirements may negatively impact future operating results. Recent Accounting Standards Not Yet Adopted In November 2023, the FASB issued ASU 2023-07, "Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures." The amendments improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. In addition, the amendments enhance interim disclosure requirements, clarify circumstances in which an entity can disclose multiple segment measures of profit or loss, provide new segment disclosure requirements for entities with a single reportable segment, and contain other disclosure requirements. ASU 2023-07 is effective for calendar year-end public business entities in 2024 annual reporting and in 2025 interim reporting. Early adoption is permitted. The Company expects to adopt ASU 2023-07 retrospectively in its 2024 annual financial reporting and its 2025 interim financial reporting, and is currently evaluating the impact of this ASU on its consolidated financial statements. In December 2023, the FASB issued ASU 2023-09, "Improvements to Income Tax Disclosures," which requires that an entity, on an annual basis, disclose additional income tax information, primarily related to the rate reconciliation and income taxes paid. The provisions of the ASU are intended to enhance the transparency and decision usefulness of income tax disclosures. The guidance may be applied on a prospective basis with the option to apply the standard retrospectively and is effective for calendar year-end public business entities in the 2025 annual period and in 2026 for interim periods with early adoption permitted. The Company is currently evaluating the impact of this ASU on its consolidated financial statements. X - ReferencesNo definition available. + Details Name: us-gaap\_AccountingPoliciesAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Our Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity. + ReferencesReference 1:



S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482400/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap NetIncomeLoss Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 27 R17.htm IDEA: XBRL DOCUMENT v3.24.3 Insider Trading Arrangements 3 Months Ended Sep. 30, 2024 Trading Arrangements, by Individual A Rule 10b5-1 Arrangement Adopted false Non-Rule 10b5-1 Arrangement Terminated false Non-Rule 10b5-1 Arrangement Terminated false X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd NonRule10b51ArrAdoptedFlag Namespace Prefix: ecd Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd NonRule10b51ArrTrmndFlag Namespace Prefix: ecd Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd Rule10b51ArrAdoptedFlag Namespace Prefix: ecd Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph A + Details Name: ecd TradingArrByIndTable Namespace Prefix: ecd Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 28 R18.htm IDEA: XBRL DOCUMENT v3.24.3 Basis of Presentation and Summary of Significant Accounting Policies (Policies) 9 Months Ended Sep. 30, 2024 Accounting Policies [Abstract] A Basis of Presentation Basis of PresentationThe accompanying unaudited condensed consolidated financial statements of the Company should be read in conjunction with the audited financial statements and notes thereto as of and for the year ended December 31, 2023 included in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC"). The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States ("U.S. GAAP") for interim financial information and in accordance with the rules and regulations of the SEC related to a quarterly report on Form 10-Q. Accordingly, since they are interim statements, the accompanying unaudited condensed consolidated financial statements do not include all of the information and notes required by U.S. GAAP for complete financial statements. In the opinion of management, the accompanying unaudited condensed consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, that are necessary for a fair statement of financial position, results of operations, cash flows, and stockholders' equity for the interim periods presented. Interim results are not necessarily indicative of results for a full year. Use of Estimates Use of EstimatesThe preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ from those estimates. Inventory InventoryInventory is carried at the lower of cost or net realizable value. The costs of inventory are determined using the standard cost method, which approximates actual cost based on a first-in, first-out method. Items in inventory relate predominantly to the Company's ClearPoint™ system and related disposables. Software license inventory related to ClearPoint systems undergoing on-site customer evaluation is included in inventory in the accompanying condensed consolidated balance sheets. All other software license inventory is classified as a non-current asset. The Company periodically reviews its inventory for excess and obsolete items and provides a reserve upon identification of potentially excess or obsolete items. Intangible Assets Intangible AssetsThe Company is a party to a license agreement that provides rights to the Company for the development and commercialization of products. Under the terms of the license agreement, the Company made payments to the licensor upon execution of the license agreement for access to the underlying technology, and future payments will be based upon achievement of regulatory and commercialization milestones as defined in the license agreement. In 2022, the Company made a payment to the licensor for the achievement of a regulatory milestone, which acts as a prepayment for future royalties. In conformity with Accounting Standards Codification (ASC) 350, "Intangibles â€" Goodwill and Other," the Company amortizes the payments related to the license rights described above over an expected useful life of up to five years, or as commercial sales occur that are related to the royalty prepayment. In addition, the Company periodically evaluates the recoverability of its investment in the license rights and records an impairment charge in the event such evaluation indicates that the Company's investment is not likely to be recovered. Revenue Recognition Revenue RecognitionThe Company's revenue is comprised primarily of: (1) product revenue resulting from the sale of neurosurgery, navigation, therapy, and biologics and drug delivery disposable products; (2) product revenue resulting from the sale of ClearPoint capital equipment and software; (3) service revenue and case support revenue in connection with customer-sponsored preclinical and clinical trials; (4) license revenue for the granting of licenses to develop and commercialize the Company's SmartFlow Cannula devices with the Company's customers' proprietary biologics as a combination product; and (5) revenue resulting from the service, installation, training, and shipping related to ClearPoint capital equipment and software. The Company recognizes revenue when (i) control of the Company's products is transferred to its customers or (ii) services are provided to customers, each in an amount that reflects the consideration the Company expects to receive from its customers in exchange for those products and services, in a process that involves identifying the contract with a customer, identifying the performance obligations in the contract, determining the transaction price, allocating the transaction price to the distinct performance obligations in the contract, and recognizing revenue when or as the performance obligations have been satisfied. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. When a contract calls for the satisfaction of multiple performance obligations for a single contract price, the Company typically allocates the contract price among the performance obligations based on the relative stand-alone selling prices for each such performance obligation customarily charged by the Company. The Company considers a performance obligation satisfied once it has transferred control of a good or service to the customer, meaning the customer has the ability to use and obtain the benefit of the good or service. The Company recognizes revenue for satisfied performance obligations only when it determines there are no uncertainties regarding payment terms or transfer of control.Lines of Business; Timing of Revenue Recognitionâ€"Neurosurgery navigation product, biologics and drug delivery systems product, and therapy product sales: Revenue from the sale of neurosurgery navigation products (consisting of disposable products sold commercially and related to cases utilizing the Company's ClearPoint system), biologics and drug delivery products (consisting primarily of disposable products related to customer-sponsored clinical trials utilizing the ClearPoint system), and therapy products (consisting primarily of disposable laser-related products used in neurosurgical procedures) is generally based on customer purchase orders, the predominance of which require delivery within one week of the order having been placed, and is generally recognized at the point in time of shipping to the customer, which is the point at which legal title, and risks and rewards of ownership, transfer to the customer. For certain customers, legal title and risks and rewards of ownership transfer upon delivery to the customer as stated in their respective contracts, in which case revenue is recognized upon delivery.â€"Capital equipment and software sales:â€"Capital equipment and software sales preceded by evaluation periods: The predominance of capital equipment and software sales (consisting of integrated computer hardware and software that are integral components of the Company's ClearPoint system) are preceded by customer evaluation periods. During these evaluation periods, installation of, and training of customer personnel on, the systems have been completed and the systems have been in operation. Accordingly, revenue from capital equipment and software sales following such evaluation periods is recognized at the point in time that the Company is in receipt of an executed purchase agreement or purchase order.â€"Capital equipment and software sales not preceded by evaluation periods:â€"Revenue from sales of capital equipment and software not having been preceded by an evaluation period is recognized upon delivery to the customer and installation. For capital equipment that does not require installation, revenue is recognized upon shipment; however, for those customers where legal title and risks and rewards of ownership transfer upon delivery, revenue is recognized at such time.For both types of capital equipment and software sales described above, the determination of the point in time at which to recognize revenue represents that point at which the customer has legal title, physical possession, and the risks and rewards of ownership, and the Company has a present right to payment.â€"Neurosurgery navigation and therapy services: The Company recognizes revenue for such services over time as the services are delivered to the customer based on the extent of progress towards completion of the performance obligation.â€"Biologics and drug delivery services and other revenue:â€"Professional and Consulting Services: The Company recognizes professional and consulting revenue over time as the services are delivered to the customer based on the extent of progress towards completion of the performance obligation. The Company may use output methods, such as time elapsed, or input methods, such as labor hours expended or costs incurred, to measure progress depending on which better depicts the transfer of control to the customer.â€"Clinical Service Access Fees: For contracts in which the Company receives a periodic fixed fee, irrespective of the number of cases attended by the Company's personnel or hours incurred during such periods, revenue is recognized ratably over the period covered by such fees. A time-elapsed output method is used for such fees because the Company transfers control evenly by providing a stand-ready service.â€"Procedure-Based Service Fees: The Company recognizes revenue at the point in time a relevant case is completed.â€"License fees: License fees represent the use of functional intellectual property as it exists at the point in time at which the license is granted and does not require any significant development or customization. Accordingly, the Company recognizes license revenue at the point in time in which the license becomes effective and the intellectual property is made available to the customer.â€"Milestone fees: Event-based payments which are subject to the customer's achievement of specified development or regulatory milestones are included in the transaction price if, in the Company's judgment, it is probable that these milestones will be achieved and a significant future reversal of cumulative revenue under the contract will not occur. The Company re-evaluates the probability of achievement of such milestones at the end of each reporting period and adjusts the transaction price as necessary.â€"Capital equipment-related services:â€"Equipment service: Revenue from service of ClearPoint capital equipment and reporting

previously sold to customers is based on agreements with terms ranging from one to three years and is recognized ratably on a monthly basis over the term of the service agreement. A time-elapsed output method is used for service revenue because the Company transfers control evenly by providing a stand-ready service. The Company may also enter into contracts with customers who own ClearPoint capital equipment, which bundle maintenance and support services and access to software and hardware upgrades made commercially available over the term of the contract, for a single contract price, typically paid on an annual basis. The Company allocates the contract price among the performance obligations based on the relative stand-alone prices for each such performance obligation and recognizes the revenue ratably on a monthly basis. A time-elapsed output method is used as the Company is providing a stand-ready service for each of the performance obligations.—Installation, training and shipping: Consistent with the Company’s recognition of revenue for capital equipment and software sales as described above, fees for installation, training and shipping in connection with sales of capital equipment and software that have been preceded by customer evaluation periods are recognized as revenue at the point in time the Company is in receipt of an executed purchase agreement or purchase order for the equipment and software. Installation, training and shipping fees related to capital equipment and software sales not having been preceded by an evaluation period are recognized as revenue concurrent with the recognition of revenue from sales of the related capital equipment. The Company operates in one industry segment, and the predominance of its sales are to U.S.-based customers. Payment terms under contracts with customers generally are in a range of 30-60 days after the customers’ receipt of the Company’s invoices. The Company’s terms and conditions do not provide for a right of return unless for: (a) product defects; or (b) other conditions subject to the Company’s approval. Net Loss Per Share Net Loss Per Share The Company computes net loss per share using the weighted-average number of common shares outstanding during the period. Basic and diluted net loss per share are the same because the conversion, exercise or issuance of all potential common stock equivalents, which comprise the Company’s outstanding common stock options and unvested restricted stock units, as described in Note 8, would be anti-dilutive, due to the reporting of a net loss for each of the periods in the accompanying condensed consolidated statements of operations. Concentration Risks and Other Risks and Uncertainties Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable. The Company may at times invest its excess cash in interest bearing accounts and U.S. government debt securities. It classifies all highly liquid investments with original stated maturities of three months or less from the date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months but less than twelve months as short-term investments. The Company holds the remainder of its cash and cash equivalents on deposit with financial institutions in the U.S. insured by the Federal Deposit Insurance Corporation. At September 30, 2024, the Company had approximately \$1.1 million in bank balances that were in excess of the insured limits. At September 30, 2024, there was one customer whose accounts receivable balance represented 11% of accounts receivable at that date. At December 31, 2023, there were four customers whose accounts receivable balances represented 80% of accounts receivable at that date. One pharmaceutical customer, a related party who is a stockholder and whose chief executive officer is a member of the Company’s Board of Directors, for whom the Company provides hardware, software, clinical services and market development services in support of the customer’s clinical trials, and from whom the Company earns a quarterly fee, accounted for 9% and 12% of total sales in both the three and nine-month periods ended September 30, 2024 and 2023, respectively. There was one additional customer, who comprised 13% of the total sales in the three-month period ended September 30, 2024, and another customer who comprised 10% of the total sales in the three-month period ended September 30, 2023. Prior to granting credit to a customer, the Company generally performs credit evaluations of the customer’s financial condition. In general, the Company does not require collateral from customers in connection with an extension of credit. The accounts receivable balance is reduced by an allowance for credit losses from the potential inability of the Company’s customers to make required payments. The allowance for credit losses at September 30, 2024, and December 31, 2023, was \$0.9 million and \$1.4 million, respectively. The Company evaluates the historic loss experience on the accounts receivable balance and also considers separately customers with receivable balances that may be negatively impacted by current economic developments and market conditions. The estimate is a result of the Company’s ongoing evaluation of collectability, customer creditworthiness, historical levels of credit losses and future expectations. The Company is subject to risks common to emerging companies in the medical device industry, including, but not limited to: new technological innovations; acceptance and competitiveness of its products; dependence on key personnel; dependence on key suppliers; its ability to maintain its third-party collaboration, license and joint development partners, and enter into new relationships; changes in general economic conditions and interest rates; its ability to obtain additional funding to support its business; regulatory uncertainty; protection of proprietary technology; compliance with changing government regulations; uncertainty of widespread market acceptance of products; access to credit for capital purchases by customers; and intellectual property and product liability claims. Certain components used in manufacturing have relatively few alternative sources of supply and establishing additional or replacement suppliers for such components cannot be accomplished quickly. The inability of any of these suppliers to fulfill the Company’s supply requirements may negatively impact future operating results. Recent Accounting Standards Not Yet Adopted Recent Accounting Standards Not Yet Adopted In November 2023, the FASB issued ASU 2023-07, “Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures.” The amendments improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. In addition, the amendments enhance interim disclosure requirements, clarify circumstances in which an entity can disclose multiple segment measures of profit or loss, provide new segment disclosure requirements for entities with a single reportable segment, and contain other disclosure requirements. ASU 2023-07 is effective for calendar year-end public business entities in 2024 annual reporting and in 2025 interim reporting. Early adoption is permitted. The Company expects to adopt ASU 2023-07 retrospectively in its 2024 annual financial reporting and its 2025 interim financial reporting, and is currently evaluating the impact of this ASU on its consolidated financial statements. In December 2023, the FASB issued ASU 2023-09, “Improvements to Income Tax Disclosures,” which requires that an entity, on an annual basis, disclose additional income tax information, primarily related to the rate reconciliation and income taxes paid. The provisions of the ASU are intended to enhance the transparency and decision usefulness of income tax disclosures. The guidance may be applied on a prospective basis with the option to apply the standard retrospectively and is effective for calendar year-end public business entities in the 2025 annual period and in 2026 for interim periods with early adoption permitted. The Company is currently evaluating the impact of this ASU on its consolidated financial statements. X - ReferencesNo definition available. + Details Name: us-gaap AccountingPoliciesAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). + ReferencesNo definition available. + Details Name: us-gaap BasisOfAccountingPolicyPolicyTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for credit risk. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 825 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478989/942-825-50-1> Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(d\) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1) + Details Name: us-gaap ConcentrationRiskCreditRisk Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1) Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1> Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2> + Details Name: us-gaap EarningsPerSharePolicyTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets. + ReferencesReference 1: [http://www.xbrl.org/2003/role/exampleRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4](http://www.xbrl.org/2003/role/exampleRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4) Reference 2: <http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-30/tableOfContentReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5> Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 920 -SubTopic 350 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478609/920-350-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 920 -SubTopic 350 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478609/920-350-50-1) Reference 5: [http://www.xbrl.org/2003/role/disclosureRef -Topic 920 -SubTopic 350 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478609/920-350-50-4](http://www.xbrl.org/2003/role/disclosureRef -Topic 920 -SubTopic 350 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478609/920-350-50-4) + Details Name: us-gaap IntangibleAssetsFiniteLivedPolicy Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(b\)\(6\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(b)(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1) Reference 2: <http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483080/330-10-50-1> Reference 3: <http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1> Reference 4: [http://www.xbrl.org/2003/role/exampleRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4](http://www.xbrl.org/2003/role/exampleRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4) Reference 5: <http://www.xbrl.org/2003/role/disclosureRef -Topic 912 -SubTopic 330 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147484119/912-330-50-1> Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483080/330-10-50-4](http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/330/tableOfContentReference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483080/330-10-50-4) Reference 8: [http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 6 -Subparagraph \(a\) -SubTopic 10 -Topic 270 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482989/270-10-45-6](http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 6 -Subparagraph (a) -SubTopic 10 -Topic 270 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482989/270-10-45-6) + Details Name: us-gaap InventoryPolicyTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity’s financial reporting. Includes, but is not limited to, quantification of the expected or actual impact. + ReferencesNo definition available. + Details Name: us-gaap NewAccountingPronouncementsPolicyTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-07\(1\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1) Reference 2: [http://www.xbrl.org/2003/role/exampleRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4](http://www.xbrl.org/2003/role/exampleRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4) Reference 3: [http://www.xbrl.org/2003/role/exampleRef -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph \(e\) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4](http://www.xbrl.org/2003/role/exampleRef -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (e) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4) + Details Name: us-gaap RevenueRecognitionPolicyTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9> Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4> Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(b\) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1) Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(c\) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1) Reference 5: <http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 11 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11> Reference 6: <http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 12 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12> Reference 7: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8> + Details Name: us-gaap UseOfEstimates Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 29 R19.htm IDEA: XBRL DOCUMENT v3.24.3 Revenue Recognition (Tables) 9 Months Ended Sep. 30, 2024 Revenue from Contract with Customer [Abstract] A Schedule of Revenue by Service Line Revenue by Service Line Three Months Ended September 30, (in thousands) 2024 2023 Biologics and drug delivery Disposable products \$2,062A \$455A Services and license fees \$2,369A 3,032A Subtotal \$4,424A Biologics and drug delivery revenue \$4,431A 3,487A Neurosurgery navigation and therapy Disposable products \$2,860A 1,874A Services \$4,444A Subtotal \$4,444A Neurosurgery navigation and therapy \$2,860A 1,918A Capital equipment and software Systems and software products \$552A 81A Services \$279A 276A Subtotal \$831A 357A Total revenue \$8,122A \$5,762A Nine Months Ended September 30, (in thousands) 2024 2023 Biologics and drug delivery Disposable products \$4,286A \$1,395A Services and license fees \$8,779A 8,136A Subtotal \$6,466A Biologics and drug delivery revenue \$13,065A 9,531A Neurosurgery navigation and therapy Disposable products \$7,373A 5,550A Services \$4,930A Subtotal \$12,303A Neurosurgery navigation and therapy \$7,373A 6,480A Capital equipment and software Systems and software products \$2,394A 432A Services \$787A 702A Subtotal \$4,181A 3,181A Total revenue \$23,619A \$17,145A Schedule of Other Current Assets September 30, 2024 December 31, 2023 (in thousands) Accounts receivable, net \$3,875A \$3,211A Other contract assets Unbilled receivables \$662A \$733A Schedule of Revenue Recognized by Contract Liability The unearned portion of all such fees is classified as deferred revenue. September 30, 2024 December 31, 2023 (in thousands) Deferred revenues \$1,732A \$3,154A X - Definition Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10> + Details Name: us-gaap ContractWithCustomerAssetAndLiabilityTableTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap RevenueFromContractWithCustomerAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition Tabular disclosure of entity revenue from external customers for each product or

service or each group of similar products or services if the information is not provided as part of the reportable operating segment information. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40> + Details Name: us-gaap ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the carrying amounts of other current assets. + ReferencesNo definition available. + Details Name: us-gaap ScheduleOfOtherCurrentAssetsTableTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 30 R20.htm IDEA: XBRL DOCUMENT v3.24.3 Inventory (Tables) 9 Months Ended Sep. 30, 2024 Inventory Disclosure [Abstract] A Schedule of Inventory Inventory consists of the following as of September 30, 2024 and December 31, 2023:(in thousands)September 30,2024December 31,2023Raw materials and work in process\$5,591A \$6,466A Software licenses174A 211A Finished goods1,294A 1,234A Inventory, net, included in current assets7,059A 7,911A Software licenses â€œ non-current198A 386A Totals7,257A \$8,297A X - ReferencesNo definition available. + Details Name: us-gaap InventoryDisclosureAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(6\)\(a\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(6\)\(b\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(6\)\(c\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1) + Details Name: us-gaap ScheduleOfInventoryCurrentTableTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 31 R21.htm IDEA: XBRL DOCUMENT v3.24.3 Stockholdersâ€™ Equity (Tables) 9 Months Ended Sep. 30, 2024 Equity [Abstract] A Schedule of Share-Based Compensation Expense The following table sets forth share-based compensation expense included in the condensed consolidated statements of operations: Three Months Ended September 30,(in thousands)20242023Cost of revenue\$31A \$26A Research and development461A 357A Sales and marketing537A 431A General and administrative875A 770A Share-based compensation expense1,904A \$1,584A Nine Months Ended September 30,(in thousands)20242023Cost of revenue\$82A \$74A Research and development1,204A 1,009A Sales and marketing1,482A 1,277A General and administrative2,436A 2,176A Share-based compensation expense5,204A \$4,536A Share-based compensation expense by type of share-based award is summarized below:(Three Months Ended September 30,(in thousands)20242023Stock options\$151A \$233A RSAs and RSUs1,719A 1,308A ESP\$34A 43A \$1,904A \$1,584A Nine Months Ended September 30,(in thousands)20242023Stock options\$554A \$747A RSAs and RSUs4,495A 3,612A ESP\$155A 177A \$5,204A \$4,536A Total unrecognized compensation expense by type of award and the weighted-average remaining requisite holding period over which such expense is expected to be recognized is as follows (in thousands, unless otherwise noted):September 30, 2024Unrecognized ExpenseRemaining Weighted-Average Recognition Period (in years)Stock options\$446A 1.13RSAs and RSUs\$9,548A 1.85 Schedule of Stock Option Activity Stock option activity during the nine months ended September 30, 2024 is summarized below:Stock OptionsWeighted-averageExercise priceper shareWeighted-averageRemaining Contractual Life (in years)Intrinsic Value(1)(in thousands)Outstanding at December 31, 20231,478,157A \$8.40A Exercised(12,000)\$2.89A Forfeited or expired(7,237)\$42.19A Outstanding at September 30, 20241,458,920A \$8.28A 4.7458,187A Exercisable at September 30, 20241,328,249A \$8.19A 4.4087,911A Vested and expected to vest at September 30, 20241,458,920A \$8.28A 4.7458,187A (1)Intrinsic value is calculated as the estimated fair value of the Companyâ€™s stock at the end of the related period less the option exercise price of in-the-money options. Schedule of Restricted Stock Activity Restricted stock award ("RSA") activity for the nine months ended September 30, 2024 is summarized below:Restricted Stock AwardsWeighted - Average Grant Date Fair ValueOutstanding at December 31, 2023376,914A \$12.02A Vested(195,173)\$12.93A Forfeited(6,019)\$12.35A Outstanding at September 30, 2024175,722A \$10.99A Restricted Stock Unit ActivityRestricted stock unit ("RSU") activity for the nine months ended September 30, 2024 is summarized below:Restricted Stock UnitsWeighted - Average Grant Date Fair ValueOutstanding at December 31, 2023768,139A \$8.15A Granted1,197,646A \$6.16A Vested(267,328)\$7.99A Forfeited(17,849)\$8.40A Outstanding at September 30, 20241,680,608A \$6.75A X - ReferencesNo definition available. + Details Name: us-gaap EquityAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionTabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph \(h\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - DefinitionTabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(d\) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(e\) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - DefinitionDisclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year. + ReferencesNo definition available. + Details Name: us-gaap ScheduleOfShareBasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 32 R22.htm IDEA: XBRL DOCUMENT v3.24.3 Description of the Business and Financial Condition (Details) \$ in Thousands 1 Months Ended 9 Months Ended 12 Months Ended Aug. 31, 2024 USD (\$) investor Mar. 31, 2024 USD (\$) investor May 31, 2021 USD (\$) Sep. 30, 2024 USD (\$) customer Sep. 30, 2023 USD (\$) Dec. 31, 2023 USD (\$) Jan. 31, 2020 investor Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] A A A A A A Number of customers (more than) | customer A A A A A A Cumulative deficit A A A A \$ 185,984 A \$ 172,456 A Net cash used in operations A A A A 7,707 \$ 12,551 13,700 A Net proceeds from offering A A A A 16,183 \$ 0 A A Secured convertible notes A A A A \$ 0 A \$ 9,949 A Public Offering A A A A A A Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] A A A A A A Public offering (in shares) | shares A 2,653,848 A A A A Net proceeds from offering A A A A 16,200 A A A A Security Purchase Agreement | Convertible Debt A A A A A A Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] A A A A A A Debt instrument, number of investors | investor 2 A A A A A A Secured convertible notes \$ 25,000 A A A A A A Debt instrument, conversion amount 15,000 A A A A A A Security Purchase Agreement | Convertible Debt | First Closing Notes A A A A A A Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] A A A A A A A A Repayments of debt \$ 10,000 A A A A A A Debt instrument, number of investors | investor A A A A A A 2 Debt instrument, conversion amount A A \$ 7,500 A A A A X - DefinitionConvertible Notes, Number Of Investors + ReferencesNo definition available. + Details Name: clpt ConvertibleNotesNumberOfInvestors Namespace Prefix: clpt Data Type: xbrli:integerItem Type Balance Type: na Period Type: instant X - DefinitionNumber Of Customers + ReferencesNo definition available. + Details Name: clpt NumberOfCustomers Namespace Prefix: clpt Data Type: xbrli:integerItem Type Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1) + Details Name: us-gaap CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionThe value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5> + Details Name: us-gaap DebtConversionConvertedInstrumentAmount1 Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25) + Details Name: us-gaap DebtConversionConvertedInstrumentAmount1 Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25) + Details Name: us-gaap NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: na Period Type: duration X - DefinitionThe cash inflow from the additional capital contribution to the entity. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph \(a\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14) + Details Name: us-gaap ProceedsFromIssuanceOfCommonStock Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionAmount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation. + ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15) + Details Name: us-gaap RepaymentsOfDebt Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph \(g\)\(2\)\(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph \(h\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-03\(a\)\(23\)\(a\)\(4\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-04\(17\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.3-04\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1) + Details Name: us-gaap RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionThe number of shares issued or sold by the subsidiary or equity method investee per stock transaction. + ReferencesNo definition available. + Details Name: us-gaap SaleOfStockNumberOfSharesIssuedInTransaction Namespace Prefix: us-gaap Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - DefinitionCarrying amount of collateralized debt obligations with maturities initially due after one year or beyond the operating cycle, if longer, excluding the current portion. Obligations include, but not limited to, mortgage loans, chattel loans, and other borrowings secured by assets. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(22\)\) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1) + Details Name: us-gaap SecuredLongTermDebt Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - Details Name: us-gaap SubsidiarySaleOfStockAxis=clpt PublicOfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap TypeOfArrangementAxis=clpt SecurityPurchaseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap LongtermDebtTypeAxis=us-gaap ConvertibleDebtMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap DebtInstrumentAxis=clpt FirstClosingNotesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 33 R23.htm IDEA: XBRL DOCUMENT v3.24.3 Basis of Presentation and Summary of Significant Accounting Policies (Details) \$ in Millions 3 Months Ended 9 Months Ended 12 Months Ended Sep. 30, 2024 USD (\$) Sep. 30, 2023 Sep. 30, 2024 USD (\$) segment Sep. 30, 2023 Dec. 31, 2023 USD (\$) Product Information [Line Items] A A A A Number of industry segments | segment A 1 A A Cash, uninsured amount \$ 1.1 A \$ 1.1 A Allowance for doubtful accounts \$ 0.9 A \$ 0.9 A \$ 1.4 Accounts Receivable | Customer Concentration Risk | Customer 1 A A A A Product Information [Line Items] A A A A Concentration risk, percentage A A 11.00% A Revenue Receivable | Customer Concentration Risk | Four Customers A A A A Product Information [Line Items] A A A A Concentration risk, percentage A A A A 80.00% Revenue Benchmark | Customer Concentration Risk | Customer 1 A A A A Product Information [Line Items] A A A A Concentration risk, percentage 9.00% 12.00% 9.00% 12.00% A Revenue Benchmark | Customer Concentration Risk | Additional Customer 1 A A A A Product Information [Line Items] A A A A Concentration risk, percentage 13.00% A A A A Revenue Benchmark | Customer Concentration Risk | Additional Customer 2 A A A A Product Information [Line Items] A A A A Concentration risk, percentage A 10.00% A A A A Minimum A A A A Product Information [Line Items] A A A A Estimated useful life 5 years A 5 years A A Term of service agreements A A 1 year A A Payment terms 30 days A 30 days A A Maximum A A A A Product Information [Line Items] A A A A Term of service agreements A A 3 years A A Payment terms 60 days A 60 days A A X - DefinitionRevenue, Performance Obligation, Payment Terms + ReferencesNo definition available. + Details Name: clpt RevenuePerformanceObligationPaymentTerms Namespace Prefix: clpt Data Type: xbrli:durationItem Type Balance Type: na Period Type: instant X - DefinitionRepresents the term for service agreements. + ReferencesNo definition available. + Details Name: clpt TermOfServiceAgreements Namespace Prefix: clpt Data Type: xbrli:durationItem Type Balance Type: na Period Type: duration X - DefinitionAmount of allowance for credit loss on accounts receivable. + ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-03\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-)

210-S99-1Reference 2:





Namespace Prefix: clpt Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - DefinitionAggregate number of common shares reserved for future issuance. + ReferencesReference 1:













31.xsd", "http://www.xbrl.org/2003/xt-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd",  
"http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/ir/role/negated-2009-12-16.xsd", "http://www.xbrl.org/ir/role/net-2009-12-16.xsd",  
"http://www.xbrl.org/ir/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",  
"https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roes-2024.xsd",  
"https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roies-2024.xsd",  
"https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",  
"https://xbrl.sec.gov/eec/2024/eec-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd", "calculationLink": { "local": { "clpt-20240930-cal.xml" }, "definitionLink": { "local": { "clpt-20240930-def.xml" } }, "labelLink": { "local": { "clpt-20240930-lab.xml" } }, "presentationLink": { "local": { "clpt-20240930-pre.xml" } }, "keyStandard": 201, "keyCustom": 16, "axisStandard": 15, "axisCustom": 0, "memberStandard": 20, "memberCustom": 24, "hidden": 9, "http://fasb.org/us-gaap/2024/2",  
"http://xbrl.sec.gov/dei/2024/5", "http://clearpointneuro.com/20240930/2", "contextCount": 176, "entityCount": 1, "segmentCount": 44, "elementCount": 443,  
"unitCount": 8, "baseTaxonomies": { "http://fasb.org/us-gaap/2024/510", "http://xbrl.sec.gov/dei/2024/30", "http://xbrl.sec.gov/eec/2024/4", "report": { "R1": { "role":  
"http://clearpointneuro.com/role/Cover", "longName": "0000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType":  
"", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null,  
"ancestors": { "span": "div", "body": "html" }, "reportCount": 1, "baseRef": "clpt-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1",  
"name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body": "html" }, "reportCount": 1, "baseRef":  
"clpt-20240930.htm", "first": true, "unique": true }, "R2": { "role": "http://clearpointneuro.com/role/CondensedConsolidatedBalanceSheets", "longName": "9952151 -  
Statement - Condensed Consolidated Balance Sheets", "shortName": "Condensed Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement",  
"subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef":  
"usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr": "table", "div": "body", "html" }, "reportCount": 1, "baseRef": "clpt-20240930.htm",  
"first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US",  
"decimals": "3", "ancestors": { "span": "td", "tr": "table", "div": "body", "html" }, "reportCount": 1, "baseRef": "clpt-20240930.htm", "unique": true }, "R3": { "role":  
"http://clearpointneuro.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "longName": "9952152 - Statement - Condensed Consolidated Balance Sheets  
(Parenthetical)", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical",  
"menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "usdPerShare",  
"xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": { "span": "div", "td": "tr", "table", "div": "body", "html" }, "reportCount": 1, "baseRef": "clpt-20240930.htm",  
"first": true, "unique": true }, "R4": { "role": "http://clearpointneuro.com/role/CondensedConsolidatedStatementsOfOperations", "longName": "9952153 - Statement - Condensed  
Consolidated Statements of Operations", "shortName": "Condensed Consolidated Statements of Operations", "isDefault": "false", "groupType": "statement",  
"subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-9", "name": "us-gaap:Revenues", "unitRef": "usd", "xsiNil": "false", "lang": "en-  
US", "decimals": "3", "ancestors": { "span": "td", "tr": "table", "div": "body", "html" }, "reportCount": 1, "baseRef": "clpt-20240930.htm", "first": true, "unique": true },  
"contextRef": "c-9", "name": "us-gaap:CostOfRevenue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr": "table", "div":  
"body", "html" }, "reportCount": 1, "baseRef": "clpt-20240930.htm", "unique": true }, "R5": { "role":  
"http://clearpointneuro.com/role/CondensedConsolidatedStatementsOfStockholdersEquity", "longName": "9952154 - Statement - Condensed Consolidated Statements of  
Stockholders' Equity", "shortName": "Condensed Consolidated Statements of Stockholders' Equity", "isDefault": "false", "groupType": "statement", "subGroupType": "",  
"menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-41", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "shares", "xsiNil": "false",  
"lang": "en-US", "decimals": "INF", "ancestors": { "span": "td", "tr": "table", "div": "body", "html" }, "reportCount": 1, "baseRef": "clpt-20240930.htm", "first": true,  
"unique": true }, "contextRef": "c-45", "name": "us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation", "unitRef": "shares", "xsiNil": "false", "lang": "en-US",  
"decimals": "INF", "ancestors": { "span": "td", "tr": "table", "div": "body", "html" }, "reportCount": 1, "baseRef": "clpt-20240930.htm", "unique": true }, "R6": { "role":  
"http://clearpointneuro.com/role/CondensedConsolidatedStatementsOfCashFlows", "longName": "9952155 - Statement - Condensed Consolidated Statements of Cash  
Flows", "shortName": "Condensed Consolidated Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements",  
"order": "6", "firstAnchor": { "contextRef": "c-9", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": {  
"span": "td", "tr": "table", "div": "body", "html" }, "reportCount": 1, "baseRef": "clpt-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-  
gaap:ProvisionForDoubtfulAccounts", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr": "table", "div": "body", "html" },  
"reportCount": 1, "baseRef": "clpt-20240930.htm", "unique": true }, "R7": { "role":  
"http://clearpointneuro.com/role/CondensedConsolidatedStatementsOfCashFlowsParenthetical", "longName": "9952156 - Statement - Condensed Consolidated Statements  
of Cash Flows (Parenthetical)", "shortName": "Condensed Consolidated Statements of Cash Flows (Parenthetical)", "isDefault": "false", "groupType": "statement",  
"subGroupType": "parenthetical", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "c-1", "name":  
"clpt:NetTransfersOfReusableComponentsFromLoanedSystems", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "5", "ancestors": { "span": "div", "td": "tr",  
"table", "div": "body", "html" }, "reportCount": 1, "baseRef": "clpt-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name":  
"clpt:NetTransfersOfReusableComponentsFromLoanedSystems", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "5", "ancestors": { "span": "div", "td": "tr",  
"table", "div": "body", "html" }, "reportCount": 1, "baseRef": "clpt-20240930.htm", "first": true, "unique": true }, "R8": { "role":  
"http://clearpointneuro.com/role/DescriptionoftheBusinessandFinancialCondition", "longName": "9952157 - Disclosure - Description of the Business and Financial  
Condition", "shortName": "Description of the Business and Financial Condition", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes",  
"order": "8", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US",  
"decimals": null, "ancestors": { "body": "html" }, "reportCount": 1, "baseRef": "clpt-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1",  
"name": "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "body": "html" },  
"reportCount": 1, "baseRef": "clpt-20240930.htm", "first": true, "unique": true }, "R9": { "role":  
"http://clearpointneuro.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies", "longName": "9952158 - Disclosure - Basis of Presentation and  
Summary of Significant Accounting Policies", "shortName": "Basis of Presentation and Summary of Significant Accounting Policies", "isDefault": "false", "groupType":  
"disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c-1", "name": "us-  
gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "body": "html" },  
"reportCount": 1, "baseRef": "clpt-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-  
gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "body": "html" },  
"reportCount": 1, "baseRef": "clpt-20240930.htm", "first": true, "unique": true }, "R10": { "role": "http://clearpointneuro.com/role/RevenueRecognition", "longName":  
"9952159 - Disclosure - Revenue Recognition", "shortName": "Revenue Recognition", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat":  
"Notes", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-  
US", "decimals": null, "ancestors": { "body": "html" }, "reportCount": 1, "baseRef": "clpt-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1",  
"name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "body": "html" },  
"reportCount": 1, "baseRef": "clpt-20240930.htm", "first": true, "unique": true }, "R11": { "role": "http://clearpointneuro.com/role/FairValueMeasurement", "longName":  
"9952160 - Disclosure - Fair Value Measurement", "shortName": "Fair Value Measurement", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat":  
"Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals":  
null, "ancestors": { "body": "html" }, "reportCount": 1, "baseRef": "clpt-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-  
gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "body": "html" }, "reportCount": 1, "baseRef":  
"clpt-20240930.htm", "first": true, "unique": true }, "R12": { "role": "http://clearpointneuro.com/role/Inventory", "longName": "9952161 - Disclosure - Inventory", "shortName":  
"Inventory", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "us-  
gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "body": "html" }, "reportCount": 1, "baseRef": "clpt-  
20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false",  
"lang": "en-US", "decimals": null, "ancestors": { "body": "html" }, "reportCount": 1, "baseRef": "clpt-20240930.htm", "first": true, "unique": true }, "R13": { "role":  
"http://clearpointneuro.com/role/Leases", "longName": "9952162 - Disclosure - Note Payable", "shortName": "Note Payable", "isDefault": "false", "groupType": "disclosure",  
"subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false",  
"lang": "en-US", "decimals": null, "ancestors": { "body": "html" }, "reportCount": 1, "baseRef": "clpt-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-  
gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "body": "html" }, "reportCount": 1, "baseRef":  
"clpt-20240930.htm", "first": true, "unique": true }, "R14": { "role": "http://clearpointneuro.com/role/Leases", "longName": "9952163 - Disclosure - Leases", "shortName":  
"Leases", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "us-  
gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "body": "html" }, "reportCount": 1, "baseRef":  
"clpt-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-  
gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "body": "html" }, "reportCount": 1, "baseRef":  
"clpt-20240930.htm", "first": true, "unique": true }, "R15": { "role": "http://clearpointneuro.com/role/StockholdersEquity", "longName": "9952164 - Disclosure -  
Stockholders' Equity", "shortName": "Stockholders' Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order":  
"15", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null,  
"ancestors": { "body": "html" }, "reportCount": 1, "baseRef": "clpt-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-  
gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "body": "html" }, "reportCount": 1,  
"baseRef": "clpt-20240930.htm", "first": true, "unique": true }, "R16": { "role": "http://xbrl.sec.gov/eec/role/PvpDisclosure", "longName": "9954410 - Disclosure - Pay vs  
Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order":  
"16", "firstAnchor": { "contextRef": "c-9", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td",  
"tr": "table", "div": "body", "html" }, "reportCount": 1, "baseRef": "clpt-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name":  
"http://xbrl.sec.gov/eec/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading  
Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-9", "name":  
"ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body": "html" }, "reportCount": 1,  
"baseRef": "clpt-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-9", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil":  
"false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body": "html" }, "reportCount": 1, "baseRef": "clpt-20240930.htm", "first": true, "unique": true },  
"R18": { "role": "http://clearpointneuro.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies", "longName": "9954471 - Disclosure - Basis of  
Presentation and Summary of Significant Accounting Policies (Policies)", "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Policies)",  
"isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "18", "firstAnchor": { "contextRef": "c-1", "name": "us-  
gaap:BasisOfAccountingPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body": "html" }, "reportCount": 1,  
"baseRef": "clpt-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body": "html" }, "reportCount": 1, "baseRef": "clpt-20240930.htm", "first": true,  
"unique": true }, "R19": { "role": "http://clearpointneuro.com/role/RevenueRecognitionTables", "longName": "9954472 - Disclosure - Revenue Recognition (Tables)",  
"shortName": "Revenue Recognition (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "19", "firstAnchor": {



"reportCount":1,"baseRef":{"cplt-20240930.htm","first":true,"unique":true},"R36":{"role":  
"http://clearpointneuro.com/role/StockholdersEquityScheduleofRestrictedStockActivityDetails","longName":"9954489-Disclosure-Stockholders\2019-Equity-Schedule  
of Restricted Stock Activity (Details)","shortName":"Stockholders\2019-Equity-Schedule of Restricted Stock Activity (Details)","isDefault":"false","groupType":  
"disclosure","subGroupType":"details","menuCat":"Details","order":"36","firstAnchor":{"contextRef":"c-169","name":"us-  
gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber","unitRef":"shares","xsiNil":"false",  
"lang":"en-US","decimals":"0","ancestors":{"span":"td","tr","table","div"},"us-  
gaap:ScheduleOfShareBasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock","ix:continuation","body","html"},"reportCount":1,  
"baseRef":{"cplt-20240930.htm","first":true},"uniqueAnchor":{"contextRef":"c-170","name":"us-  
gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber","unitRef":"shares","xsiNil":"false",  
"lang":"en-US","decimals":"0","ancestors":{"span":"td","tr","table","div"},"us-  
gaap:ScheduleOfShareBasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock","ix:continuation","body","html"},"reportCount":1,  
"baseRef":{"cplt-20240930.htm","unique":true},"tag":{"us-gaap:AccountingPoliciesAbstract":{"xbrlytype":"stringItemType","nsuri":"http://fasb.org/us-gaap/2024",  
"localname":"AccountingPoliciesAbstract","lang":{"en-us":{"role":{"terseLabel":"Accounting Policies [Abstract]"},"label":"Accounting Policies [Abstract]"}},  
"auth\_ref":{"us-gaap:AccountsPayableCurrent":{"xbrlytype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"Accounts Payable Current",  
"crdr":"credit","calculation":{"http://clearpointneuro.com/role/CondensedConsolidatedBalanceSheets":{"parentTag":"us-gaap:LiabilitiesCurrent","weight":1.0,  
"order":1.0},"presentation":{"http://clearpointneuro.com/role/CondensedConsolidatedBalanceSheets":{"parentTag":"us-  
gaap:Accounts Payable, Current","documentation":"Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been  
received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one  
year or within the normal operating cycle if longer)."}}, "auth\_ref":{"r34","r497}},"us-gaap:AccountsReceivableMember":{"xbrlytype":"domainItemType","nsuri":  
"http://fasb.org/us-gaap/2024","localname":"AccountsReceivableMember","presentation":{"  
"http://clearpointneuro.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails"},"lang":{"en-us":{"role":{"terseLabel":"Accounts  
Receivable"},"label":"Accounts Receivable [Member]"},"documentation":"Due from customers or clients for goods or services that have been delivered or sold."}}},  
"auth\_ref":{"r455}},"us-gaap:AccountsReceivableNetCurrent":{"xbrlytype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":  
"AccountsReceivableNetCurrent","crdr":"debit","calculation":{"http://clearpointneuro.com/role/CondensedConsolidatedBalanceSheets":{"parentTag":"us-  
gaap:AssetsCurrent","weight":1.0,"order":2.0},"presentation":{"http://clearpointneuro.com/role/CondensedConsolidatedBalanceSheets"},  
"http://clearpointneuro.com/role/RevenueRecognitionScheduleofOtherCurrentAssetsDetails"},"lang":{"en-us":{"role":{"terseLabel":"Accounts receivable, net"},"label":  
"Accounts Receivable, after Allowance for Credit Loss, Current","documentation":"Amount, after allowance for credit loss, of right to consideration from customer for  
product sold and service rendered in normal course of business, classified as current."}}}, "auth\_ref":{"r627}},"us-  
gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments":{"xbrlytype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":  
"AccretionAmortizationOfDiscountsAndPremiumsInvestments","crdr":"credit","calculation":{"  
"http://clearpointneuro.com/role/CondensedConsolidatedStatementsOfCashFlows":{"parentTag":"us-gaap:NetCashProvidedByUsedInOperatingActivities","weight":-1.0,  
"order":7.0},"presentation":{"http://clearpointneuro.com/role/CondensedConsolidatedStatementsOfCashFlows"},"lang":{"en-us":{"role":{"negatedTerseLabel":  
"Accretion of discounts on short-term investments"},"label":"Accretion (Amortization) of Discounts and Premiums, Investments","documentation":"The sum of the  
periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was  
purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided  
by or used in operations using the indirect method."}}}, "auth\_ref":{"r63}},"cplt:AccruedInterestIncludedInTheConversionOfDebt":{"xbrlytype":  
"monetaryItemType","nsuri":"http://clearpointneuro.com/20240930","localname":"AccruedInterestIncludedInTheConversionOfDebt","crdr":"credit","presentation":{"  
"http://clearpointneuro.com/role/NotePayableDetails"},"lang":{"en-us":{"role":{"terseLabel":"Accrued interest included in the conversion of debt"},"label":"Accrued  
Interest Included in the Conversion of Debt"},"documentation":"Accrued interest included in the conversion of debt"}}, "auth\_ref":{"r63}}},  
"ecd:Additional402vDisclosureTextBlock":{"xbrlytype":"textBlockItemType","nsuri":"http://xbrl.sec.gov/ecd/2024","localname":"Additional402vDisclosureTextBlock",  
"presentation":{"http://xbrl.sec.gov/ecd/role/PvpDisclosure"},"lang":{"en-us":{"role":{"terseLabel":"Additional 402(v) Disclosure"},"label":"Additional 402(v)  
Disclosure [Text Block]"}}, "auth\_ref":{"r52}},"cplt:AdditionalCustomer1Member":{"xbrlytype":"domainItemType","nsuri":  
"http://clearpointneuro.com/20240930","localname":"AdditionalCustomer1Member","presentation":{"  
"http://clearpointneuro.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails"},"lang":{"en-us":{"role":{"terseLabel":"Additional Customer  
1"},"label":"Additional Customer 1 [Member]"},"documentation":"Additional Customer 1"}}, "auth\_ref":{"r63}},"cplt:AdditionalCustomer2Member":{"xbrlytype":  
"domainItemType","nsuri":"http://clearpointneuro.com/20240930","localname":"AdditionalCustomer2Member","presentation":{"  
"http://clearpointneuro.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails"},"lang":{"en-us":{"role":{"terseLabel":"Additional Customer  
2"},"label":"Additional Customer 2 [Member]"},"documentation":"Additional Customer 2"}}, "auth\_ref":{"r63}},"us-gaap:AdditionalPaidInCapitalCommonStock":{"  
"xbrlytype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"AdditionalPaidInCapitalCommonStock","crdr":"credit","calculation":{"  
"http://clearpointneuro.com/role/CondensedConsolidatedBalanceSheets":{"parentTag":"us-gaap:StockholdersEquity","weight":1.0,"order":3.0},"presentation":{"  
"http://clearpointneuro.com/role/CondensedConsolidatedBalanceSheets"},"lang":{"en-us":{"role":{"terseLabel":"Additional paid-in capital"},"label":"Additional Paid  
in Capital, Common Stock"},"documentation":"Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and  
amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed  
capital, capital in excess of par, capital surplus, or paid-in capital."}}}, "auth\_ref":{"r44}},"us-gaap:AdditionalPaidInCapitalMember":{"xbrlytype":  
"domainItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"AdditionalPaidInCapitalMember","presentation":{"  
"http://clearpointneuro.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"},"lang":{"en-us":{"role":{"terseLabel":"Additional Paid-in Capital"},"label":  
"Additional Paid-in Capital [Member]"},"documentation":"Excess of issue price over par or stated value of the entity's capital stock and amounts received from other  
transactions involving the entity's stock or stockholders."}}}, "auth\_ref":{"r393","r617","r618","r619","r620","r672","r721}},"ecd:AdjToCompAmt":{"xbrlytype":  
"monetaryItemType","nsuri":"http://xbrl.sec.gov/ecd/2024","localname":"AdjToCompAmt","presentation":{"http://xbrl.sec.gov/ecd/role/PvpDisclosure"},"lang":{"en-  
us":{"role":{"terseLabel":"Adjustment to Compensation, Amount"},"label":"Adjustment to Compensation Amount"}}, "auth\_ref":{"r565}},"ecd:AdjToCompAxis":{"  
"xbrlytype":"stringItemType","nsuri":"http://xbrl.sec.gov/ecd/2024","localname":"AdjToCompAxis","presentation":{"http://xbrl.sec.gov/ecd/role/PvpDisclosure"},"lang":  
"en-us","role":{"terseLabel":"Adjustment to Compensation"},"label":"Adjustment to Compensation [Axis]"}}, "auth\_ref":{"r565}}},  
"ecd:AdjToNonPeoNeoCompFnTextBlock":{"xbrlytype":"textBlockItemType","nsuri":"http://xbrl.sec.gov/ecd/2024","localname":"AdjToNonPeoNeoCompFnTextBlock",  
"presentation":{"http://xbrl.sec.gov/ecd/role/PvpDisclosure"},"lang":{"en-us":{"role":{"terseLabel":"Adjustment to Non-PEO NEO Compensation Footnote"},"label":  
"Adjustment to Non-PEO NEO Compensation Footnote [Text Block]"}}, "auth\_ref":{"r565}},"ecd:AdjToPeoCompFnTextBlock":{"xbrlytype":"textBlockItemType",  
"nsuri":"http://xbrl.sec.gov/ecd/2024","localname":"AdjToPeoCompFnTextBlock","presentation":{"http://xbrl.sec.gov/ecd/role/PvpDisclosure"},"lang":{"en-us":{"role":  
"terseLabel":"Adjustment to PEO Compensation, Footnote"},"label":"Adjustment to PEO Compensation, Footnote [Text Block]"}}, "auth\_ref":{"r565}},"us-  
gaap:AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract":{"xbrlytype":"stringItemType","nsuri":  
"http://fasb.org/us-gaap/2024","localname":"AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract","presentation":{"  
"http://clearpointneuro.com/role/CondensedConsolidatedStatementsOfCashFlows"},"lang":{"en-us":{"role":{"terseLabel":"Adjustments to reconcile net loss to net cash  
flows from operating activities"},"label":"Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"}},  
"auth\_ref":{"r63}},"us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation":{"xbrlytype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024",  
"localname":"AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation","crdr":"debit","presentation":{"  
"http://clearpointneuro.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"},"lang":{"en-us":{"role":{"negatedTerseLabel":"Payments for taxes related  
to net share settlement of equity awards"},"label":"Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation"},"documentation":"Amount of decrease  
to equity for grantee's tax withholding obligation for award under share-based payment arrangement."}}}, "auth\_ref":{"r63}}},  
"ecd:AggtChngPnsnValInSummryCompstnTblForApblYrMember":{"xbrlytype":"domainItemType","nsuri":"http://xbrl.sec.gov/ecd/2024","localname":  
"AggtChngPnsnValInSummryCompstnTblForApblYrMember","presentation":{"http://xbrl.sec.gov/ecd/role/PvpDisclosure"},"lang":{"en-us":{"role":{"terseLabel":  
"Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table"},"label":"Aggregate Change in Present Value  
of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]"}}, "auth\_ref":{"r598}},"ecd:AggtErrCompAmt":{"xbrlytype":  
"monetaryItemType","nsuri":"http://xbrl.sec.gov/ecd/2024","localname":"AggtErrCompAmt","presentation":{"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"},"lang":{"  
"en-us":{"role":{"terseLabel":"Aggregate Erroneous Compensation Amount"},"label":"Aggregate Erroneous Compensation Amount"}}, "auth\_ref":{"r524","r534",  
"r544","r576}},"ecd:AggtErrCompNotYetDeterminedTextBlock":{"xbrlytype":"textBlockItemType","nsuri":"http://xbrl.sec.gov/ecd/2024","localname":  
"AggtErrCompNotYetDeterminedTextBlock","presentation":{"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"},"lang":{"en-us":{"role":{"terseLabel":"Aggregate  
Erroneous Compensation Not Yet Determined"},"label":"Aggregate Erroneous Compensation Not Yet Determined [Text Block]"}}, "auth\_ref":{"r527","r537",  
"r547",  
"r579}},"ecd:AggtPnsnAdjsSvcCstMember":{"xbrlytype":"domainItemType","nsuri":"http://xbrl.sec.gov/ecd/2024","localname":"AggtPnsnAdjsSvcCstMember",  
"presentation":{"http://xbrl.sec.gov/ecd/role/PvpDisclosure"},"lang":{"en-us":{"role":{"terseLabel":"Aggregate Pension Adjustments Service Cost"},"label":"Aggregate  
Pension Adjustments Service Cost [Member]"}}, "auth\_ref":{"r599}},"ecd:AllAdjToCompMember":{"xbrlytype":"domainItemType","nsuri":  
"http://xbrl.sec.gov/ecd/2024","localname":"AllAdjToCompMember","presentation":{"http://xbrl.sec.gov/ecd/role/PvpDisclosure"},"lang":{"en-us":{"role":{"  
"terseLabel":"All Adjustments to Compensation"},"label":"All Adjustments to Compensation [Member]"}}, "auth\_ref":{"r565}},"ecd:AllExecutiveCategoriesMember":{"  
"xbrlytype":"domainItemType","nsuri":"http://xbrl.sec.gov/ecd/2024","localname":"AllExecutiveCategoriesMember","presentation":{"  
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"},"lang":{"en-us":{"role":{"terseLabel":"All Executive Categories"},"label":"All Executive Categories [Member]"}},  
"auth\_ref":{"r572}},"ecd:AllIndividualsMember":{"xbrlytype":"domainItemType","nsuri":"http://xbrl.sec.gov/ecd/2024","localname":"AllIndividualsMember",  
"presentation":{"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"},"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"},  
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"},"http://xbrl.sec.gov/ecd/role/PvpDisclosure"},"lang":{"en-us":{"role":{"terseLabel":"All Individuals"},"label":  
"All Individuals [Member]"}}, "auth\_ref":{"r528","r538","r548","r572","r580","r584","r592}},"ecd:AllTradingArrangementsMember":{"xbrlytype":  
"domainItemType","nsuri":"http://xbrl.sec.gov/ecd/2024","localname":"AllTradingArrangementsMember","presentation":{"  
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"},"lang":{"en-us":{"role":{"terseLabel":"All Trading Arrangements"},"label":"All Trading Arrangements  
[Member]"}}, "auth\_ref":{"r590}},"us-gaap:AllocatedShareBasedCompensationExpense":{"xbrlytype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024",  
"localname":"AllocatedShareBasedCompensationExpense","crdr":"debit","presentation":{"  
"http://clearpointneuro.com/role/StockholdersEquityScheduleofShareBasedCompensationExpenseDetails"},"lang":{"en-us":{"role":{"terseLabel":"Share-based  
compensation expense"},"label":"Share-Based Payment Arrangement, Expense"},"documentation":"Amount of expense for award under share-based payment arrangement.  
Excludes amount capitalized."}}}, "auth\_ref":{"r285","r286}},"us-gaap:AllowanceForDoubtfulAccountsReceivable":{"xbrlytype":"monetaryItemType","nsuri":  
"http://fasb.org/us-gaap/2024","localname":"AllowanceForDoubtfulAccountsReceivable","crdr":"credit","presentation":{"  
"http://clearpointneuro.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails"},"lang":{"en-us":{"role":{"verboseLabel":"Allowance for  
doubtful accounts"},"label":"Accounts Receivable, Allowance for Credit Loss"},"documentation":"Amount of allowance for credit loss on accounts receivable."}}},  
"auth\_ref":{"r107","r165","r169","r170","r172","r689}},"dei:AmendmentFlag":{"xbrlytype":"booleanItemType","nsuri":"http://xbrl.sec.gov/dei/2024","localname":  
"AmendmentFlag","presentation":{"http://clearpointneuro.com/role/Cover"},"lang":{"en-us":{"role":{"terseLabel":"Amendment Flag"},"label":"Amendment Flag",  
"documentation":"Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."}}}, "auth\_ref":{"r63}},"us-  
gaap:AmortizationOffinancingCostsAndDiscounts":{"xbrlytype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":  
"AmortizationOffinancingCostsAndDiscounts","crdr":"debit","calculation":{"http://clearpointneuro.com/role/CondensedConsolidatedStatementsOfCashFlows":{"  
parentTag":"us-gaap:NetCashProvidedByUsedInOperatingActivities","weight":1.0,"order":5.0},"presentation":{"

"http://clearpointneuro.com/role/CondensedConsolidatedStatementsOfCashFlows", "lang": {"en-us": {"role": {"terseLabel": "Amortization of debt issuance costs and original issue discounts", "label": "Amortization of Debt Issuance Costs and Discounts", "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs."}}, "auth\_ref": {"r222", "r478", "r479", "r613", "r676"}}, "clpt\_AmountOfAccruedAndPaidInKindInterestIncludedInConvertedDebt": {"xbrltype": "monetaryItemType", "nsuri": "http://clearpointneuro.com/20240930", "localname": "AmountOfAccruedAndPaidInKindInterestIncludedInConvertedDebt", "crdr": "credit", "presentation": {"http://clearpointneuro.com/role/NotePayableDetails", "lang": {"en-us": {"role": {"terseLabel": "Amount of accrued and paid-in-kind interest included in converted debt", "label": "Amount of Accrued and Paid-in-Kind Interest Included In Converted Debt", "documentation": "Amount of related accrued and payment-in-kind interest included with converted debt."}}, "auth\_ref": {"us-gaap-ArrangementsAndNonarrangementTransactionsMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": {"http://clearpointneuro.com/role/DescriptionoftheBusinessandFinancialConditionDetails", "lang": {"en-us": {"role": {"terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."}}, "auth\_ref": {"r298"}}, "us-gaap-Assets": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "calculation": {"http://clearpointneuro.com/role/CondensedConsolidatedBalanceSheets": {"parentTag": null, "weight": null, "order": null, "root": true}}, "presentation": {"http://clearpointneuro.com/role/CondensedConsolidatedBalanceSheets", "lang": {"en-us": {"role": {"totalLabel": "Total assets", "label": "Assets", "documentation": "Amount of asset recognized for present right to economic benefit."}}, "auth\_ref": {"r79", "r89", "r106", "r127", "r152", "r154", "r159", "r160", "r166", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r299", "r301", "r326", "r497", "r637", "r638", "r679"}}, "us-gaap-AssetsAbstract": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": {"http://clearpointneuro.com/role/CondensedConsolidatedBalanceSheets", "lang": {"en-us": {"role": {"terseLabel": "ASSETS", "label": "Assets [Abstract]"}}, "auth\_ref": {"us-gaap-AssetsCurrent": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "calculation": {"http://clearpointneuro.com/role/CondensedConsolidatedBalanceSheets": {"parentTag": "us-gaap-Assets", "weight": 1.0, "order": 1.0}, "presentation": {"http://clearpointneuro.com/role/CondensedConsolidatedBalanceSheets", "lang": {"en-us": {"role": {"totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."}}, "auth\_ref": {"r101", "r110", "r127", "r166", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r299", "r301", "r326", "r497", "r637", "r638", "r679"}}, "us-gaap-AssetsCurrentAbstract": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": {"http://clearpointneuro.com/role/CondensedConsolidatedBalanceSheets", "lang": {"en-us": {"role": {"terseLabel": "Current assets", "label": "Assets, Current [Abstract]"}}, "auth\_ref": {"ecd-AwardExecPrice": {"xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExecPrice", "presentation": {"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": {"en-us": {"role": {"terseLabel": "Exercise Price", "label": "Award Exercise Price"}}, "auth\_ref": {"r587"}}, "ecd-AwardGrantDateFairValue": {"xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": {"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": {"en-us": {"role": {"terseLabel": "Fair Value as of Grant Date", "label": "Award Grant Date Fair Value"}}, "auth\_ref": {"r588}}}, "ecd-AwardTmgDiscLineItems": {"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": {"en-us": {"role": {"label": "Award Timing Disclosures [Line Items]"}}, "auth\_ref": {"r583}}, "ecd-AwardTmgHowMnpiCnsrdTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsrdTextBlock", "presentation": {"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": {"en-us": {"role": {"terseLabel": "Award Timing, How MNPI Considered [Text Block]"}}, "auth\_ref": {"r583}}, "ecd-AwardTmgMethodTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": {"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": {"en-us": {"role": {"terseLabel": "Award Timing Method", "label": "Award Timing Method [Text Block]"}}, "auth\_ref": {"r583}}, "ecd-AwardTmgMnpiCnsrdFlag": {"xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsrdFlag", "presentation": {"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": {"en-us": {"role": {"terseLabel": "Award Timing MNPI Considered [Flag]"}}, "auth\_ref": {"r583}}, "ecd-AwardTmgMnpiDiscTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": {"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": {"en-us": {"role": {"terseLabel": "Award Timing MNPI Disclosure [Text Block]"}}, "auth\_ref": {"r583}}, "ecd-AwardTmgPredtrmndFlag": {"xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": {"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": {"en-us": {"role": {"terseLabel": "Award Timing Predetermined [Text Block]"}}, "auth\_ref": {"r583}}, "us-gaap-AwardTypeAxis": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": {"http://clearpointneuro.com/role/StockholdersEquityScheduleofRestrictedStockActivityDetails"; "http://clearpointneuro.com/role/StockholdersEquityScheduleofShareBasedCompensationExpenseDetails"; "http://clearpointneuro.com/role/StockholdersEquityScheduleofUnrecognizedCompensationExpenseandWeightedAverageRequisitePeriodDetails"; "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": {"en-us": {"role": {"terseLabel": "Award Type [Axis]", "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement."}}, "auth\_ref": {"r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284"}}, "ecd-AwardUndrlygSecuritiesAmt": {"xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": {"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": {"en-us": {"role": {"terseLabel": "Underlying Securities", "label": "Award Underlying Securities Amount"}}, "auth\_ref": {"r586}}, "ecd-AwardsCloseToMnpiDiscIndName": {"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": {"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": {"en-us": {"role": {"terseLabel": "Name", "label": "Awards Close in Time to MNPI Disclosures, Individual Name"}}, "auth\_ref": {"r585}}, "ecd-AwardsCloseToMnpiDiscTable": {"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": {"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": {"en-us": {"role": {"terseLabel": "Awards Close in Time to MNPI Disclosures", "label": "Awards Close in Time to MNPI Disclosures [Table]"}}, "auth\_ref": {"r584}}, "ecd-AwardsCloseToMnpiDiscTableTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": {"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": {"en-us": {"role": {"terseLabel": "Awards Close in Time to MNPI Disclosures, Table", "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]"}}, "auth\_ref": {"r584}}, "us-gaap-BasisOfAccountingPolicyTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfAccountingPolicyTextBlock", "presentation": {"http://clearpointneuro.com/role/BasisOfPresentationandSummaryofSignificantAccountingPoliciesPolicies"; "lang": {"en-us": {"role": {"terseLabel": "Basis of Presentation", "label": "Basis of Presentation, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."}, "auth\_ref": {"us-gaap-BasisOfPresentationandSignificantAccountingPoliciesTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfPresentationandSignificantAccountingPoliciesTextBlock", "presentation": {"http://clearpointneuro.com/role/BasisOfPresentationandSummaryofSignificantAccountingPolicies"; "lang": {"en-us": {"role": {"terseLabel": "Basis of Presentation and Summary of Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity."}}, "auth\_ref": {"r64"}}, "clpt\_BiologicsAndDrugDeliveryDisposableProductsMember": {"xbrltype": "domainItemType", "nsuri": "http://clearpointneuro.com/20240930", "localname": "BiologicsAndDrugDeliveryDisposableProductsMember", "presentation": {"http://clearpointneuro.com/20240930", "localname": "BiologicsAndDrugDeliveryDisposableProductsMember", "presentation": {"http://clearpointneuro.com/role/RevenueRecognitionScheduleofRevenuebyServiceLineDetails", "lang": {"en-us": {"role": {"terseLabel": "Biologics and Drug Delivery - Disposable Products", "label": "Biologics And Drug Delivery - Disposable Products [Member]", "documentation": "Biologics And Drug Delivery - Disposable Products"}}, "auth\_ref": {"clpt\_BiologicsAndDrugDeliveryMember": {"xbrltype": "domainItemType", "nsuri": "http://clearpointneuro.com/20240930", "localname": "BiologicsAndDrugDeliveryMember", "presentation": {"http://clearpointneuro.com/role/RevenueRecognitionScheduleofRevenuebyServiceLineDetails", "lang": {"en-us": {"role": {"terseLabel": "Biologics and drug delivery", "label": "Biologics And Drug Delivery [Member]", "documentation": "Biologics And Drug Delivery"}}, "auth\_ref": {"clpt\_BiologicsAndDrugDeliveryServicesAndLicenseFeesMember": {"xbrltype": "domainItemType", "nsuri": "http://clearpointneuro.com/20240930", "localname": "BiologicsAndDrugDeliveryServicesAndLicenseFeesMember", "presentation": {"http://clearpointneuro.com/role/RevenueRecognitionScheduleofRevenuebyServiceLineDetails", "lang": {"en-us": {"role": {"terseLabel": "Biologics and Drug Delivery - Services and License Fees [Member]", "label": "Biologics And Drug Delivery - Services and License Fees [Member]", "documentation": "Biologics And Drug Delivery - Services and License Fees"}}, "auth\_ref": {"us-gaap-BusinessDescriptionAndAccountingPoliciesTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessDescriptionAndAccountingPoliciesTextBlock", "presentation": {"http://clearpointneuro.com/role/DescriptionoftheBusinessandFinancialCondition", "lang": {"en-us": {"role": {"terseLabel": "Description of the Business and Financial Condition", "label": "Business Description and Accounting Policies [Text Block]", "documentation": "The entire disclosure for the business description and accounting policies concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Accounting policies describe all significant accounting policies of the reporting entity."}}, "auth\_ref": {"r64", "r65"}}, "clpt\_CapitalEquipmentAndSoftwareMember": {"xbrltype": "domainItemType", "nsuri": "http://clearpointneuro.com/20240930", "localname": "CapitalEquipmentAndSoftwareMember", "presentation": {"http://clearpointneuro.com/20240930", "localname": "CapitalEquipmentAndSoftwareMember", "presentation": {"http://clearpointneuro.com/role/RevenueRecognitionScheduleofRevenuebyServiceLineDetails", "lang": {"en-us": {"role": {"terseLabel": "Capital Equipment and Software [Member]", "label": "Capital Equipment And Software [Member]", "documentation": "Capital Equipment And Software"}}, "auth\_ref": {"clpt\_CapitalEquipmentAndSoftwareRelatedServiceMember": {"xbrltype": "domainItemType", "nsuri": "http://clearpointneuro.com/20240930", "localname": "CapitalEquipmentAndSoftwareRelatedServiceMember", "presentation": {"http://clearpointneuro.com/role/RevenueRecognitionNarrativeDetails", "lang": {"en-us": {"role": {"terseLabel": "Capital Equipment and Software-Related Service", "label": "Capital Equipment and Software-Related Service [Member]", "documentation": "Capital Equipment and Software-Related Service"}}, "auth\_ref": {"clpt\_CapitalEquipmentAndSoftwareServicesMember": {"xbrltype": "domainItemType", "nsuri": "http://clearpointneuro.com/20240930", "localname": "CapitalEquipmentAndSoftwareServicesMember", "presentation": {"http://clearpointneuro.com/role/RevenueRecognitionScheduleofRevenuebyServiceLineDetails", "lang": {"en-us": {"role": {"terseLabel": "Capital Equipment and Software - Services", "label": "Capital Equipment And Software - Services [Member]", "documentation": "Capital Equipment And Software - Services"}}, "auth\_ref": {"clpt\_CapitalEquipmentAndSoftwareSystemsAndSoftwareProductsMember": {"xbrltype": "domainItemType", "nsuri": "http://clearpointneuro.com/20240930", "localname": "CapitalEquipmentAndSoftwareSystemsAndSoftwareProductsMember", "presentation": {"http://clearpointneuro.com/role/RevenueRecognitionScheduleofRevenuebyServiceLineDetails", "lang": {"en-us": {"role": {"terseLabel": "Capital Equipment and Software - Systems and Software Products", "label": "Capital Equipment And Software - Systems and Software Products [Member]", "documentation": "Capital Equipment And Software - Systems and Software Products"}}, "auth\_ref": {"clpt\_CapitalEquipmentRelatedServiceRevenueMember": {"xbrltype": "domainItemType", "nsuri": "http://clearpointneuro.com/20240930", "localname": "CapitalEquipmentRelatedServiceRevenueMember", "presentation": {"http://clearpointneuro.com/role/RevenueRecognitionNarrativeDetails", "lang": {"en-us": {"role": {"terseLabel": "Capital Equipment Related Service Revenue", "label": "Capital Equipment Related Service Revenue [Member]", "documentation": "The member represent capital equipment related service revenue."}}, "auth\_ref": {"us-gaap-CashAndCashEquivalentsAtCarryingValue": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": {"http://clearpointneuro.com/role/CondensedConsolidatedBalanceSheets": {"parentTag": "us-gaap-AssetsCurrent", "weight": 1.0, "order": 1.0}, "presentation": {"http://clearpointneuro.com/role/CondensedConsolidatedBalanceSheets", "lang": {"en-us": {"role": {"terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts

of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. } } } , "auth\_ref": { "r12", "r104", "r462" } } , "us-gaap\_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": { "http://clearpointneuro.com/role/CondensedConsolidatedStatementsOfCashFlows": { "lang": { "en-us": { "role": { "periodStartLabel": "Cash and cash equivalents, beginning of period", "periodEndLabel": "Cash and cash equivalents, end of period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on-hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. } } } , "auth\_ref": { "r12", "r60", "r124" } } } , "us-gaap\_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://clearpointneuro.com/role/CondensedConsolidatedStatementsOfCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } } , "presentation": { "http://clearpointneuro.com/role/CondensedConsolidatedStatementsOfCashFlows": { "lang": { "en-us": { "role": { "totalLabel": "Net change in cash and cash equivalents", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage, including effect from exchange rate change. Cash includes, but is not limited to, currency on-hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. } } } , "auth\_ref": { "r0", "r60" } } } , "clpt\_CashPaidForAbstract": { "xbrltype": "stringItemType", "nsuri": "http://clearpointneuro.com/20240930", "localname": "CashPaidForAbstract", "presentation": { "http://clearpointneuro.com/role/CondensedConsolidatedStatementsOfCashFlows": { "lang": { "en-us": { "role": { "terseLabel": "Cash paid for", "label": "Cash paid for: [Abstract]", "documentation": "Cash Paid For" } } } } , "auth\_ref": { "r0", "r60" } } } , "us-gaap\_CashUninsuredAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashUninsuredAmount", "crdr": "debit", "presentation": { "http://clearpointneuro.com/role/BasisOfPresentationandSummaryofSignificantAccountingPoliciesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Cash, uninsured amount", "label": "Cash, Uninsured Amount", "documentation": "The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation. } } } , "auth\_ref": { "r0", "r60" } } } , "ecd\_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Changed Peer Group, Footnote", "label": "Changed Peer Group, Footnote [Text Block]", "documentation": "Changed Peer Group, Footnote [Text Block]", "auth\_ref": { "r563" } } } } , "ecd\_ChngInFrValAsOfVstngDtOfPrYrEqtyAwrdsVstDnCrVdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValAsOfVstngDtOfPrYrEqtyAwrdsVstDnCrVdYrMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year", "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]", "documentation": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]", "auth\_ref": { "r560" } } } } , "ecd\_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrYrsMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested", "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]", "documentation": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]", "auth\_ref": { "r558" } } } } , "del\_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": { "http://clearpointneuro.com/role/Cover": { "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city", "auth\_ref": { "r564" } } } } , "ecd\_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Amount", "label": "Company Selected Measure Amount", "documentation": "Company Selected Measure Amount", "auth\_ref": { "r564" } } } } , "ecd\_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Name", "label": "Company Selected Measure Name", "documentation": "Company Selected Measure Name", "auth\_ref": { "r564" } } } } , "us-gaap\_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "presentation": { "http://clearpointneuro.com/role/DescriptionoftheBusinessandFinancialConditionDetails": { "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. } } } , "auth\_ref": { "r298" } } } , "us-gaap\_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://clearpointneuro.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap\_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } } , "presentation": { "http://clearpointneuro.com/role/CondensedConsolidatedBalanceSheets": { "lang": { "en-us": { "role": { "terseLabel": "Commitments and contingencies", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur. } } } , "auth\_ref": { "r40", "r83", "r362", "r404" } } } , "us-gaap\_CommonStockCapitalSharesReservedForFutureIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "presentation": { "http://clearpointneuro.com/role/StockholdersEquityNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Common stock, capital shares reserved for future issuance (in shares)", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "documentation": "Aggregate number of common shares reserved for future issuance. } } } , "auth\_ref": { "r43", "r1", "clpt\_CommonStockInitiallyOfferedAtPublicOffering": { "xbrltype": "sharesItemType", "nsuri": "http://clearpointneuro.com/20240930", "localname": "CommonStockInitiallyOfferedAtPublicOffering", "presentation": { "http://clearpointneuro.com/role/StockholdersEquityNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Common stock initially offered at public offering (in shares)", "label": "Common Stock Initially Offered At Public Offering", "documentation": "Common Stock Initially Offered At Public Offering" } } } , "auth\_ref": { "r43", "r1", "us-gaap\_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": { "http://clearpointneuro.com/role/CondensedConsolidatedStatementsOfStockholdersEquity": { "lang": { "en-us": { "role": { "terseLabel": "Common Stock", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer. } } } , "auth\_ref": { "r505", "r506", "r507", "r509", "r510", "r511", "r512", "r617", "r618", "r620", "r672", "r720", "r721" } } } , "us-gaap\_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": { "http://clearpointneuro.com/role/CondensedConsolidatedBalanceSheetsParentetical": { "lang": { "en-us": { "role": { "terseLabel": "Common stock par value (in dollars per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock. } } } , "auth\_ref": { "r43" } } } , "us-gaap\_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": { "http://clearpointneuro.com/role/CondensedConsolidatedBalanceSheetsParentetical": { "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares authorized (in shares)", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws. } } } , "auth\_ref": { "r43", "r405" } } } , "us-gaap\_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": { "http://clearpointneuro.com/role/CondensedConsolidatedBalanceSheetsParentetical": { "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares issued (in shares)", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. } } } , "auth\_ref": { "r43" } } } , "us-gaap\_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": { "http://clearpointneuro.com/role/CondensedConsolidatedBalanceSheetsParentetical": { "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares outstanding (in shares)", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. } } } , "auth\_ref": { "r5", "r43", "r405", "r423", "r721", "r722" } } } , "us-gaap\_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://clearpointneuro.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap\_StockholdersEquity", "weight": 1.0, "order": 2.0 } } , "presentation": { "http://clearpointneuro.com/role/CondensedConsolidatedBalanceSheets": { "lang": { "en-us": { "role": { "terseLabel": "Common stock, \$0.01 par value; 90,000,000 shares authorized at Septemberu00a0030, 2024 and Decemberu00a0031, 2023; 27,588,819 shares issued and outstanding at Septemberu00a0030, 2024; and 24,652,729 issued and outstanding at Decemberu00a0031, 2023", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. } } } , "auth\_ref": { "r43", "r364", "r497" } } } , "ecd\_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Company Selected Measure", "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]", "documentation": "Compensation Actually Paid vs. Company Selected Measure", "auth\_ref": { "r569" } } } } , "ecd\_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Net Income", "label": "Compensation Actually Paid vs. Net Income [Text Block]", "documentation": "Compensation Actually Paid vs. Net Income", "auth\_ref": { "r568" } } } } , "ecd\_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Other Measure", "label": "Compensation Actually Paid vs. Other Measure [Text Block]", "documentation": "Compensation Actually Paid vs. Other Measure", "auth\_ref": { "r570" } } } } , "ecd\_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return", "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]", "documentation": "Compensation Actually Paid vs. Total Shareholder Return", "auth\_ref": { "r567" } } } } , "us-gaap\_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": { "http://clearpointneuro.com/role/BasisOfPresentationandSummaryofSignificantAccountingPoliciesDetails": { "lang": { "en-us": { "role": { "verboseLabel": "Concentration Risk Benchmark [Domain]", "label": "Concentration Risk Benchmark [Domain]", "documentation": "The denominator in a calculation of a disclosed concentration risk percentage. } } } , "auth\_ref": { "r18", "r19", "r30", "r31", "r163", "r455" } } } , "us-gaap\_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": { "http://clearpointneuro.com/role/BasisOfPresentationandSummaryofSignificantAccountingPoliciesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Benchmark [Axis]", "label": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk. } } } , "auth\_ref": { "r18", "r19", "r30", "r31", "r163", "r455" } } } , "us-gaap\_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByTypeAxis", "presentation": { "http://clearpointneuro.com/role/BasisOfPresentationandSummaryofSignificantAccountingPoliciesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type [Axis]", "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender. } } } , "auth\_ref": { "r18", "r19", "r30", "r31", "r163", "r455", "r604" } } } , "us-gaap\_ConcentrationRiskCreditRisk":

{ "xbrltype": "textBlockItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskCreditRisk", "presentation": "http://clearpointneuro.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies", "lang": { "en-us": { "role": { "terseLabel": "Concentration Risks and Other Risks and Uncertainties", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for credit risk." } } }, "auth\_ref": { "r33", "r93" }, "us-gaap\_ConcentrationRiskPercentage1": { "xbrltype": "percentItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskPercentage1", "presentation": "http://clearpointneuro.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails", "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk, percentage", "label": "Concentration Risk, Percentage", "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the benchmark (or denominator) in the equation, this concept represents the concentration percentage derived from the division." } } }, "auth\_ref": { "r18", "r19", "r30", "r31", "r163" }, "us-gaap\_ConcentrationRiskTypeDomain": { "xbrltype": "domainItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskTypeDomain", "presentation": "http://clearpointneuro.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails", "lang": { "en-us": { "role": { "verboseLabel": "Concentration Risk Type [Domain]", "label": "Concentration Risk Type [Domain]", "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employee, supplier, lender) of the concentration." } } }, "auth\_ref": { "r18", "r19", "r30", "r31", "r163", "r455" }, "clpt\_ContractLiabilitiesServiceAgreementsTerms": { "xbrltype": "durationItem", "nsuri": "http://clearpointneuro.com/20240930", "localname": "ContractLiabilitiesServiceAgreementsTerms", "presentation": "http://clearpointneuro.com/role/RevenueRecognitionNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Contract liabilities, service agreements, terms", "label": "Contract Liabilities, Service Agreements, Terms", "documentation": "Contract Liabilities, Service Agreements, Terms" } } }, "auth\_ref": { "us-gaap\_ContractWithCustomerAssetAndLiabilityAbstract": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerAssetAndLiabilityAbstract", "presentation": "http://clearpointneuro.com/role/RevenueRecognitionScheduleofOtherCurrentAssetsDetails", "lang": { "en-us": { "role": { "terseLabel": "Other contract assets", "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Abstract]", "documentation": "Contract with Customer Asset and Liability Table Text Block", "presentation": "http://clearpointneuro.com/role/RevenueRecognitionTables", "lang": { "en-us": { "role": { "terseLabel": "Schedule of Revenue Recognized by Contract Liability", "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]", "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability." } } }, "auth\_ref": { "r640" }, "us-gaap\_ContractWithCustomerLiability": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiability", "crdr": "credit", "presentation": "http://clearpointneuro.com/role/RevenueRecognitionScheduleofRevenueRecognizedbyContractLiabilityDetails", "lang": { "en-us": { "role": { "terseLabel": "Deferred revenues", "label": "Contract with Customer, Liability", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth\_ref": { "r241", "r242", "r253" }, "us-gaap\_ConvertibleDebtMember": { "xbrltype": "domainItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConvertibleDebtMember", "presentation": "http://clearpointneuro.com/role/DescriptionoftheBusinessandFinancialConditionDetails", "lang": { "en-us": { "role": { "terseLabel": "Convertible Debt", "label": "Convertible Debt [Member]", "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock." } } }, "auth\_ref": { "r71", "r201", "r202", "r212", "r213", "r214", "r218", "r219", "r220", "r221", "r222", "r475", "r476", "r477", "r478", "r479" }, "clpt\_ConvertibleNotesNumberOfInvestors": { "xbrltype": "integerItem", "nsuri": "http://clearpointneuro.com/20240930", "localname": "ConvertibleNotesNumberOfInvestors", "presentation": "http://clearpointneuro.com/role/DescriptionoftheBusinessandFinancialConditionDetails", "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, number of investors", "label": "Convertible Notes, Number Of Investors", "documentation": "Convertible Notes, Number Of Investors" } } }, "auth\_ref": { "us-gaap\_CostOfRevenue": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfRevenue", "crdr": "debit", "calculation": "http://clearpointneuro.com/role/CondensedConsolidatedStatementsOfOperations", "lang": { "en-us": { "role": { "parentTag": "us-gaap\_GrossProfit", "weight": -1.0, "order": 1.0 }, "presentation": "http://clearpointneuro.com/role/CondensedConsolidatedStatementsOfOperations", "lang": { "en-us": { "role": { "terseLabel": "Cost of revenue", "label": "Cost of Revenue", "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period." } } }, "auth\_ref": { "r53", "r127", "r166", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r326", "r472", "r637" }, "us-gaap\_CostOfSalesMember": { "xbrltype": "domainItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfSalesMember", "presentation": "http://clearpointneuro.com/role/StockholdersEquityScheduleofShareBasedCompensationExpenseDetails", "lang": { "en-us": { "role": { "terseLabel": "Cost of revenue", "label": "Cost of Sales [Member]", "documentation": "Primary financial statement caption encompassing cost of sales." } } }, "auth\_ref": { "dei\_CoverAbstract": { "xbrltype": "stringItem", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "terseLabel": "Cover [Abstract]", "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth\_ref": { "dei\_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItem", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": "http://clearpointneuro.com/role/Cover", "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format -MM-DD." } } }, "auth\_ref": { "clpt\_CustomerMember": { "xbrltype": "domainItem", "nsuri": "http://clearpointneuro.com/20240930", "localname": "CustomerMember", "presentation": "http://clearpointneuro.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails", "lang": { "en-us": { "role": { "terseLabel": "Customer 1", "label": "Customer 1 [Member]", "documentation": "Customer 1" } } }, "auth\_ref": { "us-gaap\_CustomerConcentrationRiskMember": { "xbrltype": "domainItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CustomerConcentrationRiskMember", "presentation": "http://clearpointneuro.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails", "lang": { "en-us": { "role": { "terseLabel": "Customer Concentration Risk", "label": "Customer Concentration Risk [Member]", "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer." } } }, "auth\_ref": { "r66", "r163" }, "us-gaap\_DebtConversionConvertedInstrumentAmount1": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtConversionConvertedInstrumentAmount1", "crdr": "credit", "presentation": "http://clearpointneuro.com/role/DescriptionoftheBusinessandFinancialConditionDetails", "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, conversion amount", "label": "Debt Conversion, Converted Instrument, Amount", "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. Part noncash refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth\_ref": { "r14", "r15" }, "us-gaap\_DebtConversionConvertedInstrumentSharesIssued1": { "xbrltype": "sharesItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtConversionConvertedInstrumentSharesIssued1", "presentation": "http://clearpointneuro.com/role/NotePayableDetails", "lang": { "en-us": { "role": { "terseLabel": "Debt conversion, shares issued (in shares)", "label": "Debt Conversion, Converted Instrument, Shares Issued", "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. Part noncash refers to that portion of the transaction not resulting in cash receipts or payments in the period." } } }, "auth\_ref": { "r14", "r15" }, "us-gaap\_DebtDisclosureAbstract": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Debt Disclosure [Abstract]", "label": "Debt Disclosure [Abstract]", "documentation": "Debt Disclosure Text Block", "presentation": "http://clearpointneuro.com/role/NotePayable", "lang": { "en-us": { "role": { "terseLabel": "Note Payable", "label": "Debt Disclosure [Text Block]", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth\_ref": { "r70", "r125", "r178", "r179", "r180", "r181", "r182", "r189", "r190", "r200", "r206", "r207", "r208", "r209", "r210", "r211", "r216", "r223", "r224", "r226", "r333" }, "us-gaap\_DebtInstrumentAxis": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentAxis", "presentation": "http://clearpointneuro.com/role/DescriptionoftheBusinessandFinancialConditionDetails", "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Axis]", "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth\_ref": { "r9", "r35", "r36", "r80", "r82", "r128", "r201", "r202", "r203", "r204", "r205", "r207", "r212", "r213", "r214", "r215", "r217", "r218", "r219", "r220", "r221", "r222", "r475", "r476", "r477", "r478", "r479", "r495", "r615", "r631", "r632", "r633", "r675", "r677" }, "us-gaap\_DebtInstrumentBasisSpreadOnVariableRate1": { "xbrltype": "percentItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "presentation": "http://clearpointneuro.com/role/NotePayableDetails", "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, basis spread on variable rate", "label": "Debt Instrument, Basis Spread on Variable Rate", "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument." } } }, "auth\_ref": { "us-gaap\_DebtInstrumentConvertibleConversionPrice1": { "xbrltype": "perShareItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentConvertibleConversionPrice1", "presentation": "http://clearpointneuro.com/role/NotePayableDetails", "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, conversion price (in dollars per share)", "label": "Debt Instrument, Convertible, Conversion Price", "documentation": "The price per share of the conversion feature embedded in the debt instrument." } } }, "auth\_ref": { "r72", "r203" }, "us-gaap\_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": "http://clearpointneuro.com/role/NotePayableDetails", "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, face amount", "label": "Debt Instrument, Face Amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth\_ref": { "r201", "r333", "r334", "r476", "r477", "r495" }, "us-gaap\_DebtInstrumentLineItems": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentLineItems", "presentation": "http://clearpointneuro.com/role/NotePayableDetails", "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Line Items]", "label": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth\_ref": { "r128", "r201", "r202", "r203", "r204", "r205", "r207", "r212", "r213", "r214", "r215", "r217", "r218", "r219", "r220", "r221", "r222", "r225", "r475", "r476", "r477", "r478", "r479", "r495", "r615", "r677" }, "us-gaap\_DebtInstrumentNameDomain": { "xbrltype": "domainItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentNameDomain", "presentation": "http://clearpointneuro.com/role/DescriptionoftheBusinessandFinancialConditionDetails", "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Name [Domain]", "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth\_ref": { "r9", "r128", "r201", "r202", "r203", "r204", "r205", "r207", "r212", "r213", "r214", "r215", "r217", "r218", "r219", "r220", "r221", "r222", "r225", "r475", "r476", "r477", "r478", "r479", "r495", "r615", "r631", "r632", "r633", "r675", "r677" }, "us-gaap\_DebtInstrumentRepaidPrincipal": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentRepaidPrincipal", "crdr": "debit", "presentation": "http://clearpointneuro.com/role/NotePayableDetails", "lang": { "en-us": { "role": { "terseLabel": "Principal repayment", "label": "Debt Instrument, Repaid, Principal", "documentation": "Amount of principal of debt repaid." } } }, "auth\_ref": { "r391" }, "us-gaap\_DebtInstrumentTable": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentTable", "presentation": "http://clearpointneuro.com/role/NotePayableDetails", "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long-Term Debt Instruments [Table]", "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "Disclosure of information about long-term debt instrument or arrangement." } } }, "auth\_ref": { "r9", "r25", "r26", "r32", "r74", "r75", "r128", "r201", "r202", "r203", "r204", "r205", "r207", "r212", "r213", "r214", "r215", "r217", "r218", "r219", "r220", "r221", "r222", "r225", "r475", "r476", "r477", "r478", "r479", "r495", "r615", "r675", "r677" }, "clpt\_DebtInstrumentVariableInterestRate": { "xbrltype": "pureItem", "nsuri": "http://clearpointneuro.com/20240930", "localname": "DebtInstrumentVariableInterestRate", "presentation": "http://clearpointneuro.com/role/NotePayableDetails", "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, variable interest rate", "label": "Debt Instrument, Variable Interest Rate", "documentation": "Debt Instrument, Variable Interest Rate" } } }, "auth\_ref": { "us-gaap\_DeferredRevenueCurrent": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredRevenueCurrent", "crdr": "credit", "calculation": "http://clearpointneuro.com/role/CondensedConsolidatedBalanceSheets", "parentTag": "us-gaap\_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 }, "presentation": "http://clearpointneuro.com/role/CondensedConsolidatedBalanceSheets", "lang": { "en-us": {









"r701", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r719"}],  
"ecdd\_NamedExecutiveOfficersFnTextBlock": {"xbrlType": "textBlockItem", "nsuri": "http://xbrl.sec.gov/ecdd/2024", "localname": "NamedExecutiveOfficersFnTextBlock"},  
"presentation": {"http://xbrl.sec.gov/ecdd/role/PvpDisclosure": {"lang": {"en-us": {"role": {"terseLabel": "Named Executive Officers, Footnote", "label": "Named Executive Officers, Footnote [Text Block]"}}, "auth\_ref": {"r565"}}, "us-gaap\_NetCashProvidedByUsedInFinancingActivities": {"xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": {"http://clearpointneuro.com/role/CondensedConsolidatedStatementsOfCashFlows": {"parentTag": "us-gaap\_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0}}, "presentation": {"http://clearpointneuro.com/role/CondensedConsolidatedStatementsOfCashFlows": {"lang": {"en-us": {"role": {"totalLabel": "Net cash flows from financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."}}}, "auth\_ref": {"r121"}}, "us-gaap\_NetCashProvidedByUsedInFinancingActivitiesAbstract": {"xbrlType": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": {"http://clearpointneuro.com/role/CondensedConsolidatedStatementsOfCashFlows": {"lang": {"en-us": {"role": {"terseLabel": "Cash flows from financing activities", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"}}, "auth\_ref": {"r121"}}, "us-gaap\_NetCashProvidedByUsedInInvestingActivities": {"xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": {"http://clearpointneuro.com/role/CondensedConsolidatedStatementsOfCashFlows": {"parentTag": "us-gaap\_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0}}, "presentation": {"http://clearpointneuro.com/role/CondensedConsolidatedStatementsOfCashFlows": {"lang": {"en-us": {"role": {"totalLabel": "Net cash flows from investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."}}}, "auth\_ref": {"r121"}}, "us-gaap\_NetCashProvidedByUsedInInvestingActivitiesAbstract": {"xbrlType": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": {"http://clearpointneuro.com/role/CondensedConsolidatedStatementsOfCashFlows": {"lang": {"en-us": {"role": {"terseLabel": "Cash flows from investing activities", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"}}, "auth\_ref": {"r121"}}, "us-gaap\_NetCashProvidedByUsedInOperatingActivities": {"xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "crdr": "credit", "calculation": {"http://clearpointneuro.com/role/CondensedConsolidatedStatementsOfCashFlows": {"parentTag": "us-gaap\_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0}}, "presentation": {"http://clearpointneuro.com/role/CondensedConsolidatedStatementsOfCashFlows": {"lang": {"en-us": {"role": {"totalLabel": "Net cash flows from operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."}}}, "auth\_ref": {"r60", "r61", "r63"}}, "us-gaap\_NetCashProvidedByUsedInOperatingActivitiesAbstract": {"xbrlType": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": {"http://clearpointneuro.com/role/CondensedConsolidatedStatementsOfCashFlows": {"lang": {"en-us": {"role": {"terseLabel": "Cash flows from operating activities", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"}}, "auth\_ref": {"r60", "r61", "r63"}}, "us-gaap\_NetIncomeLoss": {"xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": {"http://clearpointneuro.com/role/CondensedConsolidatedStatementsOfCashFlows": {"parentTag": "us-gaap\_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0}}, "presentation": {"http://clearpointneuro.com/role/CondensedConsolidatedStatementsOfOperations": {"parentTag": null, "weight": null, "order": null, "root": true}}, "presentation": {"http://clearpointneuro.com/role/CondensedConsolidatedStatementsOfCashFlows": {"http://clearpointneuro.com/role/CondensedConsolidatedStatementsOfOperations": {"http://xbrl.sec.gov/ecdd/role/PvpDisclosure": {"lang": {"en-us": {"role": {"totalLabel": "Net loss", "terseLabel": "Net loss for the period", "verboseLabel": "Net loss", "label": "Net Income (Loss) Attributable to Parent", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."}}}, "auth\_ref": {"r54", "r63", "r85", "r100", "r111", "r112", "r115", "r127", "r132", "r134", "r135", "r136", "r137", "r138", "r141", "r142", "r146", "r166", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r294", "r297", "r312", "r326", "r368", "r425", "r441", "r442", "r513", "r637"}}, "clpt\_NetTransfersOfReusableComponentsFromLoanedSystems": {"xbrlType": "monetaryItemType", "nsuri": "http://clearpointneuro.com/20240930", "localname": "NetTransfersOfReusableComponentsFromLoanedSystems", "crdr": "credit", "presentation": {"http://clearpointneuro.com/role/CondensedConsolidatedStatementsOfCashFlowsParentetical": {"lang": {"en-us": {"role": {"terseLabel": "Net transfers of reusable components from loaned systems (less than \$0.1 million during the nine months ended September 30, 2023)", "label": "Net Transfers Of Reusable Components From Loaned Systems", "documentation": "Net Transfers Of Reusable Components From Loaned Systems"}}, "auth\_ref": {"r121"}}, "clpt\_NeuroSurgeryNavigationAndTherapyDisposableProductsMember": {"xbrlType": "domainItemType", "nsuri": "http://clearpointneuro.com/20240930", "localname": "NeuroSurgeryNavigationAndTherapyDisposableProductsMember", "presentation": {"http://clearpointneuro.com/role/RevenueRecognitionScheduleOfRevenueByServiceLineDetails": {"lang": {"en-us": {"role": {"terseLabel": "NeuroSurgery Navigation and Therapy - Disposable Products", "label": "NeuroSurgery Navigation and Therapy - Disposable Products [Member]", "documentation": "NeuroSurgery Navigation and Therapy - Disposable Products"}}, "auth\_ref": {"r121"}}, "clpt\_NeuroSurgeryNavigationAndTherapyMember": {"xbrlType": "domainItemType", "nsuri": "http://clearpointneuro.com/20240930", "localname": "NeuroSurgeryNavigationAndTherapyMember", "presentation": {"http://clearpointneuro.com/role/RevenueRecognitionScheduleOfRevenueByServiceLineDetails": {"lang": {"en-us": {"role": {"terseLabel": "NeuroSurgery Navigation and Therapy - Services", "label": "NeuroSurgery Navigation and Therapy - Services [Member]", "documentation": "NeuroSurgery Navigation and Therapy - Services"}}, "auth\_ref": {"r121"}}, "clpt\_NeuroSurgeryNavigationAndTherapyServicesMember": {"xbrlType": "domainItemType", "nsuri": "http://clearpointneuro.com/20240930", "localname": "NeuroSurgeryNavigationAndTherapyServicesMember", "presentation": {"http://clearpointneuro.com/role/RevenueRecognitionScheduleOfRevenueByServiceLineDetails": {"lang": {"en-us": {"role": {"terseLabel": "Recent Accounting Standards Not Yet Adopted", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."}}}, "auth\_ref": {"r121"}}, "ecdd\_NonGaapMeasureDescriptionTextBlock": {"xbrlType": "textBlockItem", "nsuri": "http://xbrl.sec.gov/ecdd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": {"http://xbrl.sec.gov/ecdd/role/PvpDisclosure": {"lang": {"en-us": {"role": {"terseLabel": "Non-GAAP Measure Description", "label": "Non-GAAP Measure Description [Text Block]"}}, "auth\_ref": {"r564"}}, "ecdd\_NonNeosMember": {"xbrlType": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecdd/2024", "localname": "NonNeosMember", "presentation": {"http://xbrl.sec.gov/ecdd/role/ErrCompDisclosure": {"lang": {"en-us": {"role": {"terseLabel": "Non-NEOs", "label": "Non-NEOs [Member]"}}, "auth\_ref": {"r528", "r538", "r548", "r572", "r580"}}, "ecdd\_NonPeoNeoAvgCompActuallyPaidAmt": {"xbrlType": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecdd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": {"http://xbrl.sec.gov/ecdd/role/PvpDisclosure": {"lang": {"en-us": {"role": {"terseLabel": "Non-PEO NEO Average Total Compensation", "label": "Non-PEO NEO Average Total Compensation Actually Paid Amount", "documentation": "Non-PEO NEO Average Total Compensation Amount"}}, "auth\_ref": {"r554"}}, "ecdd\_NonPeoNeoMember": {"xbrlType": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecdd/2024", "localname": "NonPeoNeoMember", "presentation": {"http://xbrl.sec.gov/ecdd/role/PvpDisclosure": {"lang": {"en-us": {"role": {"terseLabel": "Non-PEO NEO", "label": "Non-PEO NEO [Member]"}}, "auth\_ref": {"r572"}}, "ecdd\_NonRule10b51ArrAdoptedFlag": {"xbrlType": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecdd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": {"http://xbrl.sec.gov/ecdd/role/InsiderTradingArrangements": {"lang": {"en-us": {"role": {"terseLabel": "Non-Rule 10b5-1 Arrangement Adopted", "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]"}}, "auth\_ref": {"r591"}}, "ecdd\_NonRule10b51ArrTrmndFlag": {"xbrlType": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecdd/2024", "localname": "NonRule10b51ArrTrmndFlag", "presentation": {"http://xbrl.sec.gov/ecdd/role/InsiderTradingArrangements": {"lang": {"en-us": {"role": {"terseLabel": "Non-Rule 10b5-1 Arrangement Terminated", "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]"}}, "auth\_ref": {"r591"}}, "us-gaap\_NonoperatingIncomeExpenseAbstract": {"xbrlType": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": {"http://clearpointneuro.com/role/CondensedConsolidatedStatementsOfOperations": {"lang": {"en-us": {"role": {"terseLabel": "Other income (expense)", "label": "Nonoperating Income (Expense) [Abstract]"}}, "auth\_ref": {"r121"}}, "clpt\_NumberOfCustomers": {"xbrlType": "integerItemType", "nsuri": "http://clearpointneuro.com/20240930", "localname": "NumberOfCustomers", "presentation": {"http://clearpointneuro.com/role/DescriptionOfTheBusinessAndFinancialConditionDetails": {"lang": {"en-us": {"role": {"terseLabel": "Number of customers (more than)", "label": "Number Of Customers", "documentation": "Number Of Customers"}}, "auth\_ref": {"r121"}}, "us-gaap\_NumberOfOperatingSegments": {"xbrlType": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NumberOfOperatingSegments", "presentation": {"http://clearpointneuro.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetails": {"lang": {"en-us": {"role": {"terseLabel": "Number of industry segments", "label": "Number of Operating Segments", "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."}}}, "auth\_ref": {"r473", "r622"}}, "clpt\_OfficeLeaseAndManufacturingFacilityCarlsbadCaliforniaMember": {"xbrlType": "domainItemType", "nsuri": "http://clearpointneuro.com/20240930", "localname": "OfficeLeaseAndManufacturingFacilityCarlsbadCaliforniaMember", "presentation": {"http://clearpointneuro.com/role/LeasesDetails": {"lang": {"en-us": {"role": {"terseLabel": "Office Lease and Manufacturing facility - Carlsbad, California", "label": "Office Lease and Manufacturing facility - Carlsbad, California [Member]"}}, "auth\_ref": {"r121"}}, "clpt\_OfficeLeaseSolanaBeachCaliforniaMember": {"xbrlType": "domainItemType", "nsuri": "http://clearpointneuro.com/20240930", "localname": "OfficeLeaseSolanaBeachCaliforniaMember", "presentation": {"http://clearpointneuro.com/role/LeasesDetails": {"lang": {"en-us": {"role": {"terseLabel": "Office Lease - Solana Beach, California", "label": "Office Lease - Solana Beach, California [Member]", "documentation": "Office Lease - Solana Beach, California"}}, "auth\_ref": {"r121"}}, "us-gaap\_OperatingIncomeLoss": {"xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": {"http://clearpointneuro.com/role/CondensedConsolidatedStatementsOfOperations": {"parentTag": "us-gaap\_NetIncomeLoss", "weight": 1.0, "order": 1.0}}, "presentation": {"http://clearpointneuro.com/role/CondensedConsolidatedStatementsOfOperations": {"lang": {"en-us": {"role": {"totalLabel": "Operating loss", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues."}}}, "auth\_ref": {"r88", "r471", "r621", "r623", "r624", "r625", "r626"}}, "us-gaap\_OperatingLeaseLiabilityCurrent": {"xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": {"http://clearpointneuro.com/role/CondensedConsolidatedBalanceSheets": {"parentTag": "us-gaap\_LiabilitiesCurrent", "weight": 1.0, "order": 4.0}}, "presentation": {"http://clearpointneuro.com/role/CondensedConsolidatedBalanceSheets": {"lang": {"en-us": {"role": {"terseLabel": "Operating lease liabilities, current portion", "label": "Operating Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."}}}, "auth\_ref": {"r339"}}, "us-gaap\_OperatingLeaseLiabilityNoncurrent": {"xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": {"http://clearpointneuro.com/role/CondensedConsolidatedBalanceSheets": {"parentTag": "us-gaap\_Liabilities", "weight": 1.0, "order": 2.0}}, "presentation": {"

"http://clearpointneuro.com/role/CondensedConsolidatedBalanceSheets", "lang": "en-us", "role": "terseLabel", "Operating lease liabilities, net of current portion", "label": "Operating Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." }, {"parentTag": "us-gaap\_OperatingLeaseRightOfUseAsset", "localName": "us-gaap\_OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": "http://clearpointneuro.com/role/CondensedConsolidatedBalanceSheets", "weight": 1.0, "order": 3.0, "presentation": "http://clearpointneuro.com/role/CondensedConsolidatedBalanceSheets", "lang": "en-us", "role": "terseLabel", "Operating lease, right-of-use assets", "label": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." }, {"parentTag": "us-gaap\_Assets", "localName": "us-gaap\_Assets", "crdr": "debit", "calculation": "http://clearpointneuro.com/role/CondensedConsolidatedBalanceSheets", "weight": 1.0, "order": 3.0, "presentation": "http://clearpointneuro.com/role/CondensedConsolidatedBalanceSheets", "lang": "en-us", "role": "terseLabel", "Option exercises (cashless) (in shares)", "label": "Option Exercises, Cashless, Shares", "documentation": "Option Exercises, Cashless, Shares" }, {"parentTag": "us-gaap\_OtherAccruedLiabilitiesCurrent", "localName": "us-gaap\_OtherAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": "http://clearpointneuro.com/role/CondensedConsolidatedBalanceSheets", "parentTag": "us-gaap\_LiabilitiesCurrent", "weight": 1.0, "order": 3.0, "presentation": "http://clearpointneuro.com/role/CondensedConsolidatedBalanceSheets", "lang": "en-us", "role": "terseLabel", "Other accrued liabilities", "label": "Other Accrued Liabilities, Current", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." }, {"parentTag": "us-gaap\_OtherAssetsNoncurrent", "localName": "us-gaap\_OtherAssetsNoncurrent", "crdr": "debit", "calculation": "http://clearpointneuro.com/role/CondensedConsolidatedBalanceSheets", "parentTag": "us-gaap\_Assets", "weight": 1.0, "order": 6.0, "presentation": "http://clearpointneuro.com/role/CondensedConsolidatedBalanceSheets", "lang": "en-us", "role": "terseLabel", "Other assets", "label": "Other Assets, Noncurrent", "documentation": "Amount of noncurrent assets classified as other." }, {"parentTag": "us-gaap\_OtherNonoperatingIncomeExpense", "localName": "us-gaap\_OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": "http://clearpointneuro.com/role/CondensedConsolidatedStatementsOfOperations", "parentTag": "us-gaap\_NetIncomeLoss", "weight": 1.0, "order": 2.0, "presentation": "http://clearpointneuro.com/role/CondensedConsolidatedStatementsOfOperations", "lang": "en-us", "role": "terseLabel", "Other expense, net", "label": "Other Nonoperating Income (Expense)", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." }, {"parentTag": "us-gaap\_OtherPerfMeasureAmt", "localName": "us-gaap\_OtherPerfMeasureAmt", "crdr": "debit", "calculation": "http://clearpointneuro.com/role/CondensedConsolidatedBalanceSheets", "parentTag": "us-gaap\_Assets", "weight": 1.0, "order": 6.0, "presentation": "http://clearpointneuro.com/role/CondensedConsolidatedBalanceSheets", "lang": "en-us", "role": "terseLabel", "Other Perf Measure Amt", "label": "Other Perf Measure Amt", "documentation": "Other Performance Measure, Amount", "label": "Other Performance Measure, Amount" }, {"parentTag": "us-gaap\_OutstandingAggtErrCompAmt", "localName": "us-gaap\_OutstandingAggtErrCompAmt", "crdr": "debit", "calculation": "http://clearpointneuro.com/role/CondensedConsolidatedBalanceSheets", "parentTag": "us-gaap\_Assets", "weight": 1.0, "order": 6.0, "presentation": "http://clearpointneuro.com/role/CondensedConsolidatedBalanceSheets", "lang": "en-us", "role": "terseLabel", "Outstanding Aggregate Erroneous Compensation Amount", "label": "Outstanding Aggregate Erroneous Compensation Amount" }, {"parentTag": "us-gaap\_OutstandingRecoveryCompAmt", "localName": "us-gaap\_OutstandingRecoveryCompAmt", "crdr": "debit", "calculation": "http://clearpointneuro.com/role/CondensedConsolidatedBalanceSheets", "parentTag": "us-gaap\_Assets", "weight": 1.0, "order": 6.0, "presentation": "http://clearpointneuro.com/role/CondensedConsolidatedBalanceSheets", "lang": "en-us", "role": "terseLabel", "Outstanding Recovery Compensation Amount", "label": "Outstanding Recovery Compensation Amount" }, {"parentTag": "us-gaap\_OutstandingRecoveryIndName", "localName": "us-gaap\_OutstandingRecoveryIndName", "crdr": "debit", "calculation": "http://clearpointneuro.com/role/CondensedConsolidatedBalanceSheets", "parentTag": "us-gaap\_Assets", "weight": 1.0, "order": 6.0, "presentation": "http://clearpointneuro.com/role/CondensedConsolidatedBalanceSheets", "lang": "en-us", "role": "terseLabel", "Outstanding Recovery Individual Name", "label": "Outstanding Recovery, Individual Name" }, {"parentTag": "us-gaap\_PayVsPerformanceDisclosureLineItems", "localName": "us-gaap\_PayVsPerformanceDisclosureLineItems", "crdr": "debit", "calculation": "http://clearpointneuro.com/role/CondensedConsolidatedBalanceSheets", "parentTag": "us-gaap\_Assets", "weight": 1.0, "order": 6.0, "presentation": "http://clearpointneuro.com/role/CondensedConsolidatedBalanceSheets", "lang": "en-us", "role": "terseLabel", "Pay Vs Performance Disclosure Line Items", "label": "Pay Vs Performance Disclosure Line Items" }, {"parentTag": "us-gaap\_PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "localName": "us-gaap\_PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "crdr": "debit", "calculation": "http://clearpointneuro.com/role/CondensedConsolidatedBalanceSheets", "parentTag": "us-gaap\_Assets", "weight": 1.0, "order": 6.0, "presentation": "http://clearpointneuro.com/role/CondensedConsolidatedBalanceSheets", "lang": "en-us", "role": "terseLabel", "Payments Related To Tax Withholding For Share Based Compensation", "label": "Payments Related To Tax Withholding For Share Based Compensation" }, {"parentTag": "us-gaap\_PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "localName": "us-gaap\_PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "crdr": "credit", "calculation": "http://clearpointneuro.com/role/CondensedConsolidatedStatementsOfCashFlows", "parentTag": "us-gaap\_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 1.0, "presentation": "http://clearpointneuro.com/role/CondensedConsolidatedStatementsOfCashFlows", "lang": "en-us", "role": "negatedTerseLabel", "Payments for taxes related to net share settlement of equity awards", "label": "Payment, Tax Withholding, Share-Based Payment Arrangement", "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement." }, {"parentTag": "us-gaap\_PaymentsToAcquireIntangibleAssets", "localName": "us-gaap\_PaymentsToAcquireIntangibleAssets", "crdr": "debit", "calculation": "http://clearpointneuro.com/role/CondensedConsolidatedStatementsOfCashFlows", "parentTag": "us-gaap\_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0, "presentation": "http://clearpointneuro.com/role/CondensedConsolidatedStatementsOfCashFlows", "lang": "en-us", "role": "negatedTerseLabel", "Acquisition of licensing rights", "label": "Payments To Acquire Intangible Assets", "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill." }, {"parentTag": "us-gaap\_PaymentsToAcquirePropertyPlantAndEquipment", "localName": "us-gaap\_PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "debit", "calculation": "http://clearpointneuro.com/role/CondensedConsolidatedStatementsOfCashFlows", "parentTag": "us-gaap\_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 3.0, "presentation": "http://clearpointneuro.com/role/CondensedConsolidatedStatementsOfCashFlows", "lang": "en-us", "role": "negatedTerseLabel", "Acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale, includes cash outflows to pay for construction of self-constructed assets", "label": "Payments To Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale, includes cash outflows to pay for construction of self-constructed assets." }, {"parentTag": "us-gaap\_PeerGroupIssuersFnTextBlock", "localName": "us-gaap\_PeerGroupIssuersFnTextBlock", "crdr": "debit", "calculation": "http://clearpointneuro.com/role/CondensedConsolidatedBalanceSheets", "parentTag": "us-gaap\_Assets", "weight": 1.0, "order": 6.0, "presentation": "http://clearpointneuro.com/role/CondensedConsolidatedBalanceSheets", "lang": "en-us", "role": "terseLabel", "Peer Group Issuers, Footnote", "label": "Peer Group Issuers, Footnote [Text Block]" }, {"parentTag": "us-gaap\_PeerGroupTotalShareholderRtnAmt", "localName": "us-gaap\_PeerGroupTotalShareholderRtnAmt", "crdr": "debit", "calculation": "http://clearpointneuro.com/role/CondensedConsolidatedBalanceSheets", "parentTag": "us-gaap\_Assets", "weight": 1.0, "order": 6.0, "presentation": "http://clearpointneuro.com/role/CondensedConsolidatedBalanceSheets", "lang": "en-us", "role": "terseLabel", "Peer Group Total Shareholder Return Amount", "label": "Peer Group Total Shareholder Return Amount" }, {"parentTag": "us-gaap\_PeoActuallyPaidCompAmt", "localName": "us-gaap\_PeoActuallyPaidCompAmt", "crdr": "debit", "calculation": "http://clearpointneuro.com/role/CondensedConsolidatedBalanceSheets", "parentTag": "us-gaap\_Assets", "weight": 1.0, "order": 6.0, "presentation": "http://clearpointneuro.com/role/CondensedConsolidatedBalanceSheets", "lang": "en-us", "role": "terseLabel", "PEO Actually Paid Compensation Amount", "label": "PEO Actually Paid Compensation Amount" }, {"parentTag": "us-gaap\_PeoMember", "localName": "us-gaap\_PeoMember", "crdr": "debit", "calculation": "http://clearpointneuro.com/role/CondensedConsolidatedBalanceSheets", "parentTag": "us-gaap\_Assets", "weight": 1.0, "order": 6.0, "presentation": "http://clearpointneuro.com/role/CondensedConsolidatedBalanceSheets", "lang": "en-us", "role": "terseLabel", "PEO Member", "label": "PEO [Member]" }, {"parentTag": "us-gaap\_PeoName", "localName": "us-gaap\_PeoName", "crdr": "debit", "calculation": "http://clearpointneuro.com/role/CondensedConsolidatedBalanceSheets", "parentTag": "us-gaap\_Assets", "weight": 1.0, "order": 6.0, "presentation": "http://clearpointneuro.com/role/CondensedConsolidatedBalanceSheets", "lang": "en-us", "role": "terseLabel", "PEO Name", "label": "PEO Name" }, {"parentTag": "us-gaap\_PeoTotalCompAmt", "localName": "us-gaap\_PeoTotalCompAmt", "crdr": "debit", "calculation": "http://clearpointneuro.com/role/CondensedConsolidatedBalanceSheets", "parentTag": "us-gaap\_Assets", "weight": 1.0, "order": 6.0, "presentation": "http://clearpointneuro.com/role/CondensedConsolidatedBalanceSheets", "lang": "en-us", "role": "terseLabel", "PEO Total Compensation Amount", "label": "PEO Total Compensation Amount" }, {"parentTag": "us-gaap\_PlanNameAxis", "localName": "us-gaap\_PlanNameAxis", "crdr": "debit", "calculation": "http://clearpointneuro.com/role/CondensedConsolidatedBalanceSheets", "parentTag": "us-gaap\_Assets", "weight": 1.0, "order": 6.0, "presentation": "http://clearpointneuro.com/role/CondensedConsolidatedBalanceSheets", "lang": "en-us", "role": "terseLabel", "Plan Name Axis", "label": "Plan Name [Axis]" }, {"parentTag": "us-gaap\_PnsnAdjsPrrSvcCstMember", "localName": "us-gaap\_PnsnAdjsPrrSvcCstMember", "crdr": "debit", "calculation": "http://clearpointneuro.com/role/CondensedConsolidatedBalanceSheets", "parentTag": "us-gaap\_Assets", "weight": 1.0, "order": 6.0, "presentation": "http://clearpointneuro.com/role/CondensedConsolidatedBalanceSheets", "lang": "en-us", "role": "terseLabel", "Pension Adjustments Prior Service Cost Member", "label": "Pension Adjustments Service Cost [Member]" }, {"parentTag": "us-gaap\_PnsnBnftsAdjFnTextBlock", "localName": "us-gaap\_PnsnBnftsAdjFnTextBlock", "crdr": "debit", "calculation": "http://clearpointneuro.com/role/CondensedConsolidatedBalanceSheets", "parentTag": "us-gaap\_Assets", "weight": 1.0, "order": 6.0, "presentation": "http://clearpointneuro.com/role/CondensedConsolidatedBalanceSheets", "lang": "en-us", "role": "terseLabel", "Pension Benefits Adjustments, Footnote", "label": "Pension Benefits Adjustments, Footnote [Text Block]" }, {"parentTag": "us-gaap\_PnsnBnftsAdjFnTextBlock", "localName": "us-gaap\_PnsnBnftsAdjFnTextBlock", "crdr": "debit", "calculation": "http://clearpointneuro.com/role/CondensedConsolidatedBalanceSheets", "parentTag": "us-gaap\_Assets", "weight": 1.0, "order": 6.0, "presentation": "http://clearpointneuro.com/role/CondensedConsolidatedBalanceSheets", "lang": "en-us", "role": "terseLabel", "Preferred stock par value (in dollars per share)", "label": "Preferred Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." }, {"parentTag": "us-gaap\_PnsnBnftsAdjFnTextBlock", "localName": "us-gaap\_PnsnBnftsAdjFnTextBlock", "crdr": "debit", "calculation": "http://clearpointneuro.com/role/CondensedConsolidatedBalanceSheets", "parentTag": "us-gaap\_Assets", "weight": 1.0, "order": 6.0, "presentation": "http://clearpointneuro.com/role/CondensedConsolidatedBalanceSheets", "lang": "en-us", "role": "terseLabel", "Preferred stock, shares authorized (in shares)", "label": "Preferred Stock, Shares Authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." }, {"parentTag": "us-gaap\_PnsnBnftsAdjFnTextBlock", "localName": "us-gaap\_PnsnBnftsAdjFnTextBlock", "crdr": "debit", "calculation": "http://clearpointneuro.com/role/CondensedConsolidatedBalanceSheets", "parentTag": "us-gaap\_Assets", "weight": 1.0, "order": 6.0, "presentation": "http://clearpointneuro.com/role/CondensedConsolidatedBalanceSheets", "lang": "en-us", "role": "terseLabel", "Preferred stock, shares issued (in shares)", "label": "Preferred Stock, Shares Issued", "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt." }, {"parentTag": "us-gaap\_PnsnBnftsAdjFnTextBlock", "localName": "us-gaap\_PnsnBnftsAdjFnTextBlock", "crdr": "debit", "calculation": "http://clearpointneuro.com/role/CondensedConsolidatedBalanceSheets", "parentTag": "us-gaap\_Assets", "weight": 1.0, "order": 6.0, "presentation": "http://clearpointneuro.com/role/CondensedConsolidatedBalanceSheets", "lang": "en-us", "role": "terseLabel", "Preferred stock, value issued", "label": "Preferred Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." }, {"parentTag": "us-gaap\_PnsnBnftsAdjFnTextBlock", "localName": "us-gaap\_PnsnBnftsAdjFnTextBlock", "crdr": "debit", "calculation": "http://clearpointneuro.com/role/CondensedConsolidatedBalanceSheets", "parentTag": "us-gaap\_Assets", "weight": 1.0, "order": 6.0, "presentation": "http://clearpointneuro.com/role/CondensedConsolidatedBalanceSheets", "lang": "en-us", "role": "terseLabel", "Prepaid expenses and other current assets", "label": "Prepaid Expense and Other Assets, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." }, {"parentTag": "us-gaap\_PnsnBnftsAdjFnTextBlock", "localName": "us-gaap\_PnsnBnftsAdjFnTextBlock", "crdr": "debit", "calculation": "http://clearpointneuro.com/role/CondensedConsolidatedBalanceSheets", "parentTag": "us-gaap\_Assets", "weight": 1.0, "order": 6.0, "presentation": "http://clearpointneuro.com/role/CondensedConsolidatedBalanceSheets", "lang": "en-us", "role": "terseLabel", "Proceeds from issuance of common stock", "label": "Proceeds From Issuance Of Common Stock", "documentation": "Proceeds from issuance of common stock." }, {"parentTag": "us-gaap\_PnsnBnftsAdjFnTextBlock", "localName": "us-gaap\_PnsnBnftsAdjFnTextBlock", "crdr": "debit", "calculation": "http://clearpointneuro.com/role/CondensedConsolidatedBalanceSheets", "parentTag": "us-gaap\_Assets", "weight": 1.0, "order": 6.0, "presentation": "http://clearpointneuro.com/role/CondensedConsolidatedBalanceSheets", "lang": "en-us", "role": "terseLabel", "Description of the business and financial condition details", "label": "Description of the Business and Financial Condition Details" }]

"en-us": {"role": {"terseLabel": "Proceeds from public offering of common stock, net of offering costs", "verboseLabel": "Net proceeds from offering", "netLabel": "Proceeds from issuance of common stock", "label": "Proceeds from Issuance of Common Stock", "documentation": "The cash inflow from the additional capital contribution to the entity."}}, {"auth\_ref": {"r1": "1"}, "us\_gaap": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans", {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans", "crdr": "debit", "calculation": {"http://clearpointneuro.com/role/CondensedConsolidatedStatementsOfCashFlows": {"parentTag": "us-gaap\_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 4.0}}, "presentation": {"http://clearpointneuro.com/role/CondensedConsolidatedStatementsOfCashFlows": {"lang": {"en-us": {"role": {"terseLabel": "Proceeds from issuance of common stock under employee stock purchase plan", "label": "Proceeds - Issuance of Shares; Share-Based Payment Arrangement, Excluding Option Exercised", "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Excludes option exercised."}}, {"auth\_ref": {"r1": "1", "r8": "1"}, "us-gaap": "ProceedsFromMaturitiesPrepaymentsAndCallsOfShortTermInvestments", {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfShortTermInvestments", "crdr": "debit", "calculation": {"http://clearpointneuro.com/role/CondensedConsolidatedStatementsOfCashFlows": {"parentTag": "us-gaap\_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 2.0}}, "presentation": {"http://clearpointneuro.com/role/CondensedConsolidatedStatementsOfCashFlows": {"lang": {"en-us": {"role": {"terseLabel": "Proceeds from maturities of short-term investments", "label": "Proceeds from Maturities, Prepayments and Calls of Short-Term Investments", "documentation": "The cash inflow from maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term."}}, {"auth\_ref": {"r11": "1", "r57": "1"}, "us-gaap": "ProceedsFromStockOptionsExercised", {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "calculation": {"http://clearpointneuro.com/role/CondensedConsolidatedStatementsOfCashFlows": {"parentTag": "us-gaap\_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 2.0}}, "presentation": {"http://clearpointneuro.com/role/CondensedConsolidatedStatementsOfCashFlows": {"lang": {"en-us": {"role": {"terseLabel": "Proceeds from stock option exercises", "label": "Proceeds from Stock Options Exercised", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."}}, {"auth\_ref": {"r1": "1", "r8": "1"}, "us-gaap": "ProductInformationLineItems", {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProductInformationLineItems", "presentation": {"http://clearpointneuro.com/role/BasisOfPresentationandSummaryofSignificantAccountingPoliciesDetails": {"lang": {"en-us": {"role": {"terseLabel": "Product Information [Line Items]", "label": "Product Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."}}, {"auth\_ref": {}}, {"us\_gaap\_ProductMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProductMember", "presentation": {"http://clearpointneuro.com/role/CondensedConsolidatedStatementsOfOperations": {"lang": {"en-us": {"role": {"terseLabel": "Product revenue", "label": "Product [Member]", "documentation": "Article or substance produced by nature, labor or machinery."}}, {"auth\_ref": {"r481": "1"}, "srt\_ProductOrServiceAxis": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductOrServiceAxis", "presentation": {"http://clearpointneuro.com/role/RevenueRecognitionNarrativeDetails": {"http://clearpointneuro.com/role/RevenueRecognitionScheduleOfRevenuebyServiceLineDetails": {"lang": {"en-us": {"role": {"terseLabel": "Product and Service [Axis]", "label": "Product and Service [Axis]", "documentation": "Product and Service [Axis]", "auth\_ref": {"r161": "1", "r354": "1", "r371": "1", "r372": "1", "r373": "1", "r374": "1", "r375": "1", "r376": "1", "r377": "1", "r401": "1", "r498": "1", "r500": "1", "r501": "1", "r503": "1", "r504": "1", "r635": "1", "r636": "1", "r641": "1", "r690": "1", "r692": "1", "r693": "1", "r694": "1", "r695": "1", "r696": "1", "r697": "1", "r698": "1", "r699": "1", "r700": "1", "r701": "1", "r702": "1", "r703": "1", "r704": "1", "r705": "1", "r706": "1", "r707": "1", "r708": "1", "r709": "1", "r710": "1", "r711": "1", "r712": "1", "r713": "1", "r714": "1", "r715": "1", "r716": "1", "r717": "1", "r718": "1", "r719": "1"}, "srt\_ProductsAndServicesDomain": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductsAndServicesDomain", "presentation": {"http://clearpointneuro.com/role/CondensedConsolidatedStatementsOfOperations": {"http://clearpointneuro.com/role/RevenueRecognitionNarrativeDetails": {"http://clearpointneuro.com/role/RevenueRecognitionScheduleOfRevenuebyServiceLineDetails": {"lang": {"en-us": {"role": {"verboseLabel": "Product and Service [Domain]", "label": "Product and Service [Domain]", "documentation": "Product and Service [Domain]", "auth\_ref": {"r161": "1", "r354": "1", "r371": "1", "r372": "1", "r373": "1", "r374": "1", "r375": "1", "r376": "1", "r377": "1", "r401": "1", "r498": "1", "r500": "1", "r501": "1", "r503": "1", "r504": "1", "r635": "1", "r636": "1", "r641": "1", "r690": "1", "r692": "1", "r693": "1", "r694": "1", "r695": "1", "r696": "1", "r697": "1", "r698": "1", "r699": "1", "r700": "1", "r701": "1", "r702": "1", "r703": "1", "r704": "1", "r705": "1", "r706": "1", "r707": "1", "r708": "1", "r709": "1", "r710": "1", "r711": "1", "r712": "1", "r713": "1", "r714": "1", "r715": "1", "r716": "1", "r717": "1", "r718": "1", "r719": "1"}, "us\_gaap\_PropertyPlantAndEquipmentByTypeAxis": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": {"http://clearpointneuro.com/role/LeasesDetails": {"lang": {"en-us": {"role": {"terseLabel": "Long-Lived Tangible Asset [Axis]", "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."}}, {"auth\_ref": {"r4": "1", "r343": "1"}, "us\_gaap\_PropertyPlantAndEquipmentNet": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": {"http://clearpointneuro.com/role/CondensedConsolidatedBalanceSheets": {"parentTag": "us-gaap\_Assets", "weight": 1.0, "order": 2.0}}, "presentation": {"http://clearpointneuro.com/role/CondensedConsolidatedBalanceSheets": {"lang": {"en-us": {"role": {"terseLabel": "Property and equipment, net", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."}}, {"auth\_ref": {"r4": "1", "r343": "1", "r360": "1", "r367": "1", "r497": "1"}, "us\_gaap\_PropertyPlantAndEquipmentTypeDomain": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": {"http://clearpointneuro.com/role/LeasesDetails": {"lang": {"en-us": {"role": {"verboseLabel": "Long-Lived Tangible Asset [Domain]", "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."}}, {"auth\_ref": {"r69": "1", "r343": "1"}, "us\_gaap\_PropertyPlantAndEquipmentUsefulLife": {"xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentUsefulLife", "presentation": {"http://clearpointneuro.com/role/BasisOfPresentationandSummaryofSignificantAccountingPoliciesDetails": {"lang": {"en-us": {"role": {"terseLabel": "Estimated useful life", "label": "Property, Plant and Equipment, Useful Life", "documentation": "Useful life of long-lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."}}, {"auth\_ref": {}}, {"us\_gaap\_ProvisionForDoubtfulAccounts": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProvisionForDoubtfulAccounts", "crdr": "debit", "calculation": {"http://clearpointneuro.com/role/CondensedConsolidatedStatementsOfCashFlows": {"parentTag": "us-gaap\_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0}}, "presentation": {"http://clearpointneuro.com/role/CondensedConsolidatedStatementsOfCashFlows": {"lang": {"en-us": {"role": {"terseLabel": "Allowance for credit losses (recoveries)", "label": "Accounts Receivable, Credit Loss Expense (Reversal)", "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable."}}, {"auth\_ref": {"r118": "1", "r171": "1"}, "clpt\_PublicOfferingMember": {"xbrltype": "domainItemType", "nsuri": "http://clearpointneuro.com/20240930", "localname": "PublicOfferingMember", "presentation": {"http://clearpointneuro.com/role/DescriptionoftheBusinessandFinancialConditionDetails": {"http://clearpointneuro.com/role/StockholdersEquityNarrativeDetails": {"lang": {"en-us": {"role": {"terseLabel": "Public Offering", "label": "Public Offering [Member]", "documentation": "Public Offering"}}, {"auth\_ref": {}}, {"ecd\_PvpTable": {"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": {"http://xbrl.sec.gov/ecd/role/PvpDisclosure": {"lang": {"en-us": {"role": {"terseLabel": "Pay vs Performance Disclosure", "label": "Pay vs Performance Disclosure [Table]", "documentation": "Pay vs Performance Disclosure [Table]", "auth\_ref": {"r553": "1"}, "ecd\_PvpTableTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": {"http://xbrl.sec.gov/ecd/role/PvpDisclosure": {"lang": {"en-us": {"role": {"terseLabel": "Pay vs Performance Disclosure, Table", "label": "Pay vs Performance [Table Text Block]", "documentation": "Pay vs Performance [Table Text Block]", "auth\_ref": {"r553": "1"}, "srt\_RangeAxis": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": {"http://clearpointneuro.com/role/BasisOfPresentationandSummaryofSignificantAccountingPoliciesDetails": {"http://clearpointneuro.com/role/LeasesDetails": {"lang": {"en-us": {"role": {"terseLabel": "Statistical Measurement [Axis]", "label": "Statistical Measurement [Axis]", "documentation": "Statistical Measurement [Domain]", "auth\_ref": {"r185": "1", "r186": "1", "r187": "1", "r188": "1", "r255": "1", "r256": "1", "r281": "1", "r282": "1", "r283": "1", "r287": "1", "r313": "1", "r346": "1", "r347": "1", "r348": "1", "r370": "1", "r380": "1", "r387": "1", "r395": "1", "r396": "1", "r448": "1", "r449": "1", "r450": "1", "r451": "1", "r452": "1", "r456": "1", "r457": "1", "r474": "1", "r480": "1", "r488": "1", "r491": "1", "r492": "1", "r493": "1", "r494": "1", "r500": "1", "r507": "1", "r634": "1", "r639": "1", "r673": "1", "r682": "1", "r683": "1", "r684": "1", "r685": "1", "r686": "1"}, "srt\_RangeMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": {"http://clearpointneuro.com/role/BasisOfPresentationandSummaryofSignificantAccountingPoliciesDetails": {"http://clearpointneuro.com/role/LeasesDetails": {"http://clearpointneuro.com/role/RevenueRecognitionNarrativeDetails": {"lang": {"en-us": {"role": {"verboseLabel": "Statistical Measurement [Domain]", "label": "Statistical Measurement [Domain]", "documentation": "Statistical Measurement [Domain]", "auth\_ref": {"r185": "1", "r186": "1", "r187": "1", "r188": "1", "r255": "1", "r256": "1", "r281": "1", "r282": "1", "r283": "1", "r287": "1", "r313": "1", "r346": "1", "r347": "1", "r348": "1", "r370": "1", "r380": "1", "r387": "1", "r395": "1", "r396": "1", "r448": "1", "r449": "1", "r450": "1", "r451": "1", "r452": "1", "r456": "1", "r457": "1", "r474": "1", "r480": "1", "r488": "1", "r491": "1", "r492": "1", "r493": "1", "r494": "1", "r500": "1", "r507": "1", "r634": "1", "r639": "1", "r673": "1", "r682": "1", "r683": "1", "r684": "1", "r685": "1", "r686": "1"}, "ecd\_RecoveryOfErrCompDisclosureLineItems": {"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": {"en-us": {"role": {"label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]", "documentation": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]", "auth\_ref": {"r521": "1", "r531": "1", "r541": "1", "r573": "1"}, "us\_gaap\_RepaymentsOfDebt": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfDebt", "crdr": "credit", "presentation": {"http://clearpointneuro.com/role/DescriptionoftheBusinessandFinancialConditionDetails": {"lang": {"en-us": {"role": {"terseLabel": "Repayments of debt", "label": "Repayments of Debt", "documentation": "Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation."}}, {"auth\_ref": {"r611": "1"}, "us\_gaap\_RepaymentsOfSecuredDebt": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfSecuredDebt", "crdr": "credit", "calculation": {"http://clearpointneuro.com/role/CondensedConsolidatedStatementsOfCashFlows": {"parentTag": "us-gaap\_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 5.0}}, "presentation": {"http://clearpointneuro.com/role/CondensedConsolidatedStatementsOfCashFlows": {"lang": {"en-us": {"role": {"negatedTerseLabel": "Repayment of 2020 senior secured convertible note", "label": "Repayments of Secured Debt", "documentation": "The cash outflow to repay long-term debt that is wholly or partially secured by collateral. Excludes repayments of tax exempt secured debt."}}, {"auth\_ref": {"r59": "1"}, "us\_gaap\_ResearchAndDevelopmentExpense": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": {"http://clearpointneuro.com/role/CondensedConsolidatedStatementsOfOperations": {"parentTag": "us-gaap\_OperatingIncomeLoss", "weight": -1.0, "order": 3.0}}, "presentation": {"http://clearpointneuro.com/role/CondensedConsolidatedStatementsOfOperations": {"lang": {"en-us": {"role": {"terseLabel": "Research and development costs", "label": "Research and Development Expense", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."}}, {"auth\_ref": {"r288": "1", "r458": "1", "r472": "1", "r697": "1"}, "us\_gaap\_ResearchAndDevelopmentExpenseMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": {"http://clearpointneuro.com/role/StockholdersEquityScheduleofShareBasedCompensationExpenseDetails": {"lang": {"en-us": {"role": {"terseLabel": "Research and development", "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."}}, {"auth\_ref": {}}, {"ecd\_RestatementDateAxis": {"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": {"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": {"lang": {"en-us": {"role": {"terseLabel": "Restatement Determination Date", "label": "Restatement Determination Date [Axis]", "documentation": "Restatement Determination Date", "auth\_ref": {"r522": "1", "r532": "1", "r542": "1", "r574": "1"}, "ecd\_RestatementDeterminationDate": {"xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": {"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": {"lang": {"en-us": {"role": {"terseLabel": "Restatement Determination Date", "label": "Restatement Determination Date", "documentation": "Restatement Determination Date", "auth\_ref": {"r523": "1", "r533": "1", "r543": "1", "r575": "1"}, "ecd\_RestatementDoesNotRequireRecoveryTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": {"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": {"lang": {"en-us": {"role": {"terseLabel": "Restatement does not require recovery", "label": "Restatement Does Not Require Recovery [Text Block]", "documentation": "Restatement does not require recovery", "auth\_ref": {"r530": "1", "r540": "1", "r550": "1", "r582": "1"}, "us\_gaap\_RestrictedStockMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockMember"}}





balance (in dollars per share)", "periodEndLabel": "Outstanding, ending balance (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth\_ref": { "r270", "r271" } }, "us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "presentation": { "http://clearpointneuro.com/role/StockholdersEquityScheduleofRestrictedStockActivityDetails", "lang": { "en-us": { "role": { "terseLabel": "Weighted-Average Grant-Date Fair-Value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant-Date Fair-Value [Abstract]" } } } }, "auth\_ref": { "r270", "r271" } }, "us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": { "http://clearpointneuro.com/role/StockholdersEquityScheduleofRestrictedStockActivityDetails", "lang": { "en-us": { "role": { "negatedTerseLabel": "Vested (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } } }, "auth\_ref": { "r274" } }, "us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "presentation": { "http://clearpointneuro.com/role/StockholdersEquityScheduleofRestrictedStockActivityDetails", "lang": { "en-us": { "role": { "terseLabel": "Vested (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant-Date Fair-Value", "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement." } } } }, "auth\_ref": { "r274" } }, "us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": { "http://clearpointneuro.com/role/StockholdersEquityScheduleofRestrictedStockActivityDetails", "http://clearpointneuro.com/role/StockholdersEquityScheduleofShareBasedCompensationExpenseDetails", "http://clearpointneuro.com/role/StockholdersEquityScheduleofUnrecognizedCompensationExpenseandWeightedAverageRequisitePeriodDetails", "lang": { "en-us": { "role": { "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } } }, "auth\_ref": { "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284" } }, "us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": { "http://clearpointneuro.com/role/StockholdersEquityNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Grant (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant", "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } } }, "auth\_ref": { "r271" } }, "clpt\_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod": { "xbrltype": "durationItemType", "nsuri": "http://clearpointneuro.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod", "presentation": { "http://clearpointneuro.com/role/StockholdersEquityNarrativeDetails", "lang": { "en-us": { "role": { "verboseLabel": "Offering period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Offering Period", "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Offering Period" } } } }, "auth\_ref": { "r271" } }, "us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "presentation": { "http://clearpointneuro.com/role/StockholdersEquityScheduleofStockOptionActivityDetails", "lang": { "en-us": { "role": { "terseLabel": "Weighted-average Remaining Contractual Life (in years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]" } } } }, "auth\_ref": { "r271" } }, "us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": { "http://clearpointneuro.com/role/StockholdersEquityScheduleofStockOptionActivityDetails", "lang": { "en-us": { "role": { "terseLabel": "Exercisable at ending (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } } }, "auth\_ref": { "r264" } }, "us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": { "http://clearpointneuro.com/role/StockholdersEquityScheduleofStockOptionActivityDetails", "lang": { "en-us": { "role": { "terseLabel": "Exercisable at ending (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } } }, "auth\_ref": { "r264" } }, "us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "presentation": { "http://clearpointneuro.com/role/StockholdersEquityScheduleofStockOptionActivityDetails", "lang": { "en-us": { "role": { "negatedTerseLabel": "Forfeited or expired (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period", "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired." } } } }, "auth\_ref": { "r648" } }, "us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "presentation": { "http://clearpointneuro.com/role/StockholdersEquityScheduleofStockOptionActivityDetails", "lang": { "en-us": { "role": { "terseLabel": "Forfeited or expired (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price", "documentation": "Weighted average price of options that were either forfeited or expired." } } } }, "auth\_ref": { "r648" } }, "us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": { "http://clearpointneuro.com/role/StockholdersEquityScheduleofStockOptionActivityDetails", "lang": { "en-us": { "role": { "terseLabel": "Intrinsic value, outstanding", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } } }, "auth\_ref": { "r271" } }, "us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": { "http://clearpointneuro.com/role/StockholdersEquityScheduleofStockOptionActivityDetails", "lang": { "en-us": { "role": { "periodStartLabel": "Outstanding, beginning balance (in shares)", "periodEndLabel": "Outstanding, ending balance (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } } }, "auth\_ref": { "r262", "r263" } }, "us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "presentation": { "http://clearpointneuro.com/role/StockholdersEquityScheduleofStockOptionActivityDetails", "lang": { "en-us": { "role": { "terseLabel": "Stock Options", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } } }, "auth\_ref": { "r271" } }, "us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": { "http://clearpointneuro.com/role/StockholdersEquityScheduleofStockOptionActivityDetails", "lang": { "en-us": { "role": { "periodStartLabel": "Outstanding, beginning balance (in dollars per share)", "periodEndLabel": "Outstanding, ending balance (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } } }, "auth\_ref": { "r262", "r263" } }, "us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "presentation": { "http://clearpointneuro.com/role/StockholdersEquityScheduleofStockOptionActivityDetails", "lang": { "en-us": { "role": { "terseLabel": "Weighted-average Exercise price per share", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]" } } } }, "auth\_ref": { "r271" } }, "us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "crdr": "debit", "presentation": { "http://clearpointneuro.com/role/StockholdersEquityScheduleofStockOptionActivityDetails", "lang": { "en-us": { "role": { "terseLabel": "Intrinsic value, vested and expected to vest", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value", "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } } }, "auth\_ref": { "r278" } }, "us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "presentation": { "http://clearpointneuro.com/role/StockholdersEquityScheduleofStockOptionActivityDetails", "lang": { "en-us": { "role": { "terseLabel": "Vested and expected to vest at ending (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } } }, "auth\_ref": { "r278" } }, "us-

gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "xbrlType": "perShareItem", "nsuri": "http://fasb.org/us-gaap/2024", "localName": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "presentation": { "http://clearpointneuro.com/role/StockholdersEquityScheduleofStockOptionActivityDetails": { "en-us": { "role": "terseLabel", "Vested and expected to vest (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth\_ref": { "r278" } }, "us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased": { "xbrlType": "perShareItem", "nsuri": "http://fasb.org/us-gaap/2024", "localName": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased", "presentation": { "http://clearpointneuro.com/role/StockholdersEquityNarrativeDetails": { "en-us": { "role": "terseLabel", "Purchase plan, per share weighted average price of shares purchased (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Per Share Weighted Average Price of Shares Purchased", "documentation": "Per share weighted average price paid for shares purchased on open market for issuance under share-based payment arrangement." } } }, "auth\_ref": { "r27" } }, "us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward": { "xbrlType": "sharesItem", "nsuri": "http://fasb.org/us-gaap/2024", "localName": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward", "presentation": { "http://clearpointneuro.com/role/StockholdersEquityNarrativeDetails": { "en-us": { "role": "terseLabel", "Purchase plan, shares purchased (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Purchased for Award", "documentation": "Number of shares purchased for issuance under share-based payment arrangement." } } }, "auth\_ref": { "r669" } }, "us-gaap\_ShareBasedCompensationArrangementsByShareBasedPaymentAwardTypeAndPlanNameDomain": { "xbrlType": "domainItem", "nsuri": "http://fasb.org/us-gaap/2024", "localName": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardTypeAndPlanNameDomain", "presentation": { "http://clearpointneuro.com/role/StockholdersEquityScheduleofRestrictedStockActivityDetails": { "http://clearpointneuro.com/role/StockholdersEquityScheduleofShareBasedCompensationExpenseDetails": { "http://clearpointneuro.com/role/StockholdersEquityScheduleofUnrecognizedCompensationExpenseandWeightedAverageRequisitePeriodDetails": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": { "en-us": { "role": "terseLabel", "Award Type {Domain}", "label": "Award Type {Domain}", "documentation": "Award under share-based payment arrangement." } } }, "auth\_ref": { "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284" } } }, "us-gaap\_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrlType": "perShareItem", "nsuri": "http://fasb.org/us-gaap/2024", "localName": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": { "http://clearpointneuro.com/role/StockholdersEquityScheduleofStockOptionActivityDetails": { "en-us": { "role": "terseLabel", "Exercised (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth\_ref": { "r267" } }, "us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableIntrinsicValue": { "xbrlType": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localName": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableIntrinsicValue", "crds": "debit", "presentation": { "http://clearpointneuro.com/role/StockholdersEquityScheduleofStockOptionActivityDetails": { "en-us": { "role": "terseLabel", "Intrinsic value, exercisable", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable." } } }, "auth\_ref": { "r27" } }, "us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "xbrlType": "durationItem", "nsuri": "http://fasb.org/us-gaap/2024", "localName": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "presentation": { "http://clearpointneuro.com/role/StockholdersEquityScheduleofStockOptionActivityDetails": { "en-us": { "role": "terseLabel", "Exercisable at ending", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDnTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth\_ref": { "r27" } }, "us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrlType": "durationItem", "nsuri": "http://fasb.org/us-gaap/2024", "localName": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": { "http://clearpointneuro.com/role/StockholdersEquityScheduleofStockOptionActivityDetails": { "en-us": { "role": "terseLabel", "Outstanding", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDnTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth\_ref": { "r78" } }, "us-gaap\_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "xbrlType": "durationItem", "nsuri": "http://fasb.org/us-gaap/2024", "localName": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "presentation": { "http://clearpointneuro.com/role/StockholdersEquityScheduleofStockOptionActivityDetails": { "en-us": { "role": "terseLabel", "Vested and expected to vest", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDnTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth\_ref": { "r278" } }, "us-gaap\_SharesPaidForTaxWithholdingForShareBasedCompensation": { "xbrlType": "sharesItem", "nsuri": "http://fasb.org/us-gaap/2024", "localName": "SharesPaidForTaxWithholdingForShareBasedCompensation", "presentation": { "http://clearpointneuro.com/role/CondensedConsolidatedStatementsOfStockholdersEquity": { "en-us": { "role": "negatedTerseLabel", "Payments for taxes related to net share settlement of equity awards (in shares)", "label": "Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation", "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth\_ref": { "r278" } }, "clpt\_SharesSoldPursuantToExerciseOfUnderwritersOption": { "xbrlType": "sharesItem", "nsuri": "http://clearpointneuro.com/20240930", "localName": "SharesSoldPursuantToExerciseOfUnderwritersOption", "presentation": { "http://clearpointneuro.com/role/StockholdersEquityNarrativeDetails": { "en-us": { "role": "terseLabel", "Shares sold pursuant to exercise of underwriters option (in shares)", "label": "Shares Sold Pursuant To Exercise Of Underwriters Option", "documentation": "Shares Sold Pursuant To Exercise Of Underwriters Option" } } }, "auth\_ref": { "r278" } }, "us-gaap\_StatementOfEquityComponentsAxis": { "xbrlType": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localName": "StatementOfEquityComponentsAxis", "presentation": { "http://clearpointneuro.com/role/CondensedConsolidatedStatementsOfStockholdersEquity": { "en-us": { "role": "terseLabel", "Equity Components [Axis]", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth\_ref": { "r5", "r43", "r46", "r47", "r99", "r113", "r114", "r115", "r129", "r130", "r131", "r133", "r138", "r140", "r142", "r153", "r167", "r168", "r176", "r240", "r289", "r290", "r291", "r292", "r293", "r295", "r296", "r297", "r303", "r304", "r305", "r306", "r307", "r308", "r310", "r327", "r328", "r329", "r330", "r331", "r332", "r335", "r337", "r345", "r369", "r382", "r383", "r384", "r393", "r443" } } }, "us-gaap\_StatementOfFinancialPositionAbstract": { "xbrlType": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localName": "StatementOfFinancialPositionAbstract", "presentation": { "http://clearpointneuro.com/role/CondensedConsolidatedStatementsOfOperations": { "http://clearpointneuro.com/role/CondensedConsolidatedStatementsOfStockholdersEquity": { "en-us": { "role": "terseLabel", "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth\_ref": { "r129", "r130", "r131", "r153", "r164", "r337", "r354", "r389", "r394", "r397", "r398", "r399", "r400", "r401", "r402", "r405", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r418", "r419", "r420", "r421", "r422", "r424", "r426", "r427", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r443", "r508" } } }, "ecd\_StkPrOrTsrEstimationMethodTextBlock": { "xbrlType": "textBlockItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localName": "StkPrOrTsrEstimationMethodTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "en-us": { "role": "terseLabel", "Stock Price or TSR Estimation Method", "label": "Stock Price or TSR Estimation Method [Text Block]", "documentation": "Stock Price or TSR Estimation Method [Text Block]", "auth\_ref": { "r525", "r535", "r545", "r577" } } } }, "us-gaap\_StockAppreciationRightsSARSMember": { "xbrlType": "domainItem", "nsuri": "http://fasb.org/us-gaap/2024", "localName": "StockAppreciationRightsSARSMember", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": { "en-us": { "role": "terseLabel", "Stock Appreciation Rights (SARs)", "label": "Stock Appreciation Rights (SARs) [Member]", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth\_ref": { "r5", "r42", "r43", "r76" } } }, "us-gaap\_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "xbrlType": "sharesItem", "nsuri": "http://fasb.org/us-gaap/2024", "localName": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "presentation": { "http://clearpointneuro.com/role/CondensedConsolidatedStatementsOfStockholdersEquity": { "en-us": { "role": "terseLabel", "Issuance of common stock under employee stock purchase plan (in shares)", "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan." } } }, "auth\_ref": { "r5", "r42", "r43", "r76" } } }, "us-gaap\_StockIssuedDuringPeriodSharesNewIssues": { "xbrlType": "sharesItem", "nsuri": "http://fasb.org/us-gaap/2024", "localName": "StockIssuedDuringPeriodSharesNewIssues", "presentation": { "http://clearpointneuro.com/role/CondensedConsolidatedStatementsOfStockholdersEquity": { "en-us": { "role": "terseLabel", "Public offering of common stock, net of offering costs (in shares)", "label": "Stock Issued During Period, Shares, New Issues", "documentation": "Number of new stock issued during the period." } } }, "auth\_ref": { "r5", "r42", "r43", "r76", "r390", "r443" } } }, "us-gaap\_StockIssuedDuringPeriodSharesShareBasedCompensation": { "xbrlType": "sharesItem", "nsuri": "http://fasb.org/us-gaap/2024", "localName": "StockIssuedDuringPeriodSharesShareBasedCompensation", "presentation": { "http://clearpointneuro.com/role/CondensedConsolidatedStatementsOfStockholdersEquity": { "en-us": { "role": "terseLabel", "Share-based compensation (in shares)", "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture", "documentation": "Number, after forfeiture, of shares or units issued under

















































clpt:EmployeeStockPurchasePlanMember 2024-01-01 2024-09-30 0001285550 clpt:EmployeeStockPurchasePlanMember 2024-09-30 shares iso4217:USD iso4217:USD shares clpt:customer clpt:investor clpt:segment pure clpt:renewal\_option 0001285550 -12-31-2024 Q3 false P1Y P1Y P36M 10-Q true 2024-09-30 false 001-34822

ClearPoint Neuro, Inc. DE 58-2394628 120 S. Sierra Ave. Suite 100 Solana Beach CA 92075 (888) 287-9109 Common Stock \$0.01 par value per share CLPT NASDAQ Yes Yes Non-accelerated Filer true false false 27584699 21573000 23140000 3875000 32110000 7059000 7911000 1823000 919000 3433000 36172000 1695000 1389000 3210000 3564000 198000 386000 612000 1041000 148000 109000 40193000 42661000 955000 393000 3635000 2947000 1176000 1053000 536000 424000 1252000 2613000 7554000 7430000 3158000 3568000 480000 541000 0 9949000 11192000 21488000 0.01 0.01 25000000 25000000 0 0 0 0 0 0 0.01 0.01 90000000 90000000 27588819 27588819 24652729 24652729 276000 247000 214709000 193382000 -185984000 -172456000 29001000 21173000 40193000 42661000 5474000 2410000 2648000 3352000 8122000 5762000 3275000 2489000 4847000 3273000 3315000 2429000 3549000 2841000 3155000 2900000 -5172000 -4897000 -11000 -12000 209000 10000 -4974000 -4809000 -0.18 -0.18 -0.20 -0.20 27591623 27591623 24630181 24630181 14053000 7377000 9566000 9768000 23619000 17145000 9259000 7544000 14360000 9601000 9060000 9057000 10673000 9248000 8769000 9036000 -1142000 -1774000 -32000 -25000 646000 295000 -13528000 -17470000 -0.50 -0.50 -0.71 -0.71 26840119 26840119 24599191 24599191 24652729 247000 193382000 -172456000 21173000 2633848 26000 16157000 16183000 126315 1000 1503000 1504000 7500 21000 21000 44047 151000 151000 -4146000 -4146000 27416345 274000 210912000 -176602000 34584000 130447 1000 1795000 1796000 1373 22153 128000 128000 62800 1000 287000 288000 -4408000 -4408000 27588812 276000 212866000 -181010000 32132000 4547 0 1994000 1994000 860 5400 61000 61000 -4974000 -4974000 27588819 276000 214709000 -185984000 29001000 24578983 246000 187008000 -150367000 36887000 3782 1307000 1307000 514 5000 5000 -5609000 -5609000 24582251 246000 188310000 -155976000 32580000 5484 1645000 1645000 11102 77000 77000 51041 314000 314000 -7052000 -7052000 24627674 246000 190192000 -163028000 27410000 -1001 1584000 1584000 14312 15315 91000 91000 -4809000 -4809000 24625670 246000 191685000 -167937000 24094000 -13528000 -17470000 -507000 903000 740000 443000 5204000 4536000 51000 42000 692000 590000 0 126000 157000 662000 -434000 -263000 -88000 -241000 40000 -22000 1373000 -1023000 -635000 -553000 -1422000 243000 -7707000 -12551000 12000 696000 0 167000 0 10000000 -12000 9137000 16183000 0 10000000 0 21000 0 340000 173000 288000 314000 6152000 141000 -1567000 -3273000 23140000 27615000 21573000 24342000 0 0 480000 540000 400000 100000 2500000 -<div style="margin-top: 12pt; padding-left: 18pt; text-align: justify;"><span style="color: #000000; font-family: Times New Roman; sans-serif; font-size: 10pt; font-weight: 400; line-height: 120%;">The Company has exclusive global commercialization rights to the ClearPoint Prism Neuro Laser Therapy System through its Swedish partner, Clinical Laserthermia Systems ("CLS").</span></div><div style="margin-top: 12pt; padding-left: 18pt; text-align: justify;"><span style="color: #000000; font-family: Times New Roman; sans-serif; font-size: 10pt; font-weight: 400; line-height: 112%;">Since 2021, a growing part of the Company's revenue is derived from professional services to pharmaceutical and biotech companies, academic institutions, and contract research organizations having a focus on biologics and drug delivery. The Company's services include protocol consultation and solutions for preclinical study design and execution for the delivery of pharmaceutical agents to the brain. The Company also partners with customers to develop devices used for administration of therapies into the central nervous system. Currently, the Company has more than 50 biologics and drug delivery customers who are evaluating or using its products and services in trials to inject gene and cell therapies directly into the brain. These relationships involve drug development programs that are at various stages of development ranging from preclinical research to late-stage regulatory trials for multiple distinct disease states. This part of the Company's business potentially represents the largest opportunity for growth; however, the Company's ability to grow in this market is dependent on its ability to maintain and establish new relationships with customers, such customers' continuation of research and product development plans, and such customers' achievement of success in completion of clinical trials and subsequent regulatory approvals of their biologics and drugs.</span></div><div style="margin-top: 12pt; padding-left: 18pt; text-align: justify;"><span style="color: #000000; font-family: Times New Roman; sans-serif; font-size: 10pt; font-weight: 400; line-height: 120%;">Macroeconomic Trends</span></div><div style="margin-top: 12pt; padding-left: 18pt; text-align: justify;"><span style="color: #000000; font-family: Times New Roman; sans-serif; font-size: 10pt; font-weight: 400; line-height: 120%;">The Company continues to monitor the impact of various macroeconomic trends, such as global economic and supply chain disruptions, geopolitical instability (including instability resulting from military conflicts), labor shortages, inflationary conditions, and legislative and political developments. Impacts from inflationary pressures, such as increasing costs for research and development of the Company's products, administrative and other costs of doing business, and the Company's access to capital markets and other sources of funding in the future could adversely affect the Company's business, financial condition and results of operations. Additionally, these trends could adversely affect the Company's customers, which could impact their willingness to spend on the Company's products and services, or their ability to make payment, which could harm the Company's collection of accounts receivable and financial results. The continued development and fluidity of these situations preclude any prediction as to the ultimate impact they will have on the Company's business, financial condition, results of operation and cash flows.</span></div><div style="margin-top: 12pt; padding-left: 18pt; text-align: justify;"><span style="color: #000000; font-family: Times New Roman; sans-serif; font-size: 10pt; font-weight: 400; line-height: 120%;">In March 2024, the Company completed a public offering of 2,653,848 shares of its common stock from which the net proceeds totaled approximately \$16.2 million after deducting underwriting discounts and commissions, and other offering expenses paid by the Company. See Note 8 below for additional information with respect to the common stock offering.</span></div><div style="margin-top: 12pt; padding-left: 18pt; text-align: justify;"><span style="color: #000000; font-family: Times New Roman; sans-serif; font-size: 10pt; font-weight: 400; line-height: 120%;">In August 2024, the Company repaid in full the remaining \$10 million outstanding under a Securities Purchase Agreement entered into in 2020 (the "SPA"), pursuant to which the Company issued secured convertible notes to two investors raising gross proceeds of \$25 million, of which \$15 million had been previously converted to common stock. See Note 6 below for additional information with respect to these notes.</span></div><div style="margin-top: 12pt; padding-left: 18pt; text-align: justify;"><span style="color: #000000; font-family: Times New Roman; sans-serif; font-size: 10pt; font-weight: 400; line-height: 120%;">Use of Estimates</span></div><div style="margin-top: 12pt; padding-left: 18pt; text-align: justify;"><span style="color: #000000; font-family: Times New Roman; sans-serif; font-size: 10pt; font-weight: 400; line-height: 120%;">Inventory</span></div><div style="margin-top: 12pt; padding-left: 18pt; text-align: justify;"><span style="color: #000000; font-family: Times New Roman; sans-serif; font-size: 10pt; font-weight: 400; line-height: 120%;">Intangible Assets</span></div><div style="margin-top: 12pt; padding-left: 18pt; text-align: justify;"><span style="color: #000000; font-family: Times New Roman; sans-serif; font-size: 10pt; font-weight: 400; line-height: 120%;">The Company is a party to a license agreement that provides rights to the Company for the development and commercialization of products. Under the terms of the license agreement, the Company made payments to the licensor upon execution of the license agreement for access to the underlying technology, and future payments will be based upon achievement of regulatory and commercialization milestones as defined in the license agreement. In 2022, the Company made a payment to the licensor for the achievement of a regulatory milestone, which acts as a prepayment for future royalties.</span></div><div style="margin-top: 12pt; padding-left: 18pt; text-align: justify;"><span style="color: #000000; font-family: Times New Roman; sans-serif; font-size: 10pt; font-weight: 400; line-height: 120%;">In conformity with Accounting Standards Codification Section (ASC) 350, "Intangibles - Goodwill and Other," the Company amortizes the payments related to the license rights described above over an expected useful life of up to five years, or as commercial sales occur that are related to the royalty prepayment. In addition, the Company periodically evaluates the recoverability of its investment in the license rights and records an impairment charge in the event such evaluation indicates that the Company's investment is not likely to be recovered.</span></div><div style="margin-top: 12pt; padding-left: 18pt; text-align: justify;"><span style="color: #000000; font-family: Times New Roman; sans-serif; font-size: 10pt; font-weight: 400; line-height: 120%;">Revenue Recognition</span></div><div style="margin-top: 12pt; padding-left: 18pt; text-align: justify;"><span style="color: #000000; font-family: Times New Roman; sans-serif; font-size: 10pt; font-weight: 400; line-height: 120%;">The Company's revenue is comprised primarily of: (1) product revenue resulting from the sale of neurosurgery, navigation, therapy, and biologics and drug delivery disposable products; (2) product revenue resulting from the



which comprise the Company's outstanding common stock options and unvested restricted stock units, as described in Note 8, would be anti-dilutive, due to the reporting of a net loss for each of the periods in the accompanying condensed consolidated statements of operations.

**Concentration Risks and Other Risks and Uncertainties**

Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable. The Company may at times invest its excess cash in interest bearing accounts and U.S. government debt securities. It classifies all highly liquid investments with original stated maturities of three months or less from the date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months but less than twelve months as short-term investments.

The Company holds the remainder of its cash and cash equivalents on deposit with financial institutions in the U.S. insured by the Federal Deposit Insurance Corporation. At September 30, 2024, the Company had approximately \$1.1 million in bank balances that were in excess of the insured limits.

At September 30, 2024, there was one customer whose accounts receivable balance represented 11% of accounts receivable at that date. At December 31, 2023, there were four customers whose accounts receivable balances represented 80% of accounts receivable at that date.

One pharmaceutical customer, a related party who is a stockholder and whose chief executive officer is a member of the Company's Board of Directors, for whom the Company provides hardware, software, clinical services and market development services in support of the customer's clinical trials, and from whom the Company earns a quarterly fee, accounted for 9% and 12% of total sales in both the three and nine-month periods ended September 30, 2024 and 2023, respectively. There was one additional customer, who comprised 13% of the total sales in the three-month period ended September 30, 2024, and another customer who comprised 10% of the total sales in the three-month period ended September 30, 2023.

Prior to granting credit to a customer, the Company generally performs credit evaluations of the customer's financial condition. In general, the Company does not require collateral from customers in connection with an extension of credit. The accounts receivable balance is reduced by an allowance for credit losses from the potential inability of the Company's customers to make required payments. The allowance for credit losses at September 30, 2024, and December 31, 2023, was \$0.9 million and \$1.4 million, respectively. The Company evaluates the historic loss experience on the accounts receivable balance and also considers separately customers with receivable balances that may be negatively impacted by current economic developments and market conditions. The estimate is a result of the Company's ongoing evaluation of collectability, customer creditworthiness, historical levels of credit losses and future expectations.

The Company is subject to risks common to emerging companies in the medical device industry, including, but not limited to: new technological innovations; acceptance and competitiveness of its products; dependence on key personnel; dependence on key suppliers; its ability to maintain its third-party collaboration, license and joint development partners, and enter into new relationships; changes in general economic conditions and interest rates; its ability to obtain additional funding to support its business; regulatory uncertainty; protection of proprietary technology; compliance with changing government regulations; uncertainty of widespread market acceptance of products; access to credit for capital purchases by customers; and intellectual property and product liability claims. Certain components used in manufacturing have relatively few alternative sources of supply and establishing additional or replacement suppliers for such components cannot be accomplished quickly. The inability of any of these suppliers to fulfill the Company's supply requirements may negatively impact future operating results.

Recent Accounting Standards Not Yet Adopted

In November 2023, the FASB issued ASU 2023-07, "Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures." The amendments improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. In addition, the amendments enhance interim disclosure requirements, clarify circumstances in which an entity can disclose multiple segment measures of profit or loss, provide new segment disclosure requirements for entities with a single reportable segment, and contain other disclosure requirements. ASU 2023-07 is effective for calendar year-end public business entities in 2024 annual reporting and in 2025 interim reporting. Early adoption is permitted. The Company expects to adopt ASU 2023-07 retrospectively in its 2024 annual financial reporting and its 2025 interim financial reporting, and is currently evaluating the impact of this ASU on its consolidated financial statements.

In December 2023, the FASB issued ASU 2023-09, "Improvements to Income Tax Disclosures," which requires that an entity, on an annual basis, disclose additional income tax information, primarily related to the rate reconciliation and income taxes paid. The provisions of the ASU are intended to enhance the transparency and decision usefulness of income tax disclosures. The guidance may be applied on a prospective basis with the option to apply the standard retrospectively and is effective for calendar year-end public business entities in the 2025 annual period and in 2026 for interim periods with early adoption permitted. The Company is currently evaluating the impact of this ASU on its consolidated financial statements.

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements of the Company should be read in conjunction with the audited financial statements and notes thereto as of and for the year ended December 31, 2023 included in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC"). The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States ("U.S. GAAP") for interim financial information and in accordance with the rules and regulations of the SEC related to a quarterly report on Form 10-Q. Accordingly, since they are interim statements, the accompanying unaudited condensed consolidated financial statements do not include all of the information and notes required by U.S. GAAP for complete financial statements. In the opinion of management, the accompanying unaudited condensed consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, that are necessary for a fair statement of financial position, results of operations, cash flows, and stockholders' equity for the interim periods presented. Interim results are not necessarily indicative of results for a full year.

Use of Estimates

The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ from those estimates.

Inventory

Inventory is carried at the lower of cost or net realizable value. The costs of inventory are determined using the standard cost method, which approximates actual cost based on a first-in, first-out method. Items in inventory relate predominantly to the Company's ClearPoint system and related disposables. Software license inventory related to ClearPoint systems undergoing on-site customer evaluation is included in inventory in the accompanying condensed consolidated balance sheets. All other software license inventory is classified as a non-current asset. The Company periodically reviews its inventory for excess and obsolete items and provides a reserve upon identification of potentially excess or obsolete items.

Intangible Assets

The Company is a party to a license agreement that provides rights to the Company for the development and commercialization of products. Under the terms of the license agreement, the Company made payments to the licensor upon execution of the license agreement for access to the underlying technology, and future payments will be based upon achievement of regulatory and commercialization milestones as defined in the license agreement. In 2022, the Company made a payment to the licensor for the achievement of a regulatory milestone, which acts as a prepayment for future royalties.

In conformity with Accounting Standards Codification Section (ASC) 350, "Intangibles - Goodwill and Other," the Company amortizes the payments related to the license rights described above over an expected useful life of up to five years, or as commercial sales occur that are related to the royalty prepayment. In addition, the Company periodically evaluates the recoverability of its investment in the license rights and records an impairment charge in the event such evaluation indicates that the Company's investment is not likely to be recovered.

P5Y

**Revenue Recognition**

Revenue Recognition

Revenue is comprised primarily of: (1) product revenue resulting from the sale of neurosurgery, navigation, therapy, and biologics and drug delivery disposable products; (2) product revenue resulting from the sale of ClearPoint capital equipment and software; (3) service revenue and case support revenue in connection with customer-sponsored preclinical and clinical trials; (4) license revenue for the granting of licenses to develop and commercialize the Company's SmartFlow Cannula devices with the Company's customers' proprietary biologics as a combination product; and (5) revenue resulting from the service, installation, training, and shipping related to ClearPoint capital equipment and software. The Company recognizes revenue when (i) control of the Company's products is transferred to its customers or (ii) services are provided to customers, each in an amount that reflects the consideration the Company expects to receive from its customers in exchange for those products and services, in a process that involves identifying the contract with a customer, identifying the performance obligations in the contract, determining the transaction price, allocating the transaction price to the distinct performance obligations in the contract, and recognizing revenue when or as the performance obligations have been satisfied. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. When a contract calls for the satisfaction of multiple performance obligations for a single contract price, the Company typically allocates the contract price among the performance obligations based on the relative stand-alone selling prices for each such performance obligation customarily charged by the Company. The Company considers a performance obligation satisfied once it has transferred control of a good or service to the customer, meaning the customer has the ability to use and obtain the benefit of the good or service. The Company recognizes revenue for satisfied performance obligations only when it determines there are no uncertainties regarding payment terms or transfer of control.

Lines of Business: Timing of Revenue Recognition

Neurosurgery navigation product, biologics and drug delivery systems product, and therapy product sales

Revenue from the sale of neurosurgery navigation products (consisting of disposable products sold commercially and related to cases utilizing the Company's ClearPoint system), biologics and drug delivery products (consisting primarily of disposable products related to customer-sponsored clinical trials utilizing the ClearPoint system), and therapy products (consisting primarily of disposable laser-related products used in neurosurgical procedures) is generally based on customer purchase orders, the predominance of which require delivery within one week of the order having been placed, and is generally recognized at the point in time of shipping to the customer, which is the point at which legal title, and risks and rewards of ownership, transfer to the customer. For certain customers, legal title and risks and rewards of ownership transfer upon delivery to the customer as stated in their respective contracts, in which case revenue is recognized upon delivery.

Capital equipment and software sales

Capital equipment and software sales

height: 115%; padding-left: 14.46pt">Capital equipment and software sales preceded by evaluation periods.</span><span style="color: #000000; font-family: Times New Roman; sans-serif; font-size: 10pt; font-style: italic; font-weight: 400; line-height: 115%; padding-left: 14.46pt">The predominance of capital equipment and software sales (consisting of integrated computer hardware and software that are integral components of the Company's ClearPoint system) are preceded</span><span style="color: #000000; font-family: Times New Roman; sans-serif; font-size: 10pt; font-style: italic; font-weight: 400; line-height: 115%; padding-left: 14.46pt">by customer evaluation periods. During these evaluation periods, installation of, and training of customer personnel on, the systems have been completed and the systems have been in operation. Accordingly, revenue from capital equipment and software sales following such evaluation periods is recognized at the point in time that the Company is in receipt of an executed purchase agreement or purchase order.</span></div><div style="padding-left: 54pt; text-align: justify"><span style="color: #000000; font-family: Times New Roman; sans-serif; font-size: 10pt; font-style: italic; font-weight: 400; line-height: 115%; padding-left: 14.46pt">Capital equipment and software sales not preceded by evaluation periods.</span><span style="color: #000000; font-family: Times New Roman; sans-serif; font-size: 10pt; font-style: italic; font-weight: 400; line-height: 115%; padding-left: 14.46pt">Revenue from sales of capital equipment and software not having been preceded by an evaluation period is recognized upon delivery to the customer and installation. For capital equipment that does not require installation, revenue is recognized upon shipment; however, for those customers where legal title and risks and rewards of ownership transfer upon delivery, revenue is recognized at such time.</span></div><div style="padding-left: 90pt; text-align: justify"><span style="color: #000000; font-family: Times New Roman; sans-serif; font-size: 10pt; font-style: italic; font-weight: 400; line-height: 115%; padding-left: 14.46pt">For both types of capital equipment and software sales described above, the determination of the point in time at which to recognize revenue represents that point at which the customer has legal title, physical possession, and the risks and rewards of ownership, and the Company has a present right to payment.</span></div><div style="margin-top: 12pt; padding-left: 54pt; text-align: justify; text-indent: -18pt"><span style="color: #000000; font-family: Times New Roman; sans-serif; font-size: 10pt; font-style: italic; font-weight: 400; line-height: 115%; padding-left: 14.46pt">Neurosurgery navigation and therapy services.</span><span style="color: #000000; font-family: Times New Roman; sans-serif; font-size: 10pt; font-style: italic; font-weight: 400; line-height: 115%; padding-left: 14.46pt">The Company recognizes revenue for such services over time as the services are delivered to the customer based on the extent of progress towards completion of the performance obligation.</span></div><div style="margin-top: 12pt; padding-left: 54pt; text-align: justify; text-indent: -18pt"><span style="color: #000000; font-family: Times New Roman; sans-serif; font-size: 10pt; font-style: italic; font-weight: 400; line-height: 115%; padding-left: 14.46pt">Biologics and drug delivery services and other revenue.</span></div><div style="margin-top: 12pt; padding-left: 90pt; text-align: justify; text-indent: -18pt"><span style="color: #000000; font-family: Times New Roman; sans-serif; font-size: 10pt; font-style: italic; font-weight: 400; line-height: 115%; padding-left: 14.46pt">Professional and Consulting Services.</span><span style="color: #000000; font-family: Times New Roman; sans-serif; font-size: 10pt; font-style: italic; font-weight: 400; line-height: 115%; padding-left: 14.46pt">The Company recognizes professional and consulting revenue over time as the services are delivered to the customer based on the extent of progress towards completion of the performance obligation. The Company may use output methods, such as time elapsed, or input methods, such as labor hours expended or costs incurred, to measure progress depending on which better depicts the transfer of control to the customer.</span></div><div style="margin-top: 12pt; padding-left: 90pt; text-align: justify; text-indent: -18pt"><span style="color: #000000; font-family: Times New Roman; sans-serif; font-size: 10pt; font-style: italic; font-weight: 400; line-height: 115%; padding-left: 14.46pt">Clinical Service Access Fees.</span><span style="color: #000000; font-family: Times New Roman; sans-serif; font-size: 10pt; font-style: italic; font-weight: 400; line-height: 115%; padding-left: 14.46pt">For contracts in which the Company receives a periodic fixed fee, irrespective of the number of cases attended by the Company's personnel or hours incurred during such periods, revenue is recognized ratably over the period covered by such fees. A time-elapsed output method is used for such fees because the Company transfers control evenly by providing a stand-ready service.</span></div><div style="margin-top: 12pt; padding-left: 90pt; text-align: justify; text-indent: -18pt"><span style="color: #000000; font-family: Times New Roman; sans-serif; font-size: 10pt; font-style: italic; font-weight: 400; line-height: 115%; padding-left: 14.46pt">Procedure-Based Service Fees.</span><span style="color: #000000; font-family: Times New Roman; sans-serif; font-size: 10pt; font-style: italic; font-weight: 400; line-height: 115%; padding-left: 14.46pt">The Company recognizes revenue at the point in time a relevant case is completed.</span></div><div style="margin-top: 12pt; padding-left: 90pt; text-align: justify; text-indent: -18pt"><span style="color: #000000; font-family: Times New Roman; sans-serif; font-size: 10pt; font-style: italic; font-weight: 400; line-height: 115%; padding-left: 14.46pt">License fees.</span><span style="color: #000000; font-family: Times New Roman; sans-serif; font-size: 10pt; font-style: italic; font-weight: 400; line-height: 115%; padding-left: 14.46pt">License fees represent the use of functional intellectual property as it exists at the point in time at which the license is granted and does not require any significant development or customization. Accordingly, the Company recognizes license revenue at the point in time in which the license becomes effective and the intellectual property is made available to the customer.</span></div><div style="margin-top: 12pt; padding-left: 90pt; text-align: justify; text-indent: -18pt"><span style="color: #000000; font-family: Times New Roman; sans-serif; font-size: 10pt; font-style: italic; font-weight: 400; line-height: 115%; padding-left: 14.46pt">Milestone fees.</span><span style="color: #000000; font-family: Times New Roman; sans-serif; font-size: 10pt; font-style: italic; font-weight: 400; line-height: 115%; padding-left: 14.46pt">Event-based payments which are subject to the customer's achievement of specified development or regulatory milestones are included in the transaction price if, in the Company's judgment, it is probable that these milestones will be achieved and a significant future reversal of cumulative revenue under the contract will not occur. The Company re-evaluates the probability of achievement of such milestones at the end of each reporting period and adjusts the transaction price as necessary.</span></div><div style="margin-top: 12pt; padding-left: 54pt; text-align: justify; text-indent: -18pt"><span style="color: #000000; font-family: Times New Roman; sans-serif; font-size: 10pt; font-style: italic; font-weight: 400; line-height: 120%; padding-left: 14.46pt">Capital equipment-related services.</span></div><div style="margin-top: 12pt; padding-left: 90pt; text-align: justify; text-indent: -18pt"><span style="color: #000000; font-family: Times New Roman; sans-serif; font-size: 10pt; font-style: italic; font-weight: 400; line-height: 120%; padding-left: 14.46pt">Equipment service.</span><span style="color: #000000; font-family: Times New Roman; sans-serif; font-size: 10pt; font-style: italic; font-weight: 400; line-height: 120%; padding-left: 14.46pt">Revenue from service of ClearPoint capital equipment and software previously sold to customers is based on agreements with terms ranging from one</span><span style="color: #000000; font-family: Times New Roman; sans-serif; font-size: 10pt; font-style: italic; font-weight: 400; line-height: 120%; padding-left: 14.46pt">to three years and is recognized ratably on a monthly basis over the term of the service agreement. A time-elapsed output method is used for service revenue because the Company transfers control evenly by providing a stand-ready service.</span></div><div style="margin-top: 12pt; padding-left: 90pt; text-align: justify; text-indent: -18pt"><span style="color: #000000; font-family: Times New Roman; sans-serif; font-size: 10pt; font-style: italic; font-weight: 400; line-height: 120%; padding-left: 14.46pt">The Company may also enter into contracts with customers who own ClearPoint capital equipment, which bundle maintenance and support services and access to software and hardware upgrades made commercially available over the term of the contract, for a single contract price, typically paid on an annual basis. The Company allocates the contract price among the performance obligations based on the relative stand-alone prices for each such performance obligation and recognizes the revenue ratably on a monthly basis. A time-elapsed output method is used as the Company is providing a stand-ready service for each of the performance obligations.</span></div><div style="margin-top: 12pt; padding-left: 90pt; text-align: justify; text-indent: -18pt"><span style="color: #000000; font-family: Times New Roman; sans-serif; font-size: 10pt; font-style: italic; font-weight: 400; line-height: 120%; padding-left: 14.46pt">Installation, training and shipping.</span><span style="color: #000000; font-family: Times New Roman; sans-serif; font-size: 10pt; font-style: italic; font-weight: 400; line-height: 120%; padding-left: 14.46pt">Consistent with the Company's recognition of revenue for capital equipment and software sales as described above, fees for installation, training and shipping in connection with sales of capital equipment and software that have been preceded by customer evaluation periods are recognized as revenue at the point in time the Company is in receipt of an executed purchase agreement or purchase order for the equipment and software. Installation, training and shipping fees related to capital equipment and software sales not having been preceded by an evaluation period are recognized as revenue concurrent with the recognition of revenue from sales of the related capital equipment.</span></div><div style="margin-top: 12pt; padding-left: 36pt; text-align: justify; text-indent: -18pt"><span style="color: #000000; font-family: Times New Roman; sans-serif; font-size: 10pt; font-style: italic; font-weight: 400; line-height: 120%; padding-left: 14.46pt">The Company operates in one industry segment, and the predominance of its sales are to U.S.-based customers.</span></div><div style="margin-top: 12pt; padding-left: 18pt; text-align: justify"><span style="color: #000000; font-family: Times New Roman; sans-serif; font-size: 10pt; font-style: italic; font-weight: 400; line-height: 120%; padding-left: 14.46pt">Payment terms under contracts with customers generally are in a range of 30-60 days after the customers' receipt of the Company's invoices.</span></div><div style="margin-top: 12pt; padding-left: 18pt; text-align: justify"><span style="color: #000000; font-family: Times New Roman; sans-serif; font-size: 10pt; font-style: italic; font-weight: 400; line-height: 120%; padding-left: 14.46pt">The Company's terms and conditions do not provide for a right of return unless for: (a) product defects; or (b) other conditions subject to the Company's approval.</span></div><div style="margin-top: 12pt; padding-left: 18pt; text-align: justify"><span style="color: #000000; font-family: Times New Roman; sans-serif; font-size: 10pt; font-style: italic; font-weight: 400; line-height: 120%; padding-left: 14.46pt">Net Loss Per Share.</span></div><div style="margin-top: 12pt; padding-left: 18pt; text-align: justify"><span style="color: #000000; font-family: Times New Roman; sans-serif; font-size: 10pt; font-style: italic; font-weight: 400; line-height: 120%; padding-left: 14.46pt">The Company computes net loss per share using the weighted-average number of common shares outstanding during the period. Basic and diluted net loss per share are the same because the conversion, exercise or issuance of all potential common stock equivalents, which comprise the Company's outstanding common stock options and unvested restricted stock units, as described in Note 8, would be anti-dilutive, due to the reporting of a net loss for each of the periods in the accompanying condensed consolidated statements of operations.</span></div><div style="margin-top: 12pt; padding-left: 18pt"><span style="color: #000000; font-family: Times New Roman; sans-serif; font-size: 10pt; font-style: italic; font-weight: 400; line-height: 120%; padding-left: 14.46pt">Concentration Risks and Other Risks and Uncertainties</span></div><div style="margin-top: 12pt; padding-left: 18pt; text-align: justify"><span style="color: #000000; font-family: Times New Roman; sans-serif; font-size: 10pt; font-style: italic; font-weight: 400; line-height: 120%; padding-left: 14.46pt">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable. The Company may at times invest its excess cash in interest bearing accounts and U.S. government debt securities. It classifies all highly liquid investments with original stated maturities of three months or less from the date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months but less than twelve months as short-term investments.</span></div><div style="margin-top: 12pt; padding-left: 18pt; text-align: justify"><span style="color: #000000; font-family: Times New Roman; sans-serif; font-size: 10pt; font-style: italic; font-weight: 400; line-height: 120%; padding-left: 14.46pt">The Company holds the remainder of its cash and cash equivalents on deposit with financial institutions in the U.S., insured by the Federal Deposit Insurance Corporation. At September 30, 2024, the Company had approximately \$1.1 million in bank balances that were in excess of the insured limits.</span></div><div style="margin-top: 12pt; padding-left: 18pt; text-align: justify"><span style="color: #000000; font-family: Times New Roman; sans-serif; font-size: 10pt; font-style: italic; font-weight: 400; line-height: 120%; padding-left: 14.46pt">At September 30, 2024, there was one customer whose accounts receivable balance represented 11% of accounts receivable at that date. At December 31, 2023, there were four customers whose accounts receivable balances represented 80% of accounts receivable at that date.</span></div><div style="margin-top: 12pt; padding-left: 18pt; text-align: justify"><span style="color: #000000; font-family: Times New Roman; sans-serif; font-size: 10pt; font-style: italic; font-weight: 400; line-height: 120%; padding-left: 14.46pt">One pharmaceutical customer, a related party who is a stockholder and whose chief executive officer is a member of the Company's Board of Directors, for whom the Company provides hardware, software, clinical services and market development services in support of the customer's clinical trials, and from whom the Company earns a quarterly fee, accounted for 9% and 12% of total sales in both the three and nine-month periods ended September 30, 2024 and 2023, respectively. There was one additional customer, who comprised 13% of the total sales in the three-month period ended September 30, 2024, and another customer who comprised 10% of the total sales in the three-month period ended September 30, 2023.</span></div><div style="margin-top: 12pt; padding-left: 18pt; text-align: justify"><span style="color: #000000; font-family: Times New Roman; sans-serif; font-size: 10pt; font-style: italic; font-weight: 400; line-height: 120%; padding-left: 14.46pt">Prior to granting credit to a customer, the Company generally performs credit evaluations of the customer's financial condition. In general, the Company does not require collateral from customers in connection with an extension of credit. The accounts receivable balance is reduced by an allowance for credit losses from the potential inability of the Company's customers to make required payments. The allowance for credit losses at September 30, 2024, and December 31, 2023, was \$0.9 million and \$1.4 million, respectively. The Company evaluates the historic loss experience on the accounts receivable balance and also considers separately customers with receivable balances that may be negatively impacted by current economic developments and market conditions. The estimate is a result of the Company's ongoing evaluation of collectability, customer creditworthiness, historical levels of credit losses and future expectations.</span></div><div style="margin-top: 12pt; padding-left: 18pt; text-align: justify"><span style="color: #000000; font-family: Times New Roman; sans-serif; font-size: 10pt; font-style: italic; font-weight: 400; line-height: 120%; padding-left: 14.46pt">The Company is subject to risks common to emerging companies in the medical device industry, including, but not limited to, new technological innovations; acceptance and competitiveness of its products; dependence on key personnel; dependence on key suppliers; its ability to maintain its third-



























